(12) STANDARD PATENT (11) Application No. AU 2015226578 B2 (19) AUSTRALIAN PATENT OFFICE

(54) Title Heterocyclic compounds, process for preparation of the same and use thereof

(51) International Patent Classification(s) C07D 409/12 (2006.01) A61P 25/18 (2006.01) A61K 31/4709 (2006.01) A61P 25/20 (2006.01) A61K 31/496 (2006.01) A61P 25/22 (2006.01) A61K 31/517 (2006.01) A61P 25/24 (2006.01) A61K 31/519 (2006.01) A61P 25/28 (2006.01) A61K 31/538 (2006.01) C07D 409/14 (2006.01) A61K 31/5415 (2006.01) C07D 413/12 (2006.01) A61K 31/55 (2006.01) C07D 417/12 (2006.01) A61P 25/00 (2006.01) C07D 471/04 (2006.01) A61P 25/04 (2006.01) C07D 495/04 (2006.01) A61P 25/14 (2006.01) C07D 519/00 (2006.01) A61P 25/16 (2006.01)

(21) Application No: 2015226578 (22) Date of Filing: 2015.03.09

(87) WIPO No: W015/131856

(30) Priority Data

(31) Number (32) Date (33) Country 201410083602.8 2014.03.07 CN 201410853950.9 2014.12.31 CN

(43) Publication Date: 2015.09.11 (44) Accepted Journal Date: 2017.11.23

(71) Applicant(s) Suzhou Vigonvita Life Sciences Co., Ltd.;Topharman Shandong Co., Ltd.;Shanghai Institute of Materia Medica, Chinese Academy of Sciences

(72) Inventor(s) Jiang, Hualiang;Wang, Zhen;Li, Jianfeng;Zhang, Rongxia;He, Yang;Liu, Yongjian;Bi, Minghao;Liu, Zheng;Tian, Guanghui;Chen, Weiming;Yang, Feipu;Wu, Chunhui;Wang, Yu;Jiang, Xiangrui;Yin, Jingjing;Wang, Guan;Shen, Jingshan

(74) Agent / Attorney Phillips Ormonde Fitzpatrick, PO Box 323, Collins Street West, VIC, 8007, AU

(56) Related Art US 2010/0063047 Al Grembecka, J. et al, "Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in Leukemia", Nature Chemical Biology, 2012, Vol. 8, No. 3, pp 277-284 WO 2009/094279 Al WO 2013024291 A2 CAS Registry Number 1355745-62-8; STN Entry Date 7 February 2012; 6-ethyl-4 [4-[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]-l-piperazinyl]- Thieno[2,3-d]pyrimidine dimethyl-4-[4-[(3-methyl-5-isoxazolyl)methyl]-1-piperazinyl]- Thieno[2,3 d]pyrimidine CAS Registry Number 1311748-02-3; STN Entry Date 7 July 2011; 4-[3-methyl-4 [(1-methyl-1 H-imidazol-2-yl)methyl]-1 -piperazinyl]- Thieno[2,3-d]pyrimidine CAS Registry Number 1301595-14-1; STN Entry Date 27 May 2011; 2-[[4-(6 ethylthieno[2,3-d]pyrimidin-4-y)-1-piperazinyl]methyl]- 4-Quinazolinamine CAS Registry Number 1269222-01-6; STN Entry Date 21 March 2011; 5-[[4-(5 ethyl-6-methylthieno[2,3-d]pyrimidin-4-y)-1-piperazinyl]methyl]- 2-Furanmethanol CAS Registry Number 930055-49-5; STN Entry Date 13 April 2007; 42 [[4-[2-[(diethylamino)methyl]-5,6-dimethylthieno[2,3-d]pyrimidin-4-yl]-1 piperazinyl]methyl]- (3H)-Quinazolinone CAS Registry Number 1330518-02-9; STN Entry Date 9 September 2011; 5,6 dimethyl-4-[4-(3-thienylmethyl)-1-piperazinyl]- Thieno[2,3-d]pyrimidine CAS Registry Number 434916-97-9; STN Entry Date 28 June 2002; 4-[4-(1,3 benzodioxol-5-ylmethyl)-1-piperazinyl]-2,6-dimethyl- Thieno[2,3-d]pyrimidine CAS Registry Number 1294647-95-2; STN Entry Date 15 May 2011; 6-ethyl-4-[4-[2 (2-thienyl)ethyl]-1-piperazinyl]- Thieno[2,3-d]pyrimidine CAS Registry Number 1323856-54-7; STN Entry Date 26 August 2011; 4-[4-[(2,3 dihydro-1,4-benzodioxin-6-yl)methyl]-1-piperazinyl]- Thieno[2,3-d]pyrimidine CAS Registry Number 920727-99-7; STN Entry Date 13 February 2007; 5,6 dimethyl-2-[(4-thieno[2,3-d]pyrimidin-4-y-1 -piperazinyl)methyl]-Thieno[2,3 d]pyrimidin-4(1 H)-one CAS Registry Number 1331035-38-1; STN Entry Date 11 September 2011; 6,7,8,9 tetrahydro-3-[(4-thieno[2,3-d]pyrimidin-4-yl-1-piperazinyl)methyl]- 5H-1,2,4 Triazolo[4,3-a]azepine (12) I

(10) (43)E~# WO 2015/131856 A1 2015 * 9 T] 11 H (11.09.2015) WIPO I PCT

(51) 04"*j3k* : (72) tA: an (JIANG, Hualiang); NI *M

C07D 409/12 (2006.01) A61K31/5415 (2006.01) SThIfl}+t 555 5, Shanghai 201203 (CN). o C07D 471/04 (2006.01) A61K31/55 (2006.01) E (WANG, Zhen); [: SlK[TIiMtflK 1 % C07D 409/14 (2006.01) A61P 25/00 (2006.01) 555 v, Shanghai 201203 (CN) * !JI*E (LI, Jian C07D 519/00 (2006.01) A61P 25/18 (2006.01) feng); %9 9 555 Shang C07D 495/04 (2006.01) A61P 25/24 (2006.01) hai 201203 (CN)o (ZHANG, Rongxia); A C07D 417/12 (2006.01) A61P 25/22 (2006.01))N, hai Rongxi 201 C07D 413/12 (2006.01) A61P 25/20 (2006.01) i hS i I llI+Z9 S 555 r, Shanghai 201203 A61K31/496 (2006.01) A61P25/28 (2006.01) (CN)o fi# (HE, Yang); +1 l A61K 31/519 (2006.01) A61P 25/04 (2006.01) }+ Z t 555 V , Shanghai 201203 (CN) o 1Ac A61K31/4709 (2006.01) A61P 25/16 (2006.01) (LIU,Yongjian); T NSWJ 2VX1JFf A61K31/517(2006.01) A61P 25/14 (2006.01) RZ A4OLY 49 5, Shandong 262123 (CN)0 o A A61K31/538 (2006.01) M (BI, Minghao); [AdJf $ # Tir9ttm (21) 04$ift : PCT/CN2015/073854 RX (4Li7zJ 49 Shandong 262123 (CN)o tijE (LIU, Zheng); Th iJ M #)ttETVfrtt* (22) F$4*i: 2015 4 3 A 9 H (09.03.2015) a 7A L$J L 49 V, Shandong 262123 (CN) , EE% (25) $ifi . (TIAN, Guanghui); +1 1 M V5A1W' M IT_ R N Ex ItMAAE k x l 398 : D % 10 W, Jiangsu (26) &$*#: T 215123 (CN)o Mi$ (CHEN, Weiming); Ji 49 5, Shan -- (30) 'LtE: #A($$F R4Xa*7L 201410083602.8 2014 4 3 A 7 H (07.03.2014) CN dong262123(CN)o (YANG,Feipu); t'I 201410853950.9 2014 % 12 A 31 H (31.12.2014) CN 4 SIT lli4 t 555 5, Shanghai 201203 (CN)0 o #l (WU, Chunhui); + EI tT$tK (71) $iA: ~ (SHANGHAI MIl]}+i26 555 5, Shanghai 201203 (CN) o1:E* INSTITUTE OF MATERIA MEDICA, CHINESE (WANG, Yu); +' $1I4 9TIll}t 555 , ACADEMY OF SCIENCES) [CN/CN]; +' IL 4t Shanghai 201203 (CN) *MI$A (JIANG, Xiangrui); -S9itfll}+tY 555 ',tShanghai 201203 (CN)o $ + l 555 , Shanghai

= RE WE* I*EK 4jk$ (SUZHOU VIGON- 201203 (CN) o Ift (YIN, Jingjing); N1 dJfi SV VITA LIFE SCIENCES CO., LTD.) [CN/CN]; +1 Nl MZX %EX ta(74L0 49 v, Shandong V-V, ) I IR E5N A tEx A,7Y 398 262123 (CN)0 oI: (WANG, Guan); ThPI1tT 5 D%, 10W, Jiangsu 215123 (CN)0 o NA$4ltW* S 9T ll}+t9 555 , Shanghai 201203 (CN)0ot =S' (TOPHARMAN SHANDONG CO., il (SHEN, Jingshan); SI@T $$K9Tll}+ LTD.) [CN/CN]; +1 1 dJ #VX1M MAcR ZYt 555 5, Shanghai 201203 (CN)0 Z 7xJA(LY 49 5, Shandong 262123 (CN)o

(54) Title: HETEROCYCLIC COMPOUNDS, AND PREPARATION METHOD AND USE THEREOF ~=(5 4) ~U$:~T ~~tT~4~f

N R3

R2 R

B D S

(57) Abstract: Provided are heterocyclic compounds represented by formula (I), stereoisomers or pharmaceutically acceptable salts O of said compounds, a pharmaceutical composition of said compounds, and an application of said compounds in the preparation of a drug for the prevention and/or treatment of a central nervous system disease. (57) RH Xf hAY ALI k_- n J- Pi:tt4A _CKM qI-"T nAArv R W O 2 0 15/13 18 5 6 A 1|l IIl l||lIll1|||I||I|||||||||||I|||||I|||II |lllll ||I|||||||||||||||||||||I ||||| (74) 1fW 4h* {iW " Rf SMPR 4k (84) M J(TY hI' A 5*V-#-fT$ fl ttf Ex (KINGSOUND & PARTNERS); +1N LTIj tfE)): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, 7t4Fi 116 VI B 11 , Beijing NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), rX3 100097 (CN)o (AM, AZ, BY, KG, KZ, RU, TJ, TM), Wt )II (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, Fl, FR, GB, GR, (81) 4Hl! (W h ' , HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, NTtP): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, Fl, SN, TD, TG)O GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, *2[$$$ : LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY' iFArtt9tNm 21 (3))o MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW0 DESCRIPTION

HETEROCYCLIC COMPOUNDS, PROCESS FOR PREPARATION OF THE SAME AND USE THEREOF

TECHNICAL FIELD The present invention belongs to the field of medicinal chemistry. More specifically, the present invention provide a heterocyclic compound represented by general formula (1), stereoisomer or pharmaceutically acceptable salt thereof, the producing processes thereof, pharmaceutical compositions and their use in the manufacture of drugs for the treatment of central nervous system diseases. BACKGROUND ART Mental illness is a group of neurological disease mainly manifested in behavior and mental activity disorder, clinically manifested in abnormal mental activity, specifically manifested in disorders in varying degrees in perception, thinking, attention, memory, emotion, behavior, intelligence and consciousness. Due to the complexity of the central nervous system, conventional antipsychotics still have their limitations. For example, the clinical drugs for the treatment of major depressive disorder (MDD) and anxiety have slow onset of action and poor efficacy; existing antipsychotic drugs are mostly ineffective in improving the negative symptoms and cognitive impairment in schizophrenia, and they are usually associated with side effects such as extrapyramidal reactions (EPS) and metabolic disorder. Therefore, there is a need to find new antipsychotics with high efficacy, low side effect, and broad treatment spectrum. Dopamine system is involved in the regulation of many physiological functions such as movement, emotion, reward and cognition. Serotonin (5-FIT) is also involved in the regulation of many physiological functions, such as body temperature regulation, emotional activities, pain, sleep-awakening. Therefore, the therapeutic effects of existing drugs for the treatment of central nervous system disease correlate closely to the regulation of neurotransmitters such as dopamine and 5-HT in the brain.

D2 receptor antagonists are developed as typical antipsychotics and they are also used in the treatment of insomnia; 5-HT2A receptor antagonism can reduce EPS, improve negative symptoms, cognitive impairment, depression, anxiety and insomnia (European Journal of

Pharmacology, 2000, 407: 39-46). However, pure D2 antagonists or D2/5--T2A antagonists still have side effects of varying degrees. 5-HTIA receptor agonists have showed good prospect for the clinical treatment of severe depression, anxiety, depression and improvement of negative symptoms and cognitive function in patients with schizophrenia (CNS Drugs, 2013 Sep, 27: 703-16). For example, 5-HTIA

1 receptor agonist BAY-3702 showed neuroprotective, anxiolytic and antidepressant effects in animal models (European Journal of Pharmacology, 1998, 357: 1-8); gepirone can be used to alleviate specific primary depressive disorder (US4771053), such as severe depression, endogenous depression and atypical depression; buspirone can be used to treat various symptoms

5 associated with attention deficit and hyperactivity disorder (ADHD). A D 2 receptor agonist in combination with a 5-HTIA receptor agonist can be effective in the treatment of ADHD and Parkinson's disease (W0200016777A); ixabepilone can be effective in the treatment of cognitive impairment associated with Alzheimer's disease or Parkinson's disease by improving memory (US5824680). 10 Dopamine receptor partial agonists can improve the positive symptoms, negative symptoms, depression, anxiety and cognitive deficits associated with schizophrenia while rarely causing

increased serum prolactin level as D 2 receptor antagonists, rarely cause weight gain and metabolic

disorders as D2/5-HT 2A receptor antagonists. Generally, they are safe and well tolerated. Thus, a drug has multiple pharmacological effects on DA/5-HT receptors is conducive to 15 better regulation of DA / 5-HT system in the brain so as to treat central nervous system diseases.

The present invention provides a novel class of compounds endowed with D2/5-HTIA/5-HT 2A multireceptor activities that are effective for the treatment of central nervous system disorders, particularly depression, manic-depression, schizophrenia, anxiety, phobias, autism, Alzheimer's disease, bipolar disorder, hysteria, obsessive-compulsive disorder, hyperkinetic syndrome and the 20 like. The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the prior art base or were common general knowledge in the field relevant to the present invention as it existed before the 25 priority date of each claim of this application. Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification (including the claims) they are to be interpreted as specifying the presence of the stated features, integers, steps or components, but not precluding the presence of one or more other features, integers, steps or components, or groups thereof. 30 DISCLOSURE OF THE INVENTION It is an aspect of the present invention to provide a novel class of compounds having serotonin 2A (5-HT2A) receptor antagonism activity and/ or good activity on dopamine D2 receptor and/ or good activity on serotonin 1A (5-HTIA) receptor. An aspect of the present invention is to provide a heterocyclic compound represented by the general formula (1), a stereoisomer thereof or 35 a pharmaceutically acceptable salt thereof. Another aspect of the present invention is to provide a process for preparing a heterocyclic compound represented by the general formula (I), a stereoisomer thereof or a pharmaceutically

2 acceptable salt thereof. A further aspect of the present invention is to provide a heterocyclic compound of the general formula (I), a stereoisomer thereof or a pharmaceutically acceptable salt thereof in the manufacture of drugs for the prevention and/or treatment of central nervous system disease. 5 A further aspect of the present invention is to provide pharmaceutical compositions containing a therapeutically effective amount of the compound of the general formula (I) of the present invention, a stereoisomer thereof or a pharmaceutically acceptable salt thereof A further aspect of the present invention is to provide a heterocyclic compound represented by formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof:

KL

N N)-R3

E R2 R1

D S

10 wherein, A is C, and B and D are each independently C or N;

-- represents a single or double bond; E is CH, N or C; when E is CH or N, the bond connected to E represents a single bond;

15 and when E is C, the bond -- connected to E represents a double bond;

R1 is hydrogen or 1 to 4 substituents each independently selected from the group consisting of halogen, hydroxy, mercapto, oxo(=O), thioxo(=S), C1~C6 alkoxy, halogenated C1-C6 alkoxy, C1-C6 alkylthio, C1-C6 alkyl, halogenated C1-C6 alkyl, nitro, amino, C1~C6 alkyl-substituted amino, cyano, carboxyl, aldehyde group, amino C1~C6 alkyl, hydroxyl C1~C6 alkyl, cyano

20 C1~C6 alkyl, C1~C6 alkanoyl, halogenated C1-C6 alkanoyl, sulfonic group (-SO 2OH),

aminosulfonyl (-SO 2NH 2 ), carbamoyl (-CONH 2), C1~C6 alkyl-substituted carbamoyl, carboxyl C1~C6 alkyl, C1-C6 alkylsulfonyl, halogenated C1-C6 alkylsulfonyl, Cl-C6 alkyl-substituted amino CiC6 alkyl, carbamoyl C1-C6 alkyl and C1-C6 alkyl-substituted carbamoyl C1-C6 alkyl;

25 R2 does not exist, or is 1 to 3 substituents each independently selected from the group consisting of halogen, hydroxy, mercapto, Cl~C6 alkoxy, halogenated C1-C6 alkoxy, Cl-C6 alkylthio, C1-C6 alkyl, halogenated C1-C6 alkyl, nitro, amino, C1-C6 alkyl-substituted amino, cyano, carboxyl, aldehyde group, amino C1~C6 alkyl, hydroxyl C1-C6 alkyl, cyano C1~C6 alkyl,

C1~C6 alkanoyl, halogenated CI-C6 alkanoyl, sulfonic group (-SO 2 OH), aminosulfonyl ( 2a S0 2NH 2 ), carbamoyl (-CONH 2 ), C1-C6 alkyl-substituted carbamoyl, carboxy C1-C6 alkyl, C1~C6 alkylsulfonyl, halogenated C1-C6 alkylsulfonyl, C1-C6 alkyl-substituted amino C1~C6 alkyl, carbamoyl Cl-C6 alkyl and C1-C6 alkyl-substituted carbamoyl C1-C6 alkyl;

R3 is hydrogen or I to 4 substituents each independently selected from the group consisting of 5 hydroxyl and C-C6 alkyl; L does not exist or is C1~C5 alkylene, and when L is C1~C5 alkylene, the alkylene is optionally substituted with one or more substituents selected from the group consisting of hydroxy, C1~C6 alkoxy and oxo (=0); ring G is a heteromonocyclic or heterobicyclic group, wherein said heterobicyclic group is a 10 phenyl-fused heteromonocyclic group, a cyclohydrocarbyl-fused heteromonocyclic group or a heteromonocycle-fused heteromonocyclic group, wherein said heteromonocyclic group contains at least one heteroatom selected from the group consisting of N, S and 0; ring G is connected to L through a carbon atom on ring G; and ring G is optionally substituted with one or more substituents which are identical or different; 15 the substituent on the ring G is selected from the group consisting of halogen, C1 -C6 alkyl, halogenated C1~C6 alkyl, CI-C6 alkoxy, halogenated C1~C6 alkoxy, nitro, cyano, hydroxy, mercapto, amino, C1-C6 alkyl-substituted amino, azido, C1~C6 alkanoyl, halogenated C1~C6 alkanoyl, C2-C6 alkenyl, C2~C6 alkynyl, carboxy C1-C6 alkyl, cyano C1-C6 alkyl, C2~C6

alkenyloxy, C2~C6 alkynyloxy, carbamoyl (-CONH 2), C1~C6 alkyl-substituted carbamoyl,

20 carboxyl, hydroxyl C1~C6 alkyl, oxo (=0), thioxo (=S), aminosulfonyl (-SO 2NH 2 ), C1~C6 alkylthio, C1~C6 alkylsulfonyl, halogenated C1-C6 alkylsulfonyl, sulfonic group (-SO2OH), aldehyde group, amino C1-C6 alkyl, C1~C6 alkyl-substituted amino C1~C6 alkyl, carbamoyl C1-C6 alkyl, C1-C6 alkyl-substituted carbamoyl C1-C6 alkyl, C3-C10 cyclohydrocarbyl, C3-C10 cyclohydrocarbyl C1-C6 alkyl, C3-C10 cyclohydrocarbylformamido, furyl, thienyl, 25 pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, triazolyl, triazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, pyranyl, pyrazinyl, piperazinyl, pyridazinyl, pyridyl, piperidinyl, pyrimidinyl, imidazolyl, C3--C10 cyclohydrocarbyl C1~C6 alkoxy, furyl C1-C6 alkyl, furanyl C1~C6 alkoxy, thienyl C1~C6 alkyl, thienyl Cl~C6 alkoxy, pyrrolyl Cl~C6 alkyl, pyrrolyl C1~C6 alkoxy, pyrrolidinyl C1~C6 alkyl, pyrrolidinyl 30 C1~C6 alkoxy, pyrazolyl C1-C6 alkyl, pyrazolyl C1~C6 alkoxy, triazolyl C1-C6 alkyl, triazolyl C1-C6 alkoxy, thiazolyl C1~C6 alkyl, thiazolyl ClC6 alkoxy, isothiazolyl CI-C6 alkyl, isothiazolyl C1~C6 alkoxy, oxazolyl C1~C6 alkyl, oxazolyl C1-C6 alkoxy, isoxazolyl C1~C6 alkyl, isoxazolyl C1~C6 alkoxy, pyrazinyl C1~C6 alkyl, pyrazinyl C1-C6 alkoxy, pyridazinyl C1~C6 alkyl, pyridazinyl C~-C6 alkoxy, pyridyl Cl~C6 alkyl, pyridyl Cl-C6 alkoxy, pyrimidinyl 35 Cl~C6 alkyl, pyrimidinyl C1~C6 alkoxy, phenyl, phenoxy, phenylsulfonyl, phenyl C1-C6 alkyl, phenyl Cl~C6 alkoxy, phenyl Cl~C6 alkanoyl, and phenyl C1~C6 alkanoyloxy; said C3-C10 cyclohydrocarbyl, C3~C10 cyclohydrocarbyl C1~C6 alkyl, furyl, thienyl, pyrrolyl, pyrrolidinyl, 2b pyrazolyl, pyrazolidinyl, triazolyl, triazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, pyranyl, pyrazinyl, piperazinyl, pyridazinyl, pyridyl, piperidinyl, pyrimidinyl, imidazolyl, C3-C10 cyclohydrocarbyl CI-C6 alkoxy, furyl C1~C6 alkyl, furanyl C1~C6 alkoxy, thienyl C1~C6 alkyl, thienyl C1~C6 alkoxy, 5 pyrrolyl C1-C6 alkyl, pyrrolyl C1~C6 alkoxy, pyrrolidinyl C1~C6 alkyl, pyrrolidinyl C1~C6 alkoxy, pyrazolyl C1-C6 alkyl, pyrazolyl C1-C6 alkoxy, triazolyl C1~C6 alkyl, triazolyl C1-C6 alkoxy, thiazolyl C1-C6 alkyl, thiazolyl C1~C6 alkoxy, isothiazolyl CI-C6 alkyl, isothiazolyl C1~C6 alkoxy, oxazolyl C1-C6 alkyl, oxazolyl C1-C6 alkoxy, isoxazolyl CIC6 alkyl, isoxazolyl Cl~C6 alkoxy, pyrazinyl C1-C6 alkyl, pyrazinyl Cl~C6 alkoxy, pyridazinyl C1~C6 alkyl, 10 pyridazinyl Cl ~C6 alkoxy, pyridyl C1~-C6 alkyl, pyridyl C1 ~C6 alkoxy, pyrimidinyl C 1~ C6 alkyl, pyrimidinyl C1~C6 alkoxy, phenyl, phenoxy, phenylsulfonyl, phenyl C1-C6 alkyl, phenyl C1-C6 alkoxy, phenyl Cl-C6 alkanoyl and phenyl C1~C6 alkanoyloxy are optionally substituted with one or more substituents selected from the group consisting of halogen, C1~-C6 alkyl, halogenated C1-C6 alkyl, CI~C6 alkoxy, C1~C6 alkoxycarbonyl, halogenated C1~C6 alkoxy, nitro, cyano, 15 hydroxy, amino, C1-C6 alkanoyl, halogenated C1-C6 alkanoyl, carbamoyl, and carboxyl; provided that the following compounds are excluded: 1) 1-(2-(4-(2-cyano-7-fluorobenzo[b]thiophen-4-yl)-2-methylpiperazin-1-yl)ethyl)iso chroman-6-carboxamide; and 2) 1-(2-(4-(7-fluorobenzo[b]thiophen-4-yl)-2-methylpiperazin-1-yl)ethyl)isochroman-6 20 carboxamide.

2c SU M MARY OF THE IN MENTION The present invention provides a heterocyclic compound represented by formula (I), a stereoisomer, or a pharmaceutically acceptable salt thereof:

L G

-R 3

E

R2 R1

D S wherein: A, B and D are each independently C or N, and when A is N, D is N simultaneouly; =--represents a single or double bond; E is CH, N or C; when E is CH or N, the bond =--- connected to E represents a single bond; when E is C, the bond =- connected to E represents a double bond; R1 is hydrogen or I to 4 substituents each independently selected from the group comsisting of halogen, hvdroxy, mercapto, oxo(=O), thioxo(=S), C-C6 alkoxy, halogenated C1-C6 alkoxy, Cl~C6 alkylthio, Cl~C6 alkyl, halogenated Cl ~C6 alkyl, nitro, amino, C1-C6 alkyl-substituted amino, cyano, carboxy, aldehyde group, amino C1-C6 alkyl, hydroxyl CI-C6 alkyl, cyano C1-C6 alkyl, C1-C6 alkanoyl, halogenated C1-~C6 alkanoyl, sulfonic group

(-SO 2OH), aminosulfonyl(-SO 2NH 2), carbamoyl(-CONH 2), C~-C6 alkyl-substituted carbamoyl, carboxyl C1-C6 alkyl, C1-C6 alkylsulfonyl, halogenated C1-C6 alkylsulfonyl, C1-C6 alkyl-substituted amino C1-C6 alkyl, carbamoyl C1-C6 alkyl and C1 --C6 alkyl-substituted carbamoyl C 1-C6 alkyl group; preferably, R1 is hydrogen or I to 4 substituents each independently selected from the group consisting of halogen, hydroxy, mercapto, oxo(=O), thioxo(=S), Cl-C4 alkoxy. halogenated C1-C4 alkoxy, Cl~C4 alkylthio, C1-C4 alkyl, halogenated C1-C4 alkyl, nitro, amino, Cl-C4 alkyl-substituted amino, cyano, carboxy, aldehyde group, amino C1-C4 alkyl, hydroxyl C1-~C4 alkyl, cyano C1-~C4 alkyl, C1-C4 alkanoyl, halogenated C1~C4 alkanoyl, sulfonic group(-SO 2OH), aminosulfonyl(-SO 2NH 2), carbamoyl (-CONH 2), C1 --C4 alkyl -substituted carbamoyl, carboxyl C -C4 alkyl, C1~,-C4 alkylsulfonyl, halogenated C -C4 alkylsulfonyl, CI-C4 alkyl-substituted amino C~C4 alkyl, carbamoyl C1~C4 alkyl and CI--C14 alkyl-substituted carbamoyl Ci1~-C4 alkyl group; more Preferably, R, is hydrogen or I to 4 substituents each independently selected from the group consisting of fluorine, chlorine, bromine, hydroxy, mercapto, oxo(=O), thioxo(=S), methoxy, ethoxy, trifluoromethoxv, -SCH3, -SCH2CH 3, methyl, ethyl, propyl, isopropyl, t-butyl, 3 trifluoromethyl, bromomethyl, chloromethyl, nitro, amino, N-methylamino, N-ethylamino, N,

N-dimethylamino, N, N-diethylamino, cyano, carboxyl, aldehyde group, -CFH2 NH2,

-CH 2C H2NH2 , -C1 2OH, -CHH2CHO' -CH 2 CN, -CH 2CH1- 2 C N, formal, acetyl, propionyl, trifluoroacetyl, sulfonic group(-SO2OH), aminosulfonyl (-SO 2 NI- 2), carba moyi, N-methylcarbamol, N, N-dimethyl carbamoyl, N-ethilcarbamoyl, N, N-diethylcarbamoyl,

-CH 2 CO 2 H, -CH 2 CH 2 CO 2 H, -SO 2CH 3, -SO 2 CF3 , -CH 2NH-IMe, -CH 2NMez, -CH2 CONH-12,

-CH 2 CONHMe and -CH 2 CONMe2; R2 does not exist, or is 1 to 3 substituents each independently selected from the group consisting of halogen, hydroxy, mercapto, C1-C6 alkoxy, halogenated C1-C6 alkoxy, CI-C6 alkylthio, C~C6 alkyl, halogenated C-C6 alkyl, nitro, amino, C1~C6 alkyl-substituted amino, cyano, carboxyl, aldehyde group, amino Cl~C6 alkyl, hydroxyl C~C6 alkyl, cyano C-C6 alkyl. C1-C6 alkanoyl, halogenated C -C6 alkanoyl, sulfonic group (-S201H), aminosulfonyl

(-SO2NH 2 ), carbamoyl (-CONI-1 2), Cl~C6 alkyl-substituted carbamoyl, carboxy Cl~C6 alkyl, C1-C6 alkylsulfonyl, halogenated C1-C6 alkylsulfonyl, C1-C6 alkyl-substituted amino C1-C6 alkyl, carbamoyl C1~C6 alkyl and C1~C6 alkyl-substituted carbamoyl C1~C6 alkyl group;

preferably, R2 does not exist, or is I to 3 substituents each independently selected from the group consisting of halogen, hydroxy, mercapto, Ci--C4 alkoxy, halogenated C-C4 al koxy, Cl~C4 alkylthio, Ci-C4 alkyl group, halogenated C1~C4 alkyl, nitro, amino, C1~C4 alkyl-substituted amino, cyano, carboxyl, aldehyde group, amino CI-C4 alkyl, hydroxyl Cl~C4 alkyl, cyano C1-C4 alkyl, C1~C4 alkanoyl. halogenated C1~C4 alkanoyl. sulfonic group(-SO 2OHI), aminosulfonyl(-SO 2NHI2), carbamoyl(-CONH 2), Cl~-C4 alkyl-substituted carbamoyl, carboxy C1-C4 alkyl, C1~C4 alkylsulfonyl, halogenated Cl~C4 alkylsulfonyl, Cl~C4 alkyl-substituted amino C1~C4 alkyl, carbamoyl C1~C4 alkyl and C1~C4 alkyl -substituted carbamoyl C1 ~ C4 alkyl group;

more Preferably, R2 does not exist, or is I to 3 substituents each independently selected from the group consisting of fluorine, chlorine, bromine, hydroxy, mercapto, methoxy, ethoxy, trifluoromethoxy, -SCI-I, -SCH 2 C 3. methyl , ethyl, propyl, isopropyl, t-butyl, trifluoromethyl, bromomethyl, chloromethyl, nitro, amino, N-methyl amino, N-ethyl amino, N, N-dimethylamino,

N, N-diethylamino, cyano, carboxyl, aldehyde group, -CH 2 OH, -CH 2CH 2OH, -CH 2 CN,

-CH 2CH 2CN, formyl, acetyl, propionyl, trifluoroacetyl, sulfonic acid group (-S0 20H), aminosulfonyl (-SO 2NH 2), carbamoyl, N-methylcarbamoyl, N, N-dimethylcarbamoyl,

N-ethylcarbamoyl, N. N-diethyl carbamoyl, -CH 2CO2)H, -CH 2CH 2CO2IH, -SO2 CH,, -SO2 CF3,

-CH 2 NH2, -CH 2CH 2NH2 , -CH2NHMe, -CH 2NMe2, -CH2CONH 2, -CH 2CONHMe and

-CH-2CONM e2:

R3 is hydrogen or I to 4 substituents each independently selected from the group consisting of hydroxyl and C1-C6 alkyl group; preferably R3 is hydrogen or I to 4 substituents

4 each independently selected from the group consisting of hydroxyl and ClC4 alkyl group; more preferably R3 is hydrogen or I to 4 substituents each independently selected from the group consisting of hydroxyl, methyl and ethyl group; L does not exist or is CI-C5 alkylene group(e.g., CI alkylene, C2 alkylene, C3 alkylene, C4 alkylene, C5 alkylene group), and when L is C1-C5 alkylene group, the alkylene group is optionally substituted with one or more substituents selected from the group consisting of hydroxy, CI-C6 alkoxy and oxo(O=) group; Preferably, L does not exist or is C1-C4 alkylene group, and when L is C1-C4 alkylene group, the alkylene group is optionally substituted with one or more substituents selected from the group consisting of hydroxy, CI --C6 alkoxy and oxo(O:) group: ring G is a heteromonocyclic or heterobicyclic group, said heterobicyclic group is a phenyl-fused heteromonocyclic group, a cyclohydrocarbyl-fused heteromonocyclic group or a heteromonocycle-fused heteromonocyclic group, wherein said heteromonocyclic group contains at least one heteroatom selected from the group consisting of N, S and 0; preferably ring G is a 3 to 10-membered heteromonocyclic group, a phenyl-fused 3 to 10-membered heteromonocyclic group, a C3--CIO cyclohydrocarbyl-fused 3 to 10-membered heteromonocyclic group or 3 to 10-membered heteromonocycle-fused 3 to 10-membered heteromonocyclic group; more preferably, ring G is a 5 to 7-membered heteromonocyclic group, a phenyl-fused 5 to 7-membered heteromonocyclic group, a C5--C7 cyclohydrocarbyl-fused 5 to 7-membered heteromonocyclic group or a 5 to 7-membered heteromonocycle-fused 5 to 7-membered heteromonocyclic group; more preferably, ring G is a heterocyclic group selected from the group consisting of furyl, dihydrofuranyl, tetrahydrofuranyl, thienyl, dihydrothienyl, tetrahydrothienyl, pyrrolyl, dihydro-pyrrolyl, pyrrolidinyl, pyrazolyl, diliydro-pyrazolyl, pyrazolidinyl, triazolyl, dihydro-triazole, triazolidinyl, thiazolyl, dihydro-thiazolyl, thiazolidinyl, isothiazolyl, dihydro-isothiazolyl, isothiazolidinyl, oxazolyl, dihydro-oxazolyl, oxazolidinyl, isoxazolyl, dihvdro-isoxazolyl, isoxazolidinyl, pyranyl, dihydropyranyl, tetrahydropyranyl, pyrazinyl, di hydropyrazinyl, tetrahydro-pyrazinyl, piperazinyl, pyridazinyl, dihydropyridazinyl.

tetrahydro-pyridazinyl, N H H N H H N N N H

HN N HN N HN NH NN N N N KN) N N H N N H H H H H

5 HN N HN HN HN HN HN HN

O N H H H H H HN H' NNN N N NN (N )

H, N , H O N NN N- HN HN- N- HN H H

HN HN O HN N N ONN O NH O NH

H/H- H ND H H- 1- N~ 0- H1H HHN

N N KN j N N N HN NN N 0NH N - N0 ' NN N)N (N NH (-N N N N) N N H H N H H N N N N N N N H NH H IN H I H H H N (N NH H

N N

N

)0\ ~o 0 -O-- 0 0n oj H H ' N N KNJ, N INH N

N>N > N ~ N ! I H N H N H NH

H H H ' N - N '-~~N, C N -N

-S ~ ~ ~1N1 , S H .> S >

H H

NI NH N UN -" 0 0O N H N H N

-NN -N H i n ~

CN NQ Nc, Nc H N

H H H H N N - H H H NN NNHN

NN) N N 145 N N H H H H N H H

N NH N ~ NH;N ~ NH IN>N NN C N' I )I/ H H NN H00 H H ',N--N 0' Z'

N -,,H

0 S H HH zNN 1, -NN N N ~J N' SN, N HH~ ~ H s I H N N~ 0 N NH

N H N N- .NH 0.

HN 1 N NN HN N NN N N N , H NH

N . N:z N NH )

H HH NH N H ~ NN NH NN

-/ N N N

N~~N N N:0; IN/I H H H N N N N

- N \I H NH H . H N />

7N N N NNN NNH H H H S O N N H

HH SNHN N Ns H S 0 NNC

NMN N N H~NNKNINH N N N NN M-N,

N N H N N N N

NH NH N N N NH N

N NN N N

C-,NH N NHNI:,HNH ( N) SNOH HN HNH N H N N N HN NH H N N

H N N H NN

NH N N ~ NI N NH~ N~N C- N NN NNNN NN H H . H H H HH

HH N NH 0 N N N N N N N

H H H HN /NN HN N

N N H HN 2<) N N\., HN N HNC

H H H

H: 2 N N /N_ N N ---N I--- N- H S SN 0

N HA

-and Ring G is connected to L through a carbon atom on G ring rather than other atorns; and ring G is optionally substituted with one or more substituents which are identical or different; the substituent on the ring G is selected from the group consisting of halogen, C1-C6 alkyl, halogenated C1~C6 alkyl, C1~C6 alkoxy, halogenated C1-C6 alkoxy, nitro, cyano, hydroxy,

8 mercapto, amino, C1-C6 alkyl-substituted amino, azido, C1-C6 alkanoyl, halogenated Ci-C6 alkanoyl, C2-C6 alkenyl, C2C6 alkynyl, carboxy C1-C6 alkyl, cyano Ci~C6 alkyl, C2~C6 alkenvioxy, carboxy C1~C6 alkyl, cyano C1C6 alkyl, C2C6 alkenyloxy, C2-C6 alkynyloxy, carbamoyl(-CONH:), C1-C6 alkyl-substituted carbanoyl, carboxyl, hydroxyl Cl~C6 alkyl, oxo(O), thioxo(:S), sulfonamido, C1~C6 alkylthio, Cl~C6 alkylsulfonyl, halogenated CI-C6 alkylsulfonyl, sulfonic group(-SO 2OH), aldehyde group, amino C1~C6 alkyl, C1~C6 alkyl-substituted amino C1-C6 alkyl, carbamoyl C1~C6 alkyl, C1~C6 alkyl -substituted carbamoyl C1~C6 alkyl, C3~C10 cyclohydrocarbyl, C3-C10 cyclohydrocarbyl CI~C6 alkyl, C3~-C10 cyclohydrocarbylformamido, furyl, thienyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, triazolyl, triazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, pyranyl, pyrazinyl, piperazinyl, pyridazinyl, pyridyl, piperidinyl, pyiirnidinyl, imidazolyl, C3~-C10 cyclohydrocarbyl Cl~C6 alkoxy, furyl C1-C6 alkyl, furanyl C1~C6 alkoxy, thienyl CI-C6 alkyl, thienyl C1~C6 alkoxy, pyrrolyl C1~C6 alkyl, pyrrolyl C1~C6 alkoxy, pyrrolidinyl CI-C6 alkyl, pyrrolidinyl C1~C6 alkoxy, pyrazolyl C1~C6 alkyl, pyrazolyl C1-C6 alkoxy, triazolyl C1-C6 alkyl, triazolyl C1~ C6 alkoxy, thiazolyl C1~-C6 alkyl, thiazolyl C1~C6 alkoxy, isothiazolyl C1~C6 alkyl, isothiazolyl C1-C6 alkoxy, oxazolyl C1-C6 alkyl, oxazolyl Ci-C6 alkoxy, isoxazolyl C1~C6 alkyl, isoxazolyl (l--C16 alkoxy, pyrazinyl Ci~C6 alkyl, pyrazinyl Cl~C6 alkoxy, pyridazinyl CI--C6 alkyl, pyridazinyl C1-C6 alkoxy, pyridyl C1-C6 alkyl, pyridyl C1~(C.6 alkoxy, pyrimidinyl C~C6 alkyl, pyrimidinyl C1~(C.6 alkoxy, phenyl, phenoxy, phenylsulfonyl, phenyl Cl~C6 alkyl, phenyl Cl~C6 alkoxy, phenyl C1~C6 alkanoyl and phenyl CI~-C6 alkanoyloxy group; said C3C10 cyclohydrocarbyl, C3C10 cyclohydrocarbyl C1-~C6 alkyl group, furyl, thienyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, triazolyl, triazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, pyranyl, pyrazinyl, piperazinyl, pyridazinyl, pyridyl, piperidinyl, pyrimidinyl, imidazolyl, C3~C10 cyclohydrocarbyl C1-C6 alkoxy, furyl C1~C6 alkyl, furanyl CI-C6 alkoxy, thienyl

Cl~C6 alkyl, thienyl C1~C6 alkoxy, pyrrolyl Ci-C6 alkyl, pyrrolyl Cl~C6 alkoxy, pyrrolidinyl C1~C6 alkyl, pyrrolidinyl C1~C6 alkoxy, pyrazolyl C1~C6 alkyl, pyrazolyl CI-C6 alkoxy, triazolyl CI-C6 alkyl, triazolyl CI-C6 alkoxy, thiazolyl C1~C6 alkyl, thiazolyl

CI--C16 alkoxy, isothiazolyl C1~C6 alkyl, isothiazolyl C1~C6 alkoxy, oxazolyl C1~-C6 alkyl, oxazolyl C1~C6 alkoxy, isoxazolyl C1~C6 alkyl, isoxazolyl C1-C6 alkoxy, pyrazinyl C1~C6 alkyl, pyrazinyl C1--C6 alkoxy, pyridazinyl C1~-C6 alkyl, pyridazinyl C1-C6 alkoxy, pyridyl

C1--C6 alkyl, pyridyl C1~C6 alkoxy, pyrimidinyl C1-C6 alkyl, pyrimidinyl C1-C6 alkoxy, phenyl, phenoxy, phenisulfonyl, phenyl Cl~C6 alkyl, phenyl Cl~C6 alkoxy, phenyl C1~C6 alkanoyl or phenyl C 1-C6 alkanoyloxy group is optionally substituted with one or more

9 substituents selected from the group consisting of halogen, C1-C6 alkyl, halogenated C1--C6 alkyl. Cl~C6 alkoxy, CI-C6 alkoxycarbonyl , halogenated CI-C6 alkoxy, nitro, cyano, hydroxy, amino, CI-C6 alkanoyl, halogenated C1~C6 alkanoyl, carbamoyl and carboxyl group;

preferably, the substituent on the ring G is selected from the group consisting of halogen,

C1-C4 alkyl, halogenated Cl~C4 alkyl, C1~C4 alkoxy, halogenated CI-C4 alkoxy, nitro, cyano, hydroxy, mercapto, amino, C1~C4 alkyl-substituted amino, azido, C1~C4 alkanoyl, halogenated Cl~C4 alkanoyl., C2~-C4 alkenyl, C2~C4 alkynyl, carboxy C1~C4 alkyl, cyano

C1-C4 alkyl, C2~C4 alkenyloxy, C2~C4 alkynyloxy, carbamoyl(-CONH 2), C1 C4 al kyl -substituted carbarnoyl, carboxyl, hydroxyl C1--C4 alkyl group, oxo(O), thioxo(=S), sulfonamido, C1~C4 alkylthio, C1-~C4 alkylsulfonyl, halogenated C1-C4 alkylsulfonyl, sulfonic group (-S0 20H), aldehyde group, amino C1-C4 alkyl, C1~-C4 alkyl-substituted amino

Cl~C4 alkyl, carbamoyl Cl~C4 alkyl, C1-C4 alkyl-substituted carbamoyl Cl~C4 alkyl, C3~C7 cyclohydrocarbyl, C3~C7 cyclohydrocarbyl C1-C4 alkyl, C3~C7 cyclohydrocarbyl forrnamido, furyl, thienyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, triazolyl, triazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, pyranyl, pyrazinyl, piperazinyl, pyridazinyl, pyridyl, piperidinyl, pyrimidinyl, imidazolyl, C3~C7 cyclohydrocarbyl C1~C4 alkoxy, furyl C1~-C4 alkyl, furanyl C 1~(C4 alkoxy, thienyl C1~C4 alkyl, thienyl C1-C4 alkoxy, pyrrolyl C1~C4 alkyl, pyrrolyl C1~C4 alkoxy, pyrrolidinyl C1~ -C4 alkyl, pyrrolidinyl C1~--C4 alkoxy, pyrazolyl C1~ -C4 alkyl, pyrazolyl

CI-C4 alkoxy, triazolyl C1~C6 alkyl, triazolyl C1~C4 alkoxy, thiazolyl Cl~C4 alkyl, thiazolyl

C1-C4 alkoxy, isothiazolyl C1~C6 alkyl, isothiazolyl C1~C4 alkoxy, oxazolyl C1~C4 alkyl, oxazolyl Cl--C4 alkoxy, isoxazolyl C1~C4 alkyl, isoxazolyl C~C4 alkoxy, pyrazinyl CI- C4 alkyl, pyrazinyl CI-C4 alkoxy, pyridazinyl Cl~C4 alkyl, pyridazinyl Ci-C4 alkoxy, pyridyl

Cl~C4 alkyl, pyridyl C1-C4 alkoxy, pyrimidinyl C1~C4 alkyl, pyrimidinyl C1~ C4 alkoxy, phenyl, phenoxy, phenylsulfonyl, phenyl C1~-C4 alkyl, phenyl C1~-C4 alkoxy, phenyl Ci-C4 alkanoyl and phenyl Ci-C4 alkanoyloxy group; said C3~C7 cyclohydrocarbyl, C3~C7 cyclohydrocarbyl C1-~C4 alkyl, furyl, thienyl, pyrrolyl, pyrrolidinyl, pyrazolvl, pyrazolidinyl, triazolyl, triazolidinyl, thiazolyl, thiazolidiny], isothiazolyl, isothiazolidinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, pyranyl, pyrazinyl, piperazinyl, pyridazinyl, pyridyl, piperidinyl, pyrimidinyl, imidazolyl, C3~C7 cyclohydrocarbyl Cl~C4 alkoxy group, furyl Cl1~-C4 alkyl, furanyl Ci-C4 alkoxy, thienyl C1

10 C4 alkyl, thienyl CI~C4 alkoxy, pyrrolyl C1~C4 alkyl, pyrrolyl C1~C4 alkoxy, pyrrolidinyl CI-C4 alkyl, pyrrolidinyl C1~C4 alkoxy, pyrazolyl C1~C4 alkyl, pyrazolyl C1-C4 alkoxy, triazolyl C1~-C4 alkyl, triazolyl C1~-C4 alkoxy, thiazolyl C1~C4 alkyl, thiazolyl C1-C4 alkoxy, isothiazolyl C1~C4 alkyl, isothiazolyl C1-C4, oxazolyl C1~C4 alkyl, oxazolyl C1~C4 alkoxy, isoxazolyl C1-C4 alkyl, isoxazolyl C(~4 alkoxy, pyrazinyl C1-(4 alkyl, pyrazinyl C1-C4 alkoxy, pyridazinyl C1-C4 alkyl, pyridazinyl C1 ~C4 alkoxy, pyridyl C1~C4 alkyl, pyridyl CI-C4 alkoxy, pyrimidinyl C1-C4 alkyl, pyrinidinyl C1-C4 alkoxy, phenyl., phenoxy, phenylsulfonyl, phenyl C1~-C4 alkyl, phenyl C1~C4 alkoxy, phenyl C1-C4 alkanoyl or phenyl Cl~C4 alkanoyloxy group is optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C4 alkyl, halogenated C1~C4 alkyl, C1~C4 alkoxy, C1-C4 alkoxycarbonyl, halogenated C1~C4 alkoxy, nitro, cyano, hydroxy, amino, C1-C4 alkanoyl, halogenated Cl-C4 alkanoyl, carbamoyl and carboxyl group; more preferably, the substituent on the ring G is selected from the group consisting of fluorine, chlorine, bromine, methyl, ethyl, propyl, isopropyl, t-butyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, nitro, cyano, hydroxy, mercapto, amino, N-methylamino, N-ethylamino, N, N-dimethylamino, N, N-diethylamino, azido, formyl, acetyl, propionyl, trifluoroacetyl, -CH-12C 2H, -CH2CH 2 CO2H, -CH2CN -CH2CH 2 CN, carbamoyl, N-methylcarbamoyl, N, N-dimethylcarbarnoyi, N-ethylcarbamoyl, N, N-diethylcarbamoyl, carboxyl, -CH 2OH, -CH 2 CH-2 0H, oxo(:=0), thio(=S). aminosulfonyl group(-SO 2 NI-1 2 ), -SC- 3 ,

-SCH 2 C3I, -SOICH3, -SO2CF 3, sulfonic acid group (-S02011), aldehyde group, -CH 2NH 2 ,

-CH 2CH2NH2, -CH2-NMe, -CH 2NMez, -CH 2 NHEt, -CH 2 NEt2 , -CH 2CH 2NHMe,

-CH 2CH2NHEt, -CH2CH 2NMe 2, -CH 2CH2NEt 2, -CH2CONH2 , -CH 2CONHIMe, -CH2CONMe 2,

-CH 2CONHEt, -CH 2CONEt 2, -CH 2CH 2CONH2, -CH2CH2ICONHMe, -CH 2 CIH2CONMe 2,

-CH2CH2CONHEt, -CH2CH 2CONEt2, phenyl, phenoxy, phenylsulfonyl. -CHIPh -CH-CH2IPh,

-OCH 2Ph, -O CH2 CH2 Ph, -COICPh, -COCI-Ph and -CH2Ph(OMe) 2 : provided that the following compounds are excluded:

1)1- 2-(4-(2-cyano-7-fluorobenzo[b]thiophen-4-yl)-2-m ethylpiperazin-I -yl)ethyl)isochroman-6 -carboxamide; 2)1-(2-(4-(7-fluorobenzo[b]thiophen-4-yl)-2-methylpiperazin-1-yl)ethyl)isochroman-6-carboxa mide: 3) 6-ethyl -4-(4-(2-(thiophen-2-yl )ethvl)piperazin- I -yl)thieno[2, 3 -d]pyri midine;

4)6-(2-(4-(5-methylthieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)ethyl)-2H-benzo[b][1,4]oxazin

3(4H)-one: 5)5-(3-(4-(6-ethylthieno[2, 3-d]pyrimi din-4-vl)piperazin-1-yl)propyl)-3-(thiophen-2-yl)-I ,2,4-o xadiazole;

11 6)5-(3-(4-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)piperazin- I-yl)propyl)-3-(p-tolyl)-1,2,4-oxa diazole.

A

In a preferred embodiment, D S in the heterocyclic compound of the

formula (I) of the present invention is selected from the group consisting of S

-~' S N N ~ NxN S N N and N Preferably,

A' B S D S represents .

In a preferred embodiment the heterocyclic compound of the formula (I) of the present invention is represented by the compounds selected from the following: L L 0G L L

N N N N R3 -R3 RR-R3 N N

2R R R2- R2 S S S S (1-a) (1-b) ( - )(1-d)

N N N )N-R 3 R, R -R 3 NN

R 2R

R2- R2-- R2R N N N N S S S S (I-e) (1-f ) ( -g) (1-h)

12 L GL L G

N N NN

-R3 -N R -3 -R 3 N N

R2- R2- R2- R2NS N S N S N S N S (1-k)( -)

LL G L G L-4cG)

N N N N

R3 -R3 -R 3 N -R 3

R1 R, R1 R1 N R2 R2 R R2- N S S S S ( I-n )(1-n ) (I-o0) ( -p )

N N N -R 3 -R 3 -R 3

R1 R1 R1

R2T R2-- 2 S N S N S (I-q) (I-r) and (I-s)

more preferably, the heterocyclic compound of the formula (1) of the present invention is represented by a compound selected from the following:

13 L G L

N .N

-R3 ( -R 3 N N

S S F (a1) an)d

wherein, RI, R2, R3, L and ring G are defined and preferred as hereinbefore. Among the heterocyclic compound of general formula (I), stereoisomers or pharmaceutically acceptable salt thereof, most preferable compounds include a compound or a pharmaceutically acceptable salt thereof selected from: (1) 6-chloro-5-(2-(4-(2,3-dihydrobenzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)indolin-2-one; (2) 3-(2-(4-(2,3 -dihydrobenzo[b]thiophen-4-vl)piperazin-1I -yl)ethyl)-9-hydroxy-2-methyl-6,7,8, 9-tetrahydro-41H-pyrido[1,2-a]pyrimidin-4-one; (3) 3-(2-(4-(benzo[b]thiophen-4-vl)piperazin-1-y 1l)ethlv)-2-methyl-6,7,8,9-tetrahydro-4H-pyri d o[ 1,2-a]pyrimidin-4-one; (4) 3 -(2-(4-(benzo[b]thi ophen-4-yl)piperazin- 1-yl)ethyl)-9-hydroxy-2-m ethyl-6,7,8, 9-tetrahydr o-4H-pyrido[1,2-a]pyrimidin-4-one; (4a)(+t )-3-(2-(4-(benzo[b]thiophen-4-vl)piperazin-1-yl1)ethlv)-9-hydroxy-2-methlv-6,7,8,9-tetrah ydro-4H-py rido[1, 2-a]pyrimidin-4-one; (4b)(-)-3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-vl)ethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrah ydro-4H-pyrido[ 1,2-a]pyrimidin-4-one; (5) 3 -(2-(4-(benzo[b]thi ophen-4-yl)piperazin- 1-yl)ethyl)-2-methyl-7,8-di hydro-4H-pyrido[ 1,2-a ]pyrimidine-4,9(61)-dione; (6) 3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-9-hydroxy-2,9-dimethyl-6,7, 8,9-tetrah ydro-4H-pyrido[ I ,2-a]pyrimi din -4-one; (7) 3 -(2-4-(benzo[b]thiophen-4-vl)piperazin-1-yl)ethlv)-9-fluoro-2-methyl- 6 ,7 ,8,9-tetrahydro 4H-pyrido[ 1,2-a]pyrimidin-4-one; (8) 5-('2-(4-(benzo[b]thiophen-4-yI)piperazin- I -yl)ethyl)indolin-2-one; (9) 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin- -y)ethlv)quinolin-2(l1 1)-one; (10)7-(5-(4-(benzo[b]thiophen-4-vl)piperazin-1-yl)pentyl)-3,4-dihydroquinolin-2(111)-one; (11)7-(5-(4-(tbenzo[b]thiophen-4-yl)piperazin-1-vl)pentyl)quinolin-2(IH)-one; (12) 7-(5-(4-(2-chlorobenzo[b]thiophen-4-yl)piperazin-1-yl)pentyl)quinolin-2(1H)-one; 14 (I13))7-(5-(4-(2-fluorobenzo[b]thi ophien-4-vi)piperazin- I -yI)pentvI)quinoIin-2( 11-1)-one; (14')7-(5-('4-(benzorb]thiophen-4-vl)-5,6-dihvdrop 'ridin- 1(2!H)-'I )pentyl)qu-inolin-2( 111)-one; (15) 5-(2-(4-(benzo[b]thiophen-4-yi)piperazin- I -v1)eth '1)-6-chloroind olin-2-one; (16)3 -(2-(4-(benzo[b]thiophen-4-yi)piperazini- I -vi)ethyl )-2 -myethyi-6.7-dihydro-41-1-pyri do[ 1,2 a] pyrirnidin-4-one; (1 7)3 -(2--(44btenizo[b~thiophen-4-'i )piperazin- I-vl)ethy'-9-(b enzyl oxy)-2-m ethyl -4H-pyfrido[ 1, 2-a]pynimidin-4-one, (1 8)3 -(2-(4-4benzo[b] thi ophen-4-vi)piperazin- I-V 1 )ethyi)-9-hvdr-oxv-2-rneth~v-41-I-pyr-ido[l,'2-a ]pyriidin-4-one; (19) 7-(2/--( 4-(benzorb]thiophen-4-vl)piperazin- I1-y'1)ethvl)-3 ,4-dihvdroquinolin-2( 111)-one; (20) 9-h 'droxy-2-rnethyl-3 -(2-(4-(thienor2,3 -dipyrimi lin-4- '1)piperazin- I -vl)ethyl)-6,,8,9-tetr ahydio-41-1-pyrido[ I ,2--a]pyrimidin-4-one, (21) 2metyl1-3 -(2 -(4-(thien o[2,3 -d] pyri mi di n-4-yi) piperazi n- I -y I)ethyl)-6,7,8,9-tetrahydio-4[I pyrido[lI,2'-a]pyrirnidi n-4-onie; (22:'') 7-(4-(4-(benzorb]thiophen-4.-vi)piperazin-1I-yi)bLutyi)-3 ,4-dihvdroquinolin-2( 11)-one; (2/3) 7-(2-(4-4benzo[b] thiiopheni-4-vi)piper-azin- i-V1 )ethyl)-6-chloro-3 ,4-dihydroquiniol in-2L(11-1) onle; (24')6-(5 -( 4-(benzorb]thiophen-4-vl)piperazin- 1-y'1)pentyl)-2-rnethvlquinazol in-4(3)H)-one;, (25) 7-(2-(4.-(-, 3-dihvdrobenzorb]thiophen-4 -yl)piperazin-lI-vi)ethvl)quinolin-2(11)-one; (' 6) 5-(2L-(4-(benzo[b]thiophen-4-vi)piperazini-I -vi)ethyi)-4-m-rethyithii z ole;, (27-)5-(2-(4-(benzo[b]thi ophien-4-vi)piperazin-1I-yi)ethyl)-l 111-benizol-d-itni dazoi-2'(311)-one; (28)3 -(2--(44btenizo[b~thiophen-4-'I )piperazin-l1-vl)ethy ')-9,9-difluoro-2l-rnethyl-6,7, 8,9-tetrahy7 dro-411-pyrido[ I ,2-a]pyrimnidin-4-one; (29) 6-(2-(4-4benzo[b] thi ophen-4-vi)piperazin- I-v 1 )ethyl)benzo[d]thiazoi-2(3 11)-one; (3 0) 6-(2?-(4-(tb enzo[b]thiophen-4-yi)piperazin- I -yi)ethyl )-2f-I-benzolb] [,4]oxazin-3 (4[-10-one, (3 1') 6- /(2-4-(benzorb]thiophen-4-vl)piperazin- I1-yI1)ethvl)-211-benzo[b] [ 1,4]thiazin-3 (411)-one; (32) "-(2-(4--(thieno[2, 3 -d]pyrirnidin-4l-yl)piperazin- I -vi)ethvl)quinolIn-2( 11)-one; (3)3) 7-(4-(4-(benzo[b]thiophen-4-vi)piperazini- -vi)buitv i)quiioii-(111)-onle; (34) 6-(5 -( 4-(benzo[b]thi ophien-4-vi)pi perazin -1 -yI)pentyi )quin azoli n-4(31-L)-onie, (315)2-(2--(44btenizo[b~thiophen-4-'i )piperazin-l1-vl)ethy 'quinazolin-4(311)-one; (3 6)3 -(2/'-(4-(benzorb]thiophen-4.-yi)piperI din- I -yl)ethyi)-9-hydroxy-2-methyl-6, 7,,8_9-tetrah 'dr o-4f--pyrido[ 1,2-a]pyrimidini-4-one;. (3)7) '-('-(4-(tbenizo[b]thiophen-4-yi)piperidini-lI-yl)ethivi)-6-chllioinidoiin-2-one

15 (3 8)4-(2?-(4-(tbenzo[b]thiophen-4-yl)piperazin- I -vi)ethyl )indolin-2-one, (3 9' 6-(2/--( 4-(benzorb]thiophen-4-vl)piperazin- I-yl )ethvl)indolin-2-one, (40)" -(2-{4-(benzo[b]thiophen-4-yi)piperazin- I -yl)ethyl)-6-chloroquinolin-2( IH1)-one; (41) 9-hydroxy-2-tn ethyi-3 -(2-(4-(thi eno[2,3 -c]pyri din-4- I )piperazin- I -yi)ethyi)-6,7, 8.9-tetrah

Ydro-4H4-pyrido[ I , -]py ritni din -4-one, (42) 6-chloro-5 -(2'-( 4-(thieno[2',3-) -c]pyridin-4-yl)piperazin- 1-yl'ethvl)indolin-2-one; (43) 7-(2'-(4-(thieno[2,3 -clpyridin-4-vi)piperazin- I -yl)ethyi)qujinoiin-2(iH)-one; (44)' 7-(3 -(4-(benzo[b] thi ophen-4-vi)piperazin- I-v 1 )propyi)quiioii-(111)-onie; (45) 7-(3 -(4-(tbenzo[b]thiophen-4-yI)piperazin- I -vi)propy[)-3 ,4-diliydroquinioin-2?( I 14)i-one, (46')3-(2 "--( 4-(benzorb]thiophen-4-vl)piperazin- l-yI )ethvl)- IH1-indole; (47) C-(2-(4-(benzo[b]thiophen-4-yi)piperazin-lI-vl)ethy'1)-3 ,4-dihydroquinolin-2.( 11)-one; (48) 5-(3 -(4-(benzo[b]thioplien-4-vl)piperazini-1-vi)propyi)indoiin-2-one; (49) 7-(2- 4-(benzo[b]thi ophien-4-vi)piperazin-1I-yi)ethyl)-4,5-dihyvdro- 1H-benzo[blazepin-2(3[1 )-one; (50)3 -(2'-(4-(benzorb]thiophen-I-y7I)pI perazin- I -yi)ethyl1)-2 -methyl-/l11-pyri do[ 1,2-a ]pyri mi din 4-one;

(51) 6-('-(4-(tbenzo[b]thiophen-4-yi)piperazin- I-vi)ethyl )-3 -inethyv -3,A-dihydroquinazolini-2(I 111 )-one, (52)3 -(2-{4-(benzo[b]thiophen-4-yi)piperazin- I-v71)eth '1)-9-chloro-.-rnethyi-6,7, 8,9-tetrahy7dro

41-1-pyri do[ 1I, -']pyrimi din -4-one; (53) 5-(2-(4-(benzo[b]thi ophien-4-vi)piperazin- I -yl)ethyl)indoiine-2-thi one, (54) 7-(-{4-(tbenizo[b]thiophen-4-'i )piperazin-l1-vl)ethyi'quinoline-2(1 H)-thione; (5 5)2-(2'-(4-(benzorb]thiophen-4.-yi)piperazin-1I-yi)ethyl)-5,6-diethyipyrirnidin-4(3H)-one (5-6) 2--(2-(4-(benzo[b] thiiopheni-4-vi)piper-azin- i-v1 )ethyl)pyrirniidi n-4(3H-)-one (57) 7-('?-(4-(2-fluorobenzo[b]thi ophien-4-vi)piperazin-1I-yl)ethyl)quiniolini-2( 1-11)-onie; (5 8')2!-('4-(benzorb]thiophen-4-y1I)piperazini-I-yI')methyl)-1 H-benzord]irnidazole;, (59) C-(2-(4-('benzo[b]thiophen-4-yi)piperazin- I-v71)eth '1)benzord]thiazoie; 1 (60) 7-(2L-(4-(2-tlu orobenzo[b]tliiopheni-4-vi)piper-azin - i-v )ethyl)benizo[d]thiazoi-2-arnine; (61) N-(7,-(2L-(4-(2-tliuorobenizo[b] thioplhen-4-yl)piper-azin- i-v1 )etiiyi)benzo[d]thiazol -2-yl)aceta mide, (62L)5 -(2-(4-(2-flu orobenzo[b]thiophen-4-yi)piperazin-lI-vl)eth '1)benzord]thiazoi-2.-amine, (63) N-(5 -(2--(4-(2-tl uorobenzio[b]thioplhen-4-yi)piper-azin-l1-vi)ethyi)benzo[d]thiazoi-2.-yi)aceta tni de,

16 (64) 7-(2-{4-(2-fluorobenzo[b]thi ophien-4-vi)piperazin- I -yi)ethyl)-3 ,4-dilhvdroqi inolin-2( I FlI)-o ne; (65) C-(2-(4-(2--fluorobenzorb]thiophen-4-y I)piperazin- I -yi)ethyl)-3,/,4-dihydro quinoiin-2( iH)-o ne, (66) 6-(2-(4-(benzo[b]thi ophien-4-vi)piperazin- I -yl)ethyl)-7 -fluoro-2H-benzo[b] [I ,4]oxazin-3 (4 H'.)-one; (67) 7-(2/'-(4-(3 )-methyibenzo[b]thiophen-4-yl)piperazin-lI-vl)ethyl)-3 ,4-dihydroquinolin-2:( I J)-o no;: (68) 6-('-(4-(tbenzo[b]thiophen-4-yi)piperazin- I -yi)ethyl )benzo[d]oxazol -231]1)-one; (69')4-('(4-(benzorbjthiophen-4-y1I)piperazini-lI-vi .)methyl)quinolin-2-(IH1)-one; (7.0)3 -(4 -{4-(benzo[b]thiophen-4-yi)piperazin- I -vl)butv7l)- I H-indole-5 -carbonitrile, (71) 7-(5 -(4-(6-tlu orobenzo[b] thi ophen-4-vi)piperazin- I -7I )pentyl)quin olini-(11-1)-one; (72) 6-(4-(4-(benzo[b]thi ophien-4-vi)piperazin- I -yi)bujtyl)-8-tlujoro-211I--benzo[b] [I ,4]oxazi n-3 (4 11)-one; (73) 1-('benzo[b]thiophen-4-yi)-4-((2 ,3Z-dilhydrobenzo[b] rIA] ioxin-2-yl)rnethyl)piperazine; (74) 6-(4-(4-(2L-fluor-obenzo[b]thiophen-4-y7i)piperazini-I-vi)btiy)-3 ,4-dihidroquinoiin-2(l1 --i)-o lie; (75'.)2-(2/-(4-(benzorb]thiophen-4-vl)piperazin- I-yi )ethvl)- I i-benzo[d]imi dazole; (716)N-(6-(2-(4-(2 -fluorobenzo[b]thiophen-4- '1)piperazin-l-I-l)ethyl)benzord]thiazol-2:-vl)aceta mide; (77,) 5-(2-( ,4-(2-flujorobenizo[b]thiophen-4-yi)piperazin- I-vi)ethyl )- If-I-benzold]irniidazol -243-1) one: (78) 6-(2/--(4-(6-tlu orobenzo[b]thiophen-4-yi)piperazin-lI-yl1)eth '1)-211-benzo[b][r1,4] oxazin-3 (4 1-1)-one; (79,) '--(4-(2-fluorobenzo[b]thi ophien-4-vi)piperazin-1I-yi)ethyl)inidoiin-2L-one; (80')6-(2/--( 4-(benzorb]thiophen-4-vl)piperazin- I-yi )ethvl)-2'-rnethvlquinazolini-4( 3H)-one; (81) 7-(2-(4-(benzo[b]thiophen-4-yi)piperazin-lI-yl)eth '1)- 1,1-dioxi Ie-3 ,4-dihv iro-211-benzore] [I thiazinen; (82) 5 -(2-(4-(b enzo [b ]thi oph en-4-yl) piperi di n- I -vi)ethylhi ndol ill-2-one, (83-) 7-(-{44btenzo[b]thiophen-4-yi )piperidini- I-yI )ethvl)-3 ,4-dihydroquinolini-2(I H)-one (84)5 -(2/--(4-(6-flu orobenzo[b]thiophen-4-yi)piperazin-lI-yl1)eth '1)in Ioiin-2-one; (85) 7-(2-(4-(6-fluor-obenzo[b]tliioplien-4-y7i)piperazi n-i -vi)ethyi)-3 ,4-dihy7droquinioiin-2(1iH)-o tie;

17 (86) 6-('?-(4-(tbenizo[b]thiophen-4-yi)piperazin- I -vi)ethyl )- I -Inethyl- I [-1-benzo[dlimi dazo-2( 3 H )-one, (87) 5-(2-(4-(benzo[b]thiophen-4-yi)piperazin- I -y1)eth '1)- 1,3 -dimethyl- IH-benzord]imidazol-2( 31-1)-onie; (88) 5-(2-(4-(benzo[b]thi oplhen-4-vi)piperazin-1I-yi)ethyl)- 1-methyvl- I H_-benzo[d]imnidazol-2(3 )-one; (89) 6-(2'-(4-(2-methox 'benzorb]thiophen-4.-yl)piperazin-1I-y1)ethyl)-3 ,4-dihydroqLuinolin-2( 11) -one; (90). -(2?-(4-(6-fluorobenzo[b]thi oplhen-4-vi)piperazin-1I-yi)ethy1)-2-methy1-6,7,8,9-tetra hydro-4 H--pyrido[ I .2-a]pyrimidin-4-one; (9 1) "-(2-(4-(/2-oxo-.?,3 -dihydrobenzo[b]thiophen-4-yi)piperazin- I -yl)eth 'l)-3 ,44dhydroquinoli n-2(iI1)-one, (92) 6-(2- 4-(2-flujorobenizo[b]thiophen-4-yi)piperazin- I -yi)ethyl )-2f-1-benzolb] [i,4]oxazin-3 (4 11)-one; (93) 5-(2/--(4-(2-fluloro~benzo[b]thiophen-4-yi)piperazin-lI-yl1)eth '1)- 1,3 -dimethyl- iH-benzord]imi dazoi-2(31H)-one; (94) 6-tliuoro-5 -(2-(4-(2L-fluorobenzo[b]thiophen-4-yl)pi perazini- I-yl)ethyl )i ndol in -2-onie, (95'.5 -(2/-( 4-(benzorb]thiophen-4-vl)piperazin- 1-y'1)ethvl)-6-fluoroi ndolin-2-one; (96) 7-(2-(4-(benzo[b]thiophen-4-yi)piperazin-lI-yl)eth '1)-I-benzyl'1-3-methylquinazoline-2, 4(1 H ,31-I)-dion e, (97,)6-(2-(4-(benzo[b]thi oplhen-4-yl)piperidi n-I -vi)ethyl )-21H-benizo[b] [1 ,4]oxazin-3 (41-1)-one; (98)6(--(4-(tbenzo[b]thiophen-4-'i )piperidini-l-yI .)ethyl)-3 ,4-dihydroquinolini-2(1 H)-one (99)3 -(2/'-(4-(benzorb]thiophen-4-y i)piperI din- I -yl)ethyi)-2-methyl -6,7, 8,9-tetrah 'dro-411-pyrid o[ 1,2-a]pyrimidini-4-one.: (100) 6-(2-(4-(2-fluorobenzo[b]thi ophen-4-vi)piperazini- I -yl,)etlhvi)quiniolin-2( 1-11)-onie; (101) 5 - 4-('4-(2--tuorobenizo[b]thiopheni-4-'i )piperazin- I -yl)butyl)indoli n-2 -one; (102) '7-(2-(4I-(6-fluorobenzorb]thiophen-4I-yi)piperazin- I-vi)ethvl)quinolin--2( 11)-one; (103) 3 -(4-(4-(benzo[b]thiophen-4-vi)piperazi n-I -vi)butvi)-6,7-dim ethoxv-411-chrornen-4-oni

(104) 6-(4-(4-(benzo[bjthio hen-4-'i )piperidin-lI-vl)butyl)-3 .4-dihvdroquinolin-2( 11)-one; (105) 3-(2:- (4-(benzorb]thiophen-4I-yi)piperazin-1I-yi)ethyl)-5 -methoxv- IH1-indole; (106) 3 -(3 -(4-(benzo[b]thiopi -- lpiea i--vi )propyi)-5 -nmethoxy--1H-i ndoie; (107) 3-(4-(4-(benizo[b]thiopheni-4-yi)piperazi n- I -vi)butvi)-5-miethoxv- 11-1-i ndole,

18 (108) 3 -(3 -(4-(benizo[b]thiopheni-4-yi)piperazi n- I -vi)propy[l)- I 1H-indoie-5-carbonitrile; (109) 3 -(2-(4-(benzorb]thi ophen-4-yl)piperazin- 1- 1 )ethyl)- IF-indole-5-carbonitrile; (1 10) 1-acetyi-3 -(I-('4-(benizo[b]thiophen-4-yl)piperazin- I -vl)butyl)- I J--indole-5 -carbonitrile

(111) 6-(4-(4-(benzoi-b]thiophen-4-vi)piperazin- I -yI)bi tyv )-3 ,4-dihvdroquiniolin-2?(I11-1-one, (112) 5 -(4-(4-(benzo[bjthio hen-4-'i )pi perazin- I -yl)butyl)indoli n-2 -one; (113) 6-chloro-5 -(2-(4 -(2 -fluorobenizo[b]thiophen-4-yl)piperazin-lI-vl)ethyl)ind ollin-2-one (114) 6-(2/-(4-(benzo[b] thiiophien-4-vi)piper-auin- i-y )ethivi)-4-mieth iy-2 1--benzo[b] [I,4]oxazi i-3 (4-1-1)-one; (115) 7-(2-(4-(b enzo[b ]thi ophen-4-vl)piperazin- 1- 1)ethyl)- I -methyl -3),4-di h droquin olin-2( 111)-one; (116) 5-(' -(4-(benzo[b]thiophen-4-vi)piperazini- I -vi)ethvi)benzo[jd]thiazoi-2'-amine, (117) 7-(-4-(benzoi-blthiophen-4-vi)piperazin-1I-yi)ethivi)benizo[d]thiazol -2-amninie; (1 18) N-(5 -(2-(4-(benzo[b]thiophen-4-vl)piperazin- 1-yi'ethvl)benzo[d]thiazol-2-yl)acetarnid e; (119) N-(7I-(2'-(4-(benzo[b]thiophen -4-yl )pi perazin-1I-yi)etliyi)benizo[d]tliiazoi-2/-yi)acetamid e; (12 0) 4-('2-(i4-(benzorb]thi ophen-4-vl)piperazin- 1- 1)ethvl)benzord~thiazol-2-amine: (121) N-(4-(2-(4-(benzo[b]thiophen-4-vl)piperazini-1I-yl)ethvl)benzo[d]thiazol-2-yl)acetamid e; (122) 7(-4(-ntybnobtipe--l)ieai-I-iehl)3,-iIdounin2 11)-one; (123) 3 -((4-(benizo[b]thiophen-4 -yl)piperazin-lI-vi)methyl)- 1-methyl-IH1-indole; (124) 1-(3 -(2-(4-(benzo[b] thiopheni-4-yl)piperazi n-i -yi)ethyi )indoii-1I-yi)eth'anione; ( 12 5) 3 -(2-(4-(benizo[b]thiophi-4-yi)piperazi n-I -vi)ethyl)- 1-tosvi- 11-1-i ndole-5-carbonitriie; ( 126) _3-(3 -('4-(benzorb]thi ophen-4-yl)piperazin- I-yi )propyl)- 1-tosyl -I1-I-indol e-5 -carbonitri I

0. (127) 3 -(4-(4-(benzo[b]thiophen-4-vl)piperazii- I -vi)butvi)-5-nmethoxv-lI-tosyl -1 H-indoie;, (128~) 34-( -4-(benzo[b]thi ophen-4-vi)piperazin-1I-yi)propyi)-5-miethoxv-1I-tosyl -1 H-indole; (12 9) 3-(2-(4-(benzo[bjthio hen-4-yi )piperazin- i-vl)ethyl)-5-methoxy- I-tosyl- 11-indole; (130) 6-(.2:-(4-(2-oxo-2, 3-dihydrobenzorb]thiophen-4I-yi)piperazin- I-vi)ethvl)-3 ,4-dihydro quI noiin-2( I11)-one:

(13 1) - -(-(4-(2-fluorobenzo[b]thi ophen-4-vi)piperazini-lI-y[)etlhvi)-9-hydroxv-2-methivi-6,7,

19 8,9-tetrahydro-4H_-pyri do[ 1,2-a.]pyrimridin-4-one, (132) ' 2-(-4-(benzorb]thi ophen-4-vl)piperazin-. - -y)ethvl)-2H-benzo[b] [1,4]oxazin-3(4H)-o

(133) 74(' -(4-(benzo[b]thiophen-4-vi)piperazini-I .- vi)ethyl)-3 ,4-dihvdroquiioliie-2 (I H-)-thio ne: ( 14) ('3aR,4t, 6aS' -4.-(5 -(4-(benzo[b]thiophen-4-yl'pi perazin- 1-yl)pentyl)tetrahydro- 1H-thec no[3 ,4-d]Irnidazol-2(311)-one; (135) pentyl (6-(2-(4-(benzo[b]thi ophen-4-yl)piperazin -I -yI )ethyl)benizo[d]thiazol -2 -yl )cartarnate;1 (136C) 3 -('2-(4-(benzorb]thi ophen-4-vl)piperazini- 1- 1 )ethyl)-2-rnethyl -4-oxo-6,7, 8,9-tetrahydr o-4H-pyrido[1I,2-a]pyrimidin-9-yl benzoate, (137) 6-(4-(4-(benzo[b]thiophen-4-vl)piperazin- I -yi)butNi)-2H-benzo[b] [1 4oain3(H ne,

(13 8) 1-(benzorb]thi ophen-4-vl)-4-(4-(1 -c clohexyl- if-tetrazol-5-vl)butvlI)piperazinie; (139) 6-(.'-(4-(benzorb]thiophen-4I-yi)piperazin-1I-yi)ethvl)-8-fluoro-211-benizo[b][r1,4] oxazin

-3 ,4H-one; (140) 7-(2-(4-(benizo[b]thIiophen-4-yi)piperazin- I -vi)- I-hydroxvethyl)quinolin-2(1H1)-one, (141) 6-(2-(i4-(benzorb]thi ophen-4-vl)piperazin- I-y1)- I -hvdroxyethvl)-2}1-benzo[b] [1,4]oxaz in-3 (4H)-one: ( 14 2) 6-(' -(4-(benzo[b]thiophen-4-vi)piperazini- I-vi)-I -hy droxvethyl )-21-benzo[b] [1,4]thiaz in-3 .,4H_)-one; (43) 5-(2-(4-(benzo[bjthio heni-4-yi )piperazin- i-vl)acetvl)indolin-2I-one; (144) 8-(.'2-(4-(benzorb]thiophen-4I-yi)piperazin- i-yi)-I -rethoxvethyl)-2-H-benzo[b] [1 ,4]oxa zin-3 (4H)-one; (145) 5-(2-(4-(benizo[b]thiopheni-4-yi)piperazi n-i -v1)-I-hydroxvethyl )indol in-2-onie, (146) 6-('2-(i4-(benzorb]thi ophen-4-vl)piperazin-1-y'1)acet'i )benzor.dlthiazol-2-(3H )-one; (147) 5-(2-(4I-('benzo[b]thiophen-4-yi)piperazin- 1-vl)acetv7l)- IH-benzord]imidazoI-2(3H)-one

(148) 7-(4-(benzoi-blthi ophen-4-vi)piperazini-1I-yi)acetyl)-3 ,4-dihydroquinioli n-2(111)-onie; (149) 7-(5 -(4-(benzo[bjthio heni-4-yi )piperazin- 1-vl)pentanoy 'quinolin-2( IH)-one; (150) '7-(5 -(4-(benzorb]thiophen-4I-vi)piperazin- i-yi)-i -hydroxvpentyl)-3 ,4-dihy Iroquinolin 2(1 11)-one: (1 51) 7-(5-(4-(benizo[b]thIiophen-4-yi)piperazin- I -yi)pentanoy1)-3 ,4-di hy droquinolin-2(l iH)

20 one; (152) N-(6-(.-(4-(benzo[b]thiophen-4-yl)piperazin- I -vl)ethyl)benzo[d]thiazol-2-vl)cvclopent anecarboxamide; (153) N-(6-(2-(4-(benzo[b]thiophen-4-yl)piperazin -1 -yl)ethyl)benzo[d]thiazol-.-yl)acetamid e; (154) 6-(2-(4-(benzo[b]thiophen-4-yi)piperazin-i-vl)ethyi)benzo[d]thiazol-2-amine.

The present invention provides a process for producing a heterocyclic compound represented by formula (I) as shown in methods I to 5. Method I: The method comprises the step to obtain the compound of formula (I) or a salt thereof by the N-alkylation reaction of the compound of formula (II) or a salt thereof with the compound of formula (III) or a salt thereof, as shown in Reaction Formula 1:

L G H N N R 0 E

x ~ J R2 R1 ------+ R2 R (I)A A' --- Reaction Formula I

D S D S (111) (I)

wherein, ring Q L, A, B, D, E, R1 , R 2 and R3 are defined and preferred as hereinbefore; X represents a leaving group such as halogen, C1--C6 alkylsulfonyloxy, phenylsulfonyloxy, naphthylsulfonyloxy, said C1-C6 alkylsulfonyloxy, phenylsulfonyloxy or naphthylsulfonyloxy is optionally substituted with one or more substituents selected from the group consisting of halogen, C1~C6 alkyl, Cl~C6 alkoxy, nitro, hydroxy, amino and C1~--C6 alkanoyl group; preferably X represents halogen, C1-C4 alkylsulfonyloxy, phenylsulfonyloxy and naphthyl sulfonyloxy group, said C1-C4 alkylsulfonyloxy, phenyl suilfonyl oxy or naphthylsulfonyloxy group is optionally substituted with one or more substituents selected from the group consisting of halogen, Cl--C4 alkyl, C1-C4 alkoxy, nitro, hydroxy, amino and Ci-C4 alkanoyl; most preferably, X represents chlorine, bromine, methylsulfonyloxy, trifluoromethylsulfonyloxy, phenylsulfonyloxy, naphthylsulfonyloxy, methyl phenylsulfonyloxy. nitro-phenylsulfonyloxy, amino-phenylsulfonyloxy, chloro phenylsulfonyloxy, bromo-phenylsulfonyloxy or methoxy-phenylsulfonyloxy group. Said N-alkylation reaction between the compound of formula () or a salt thereof and the compound of formula (III) or a salt thereof was conducted in solvents in the presence or absence of a base, or it may be conducted without solvents. Said solvents include water; ethers

21 such as dioxane, tetrahydrofuran, diethyl ether, methyl t-butyl ether, diisopropyl ether, diglyme, ethylene glycol dimethyl ether; aromatic hydrocarbons such as benzene, toluene, xylene, nitrobenzene, chlorobenzene; alcohols such as methanol, ethanol, isopropanol, butanol, tert-butanol, ethylene glycol; ketones such as acetone, methyl ethyl ketone, 4-nethyl-2-pentanone; amides such as N,N-dimethyiformamide, N,N-dimethylacetamide, I -methyl-2-pyrrolidinone; halogenated hydrocarbons such as chloroform, dichloromethane, dichloroethane, carbon tetrachloride; esters such as ethyl acetate, ethyl formate, methyl acetate, isopropyl acetate; others such as dimethyl sulfoxide, acetonitrile. These solvents may be used singly or in combination with two or more. Said base may be inorganic or organic base, the inorganic base is selected from the group consisting of alkali metal hydroxides(e.g., sodium hydroxide, potassium hydroxide, cesium hydroxide, lithium hydroxide); alkali metal carbonates(e.g., sodium carbonate, potassium carbonate, cesium carbonate, lithium carbonate); alkali metal bicarbonates such as sodium hydrogencarbonate, potassium hydrogencarbonate, lithium hydrogencarbonate; alkali metal such as potassium, sodium; others such as sodium amide, potassium amide, sodium hydride, potassium hydride; the organic base is selected from the group consisting of sodium methoxide, sodium ethoxide, potassium methoxide, potassium ethoxide, sodium acetate, triethylamine, pyridine, diisopropylamine, diisopropylethylamine, tripropylamine, diethylamine, pyrimidine, quinoline, piperidine, piperazine, imidazole, dimethylaminopyridine, trimethylamine, N-ethyldiisopropylamine, N-methylmorpholine, dimethylaniline, 1,8-diazabicyclo[5.4.0] undec-7-ene (DBU), 1,5- diazabicyclo[4.3.0]non-5-ene (DBN). 1,4-diazabicyclo[2.2.2] octane (DABCO). These bases may be used singly or in combination with two or more. The above reaction may be conducted in the presence of an iodide of alkali metal such as potassium iodide and sodium iodide as a catalyst if necessary. The reaction temperature is room temperature to 200C, preferably from room temperature to 150 0C. The reaction time is 1 hour to 30 hours, preferably 5 hours to 20 hours. Method 2: The method comprises the step to obtain the compound of formula (Ia) or a salt thereof by the coupling reaction of the compound of formula (IV) or a salt thereof with the compound of formula (V) or a salt thereof, as shown in Reaction Formula 2:

22 LL

X1 R3 R?2 R?1

-R 3 R2 R1 ~~~~~~-ReactionFormula2

B D S H (V)B (IV) D S (1a)

wherein, ring Q L, A, B, D, R 1, R2 and R3 are defined and prefered as hereinbefore, Ei represents a nitrogen atom; X1 represents halogen or trifluoromethylsulfonyloxy, preferably,

X1 is selected from the group consisting of bromine, iodine, chlorine and trifluoromethylsulfonyloxy group; the coupling reaction is carried out in the presence of a base and a palladium catalyst and the compounds of formula (Ia) is a special case of the compound of formula (I). Said palladium catalyst is selected from the group consisting of palladium acetate (Pd

(OAc)2), bis(triphenylphosphine)palladium(1) chloride((Ph 3P) 2PdCl 2), bis(benzonitrile) palladium(II) chloride ((PhCN) 2PdCl2), Tetrakis(tripheniphosphine)palladium (Pd(PPh 3)4), bis

(triphenylphosphine)palladium acetate ((Ph3P) 2Pd(OAc) 2 ),

[1 ,2-Bis(diphenylphosphino)ethane]dichloropalladium(II )(PdCI 2 (dppe)), bis (1,2-bis (diphenylphosphino) ethane) palladium (Pd(dppe)2), bis(dibenzylideneacetone)palladi um(Pd(dba) 2), tris(dibenzylideneacetone) dipalladium

(Pd2 (dba) 3), [1,3-bis(diphenylphosphino)propane]palladiim dichloride (PdC[2 (dippp)), and [1,1'-bis(diphenvlphosphino)ferrocene] dichloropalladium (Pd(dppf)Cl2); said base is one or more selected from the group consisting of sodium bis (trimethylsilyl) amide, potassium tert-butoxide, sodium tert-butoxide, potassium phosphate, sodium phosphate, sodium methoxide, sodium ethoxide, potassium hydroxide, sodium hydroxide, potassium fluoride, sodium fluoride, tetrabutylammonium fluoride (TBAF), sodium acetate, potassium acetate, cesium carbonate , potassium carbonate or sodium carbonate. The reaction solvent is not particularly limited and include water; ethers such a dioxane, tetrahydrofuran; aromatic hydrocarbons such as toluene, xylene; alcohols such as t-butanol; ketones such as acetone; aides such as N, N-dimethyiformamide; others such as dimethylsulfoxide, acetonitrile; or a mixture of the above solvents; a suitable ligand can be added thereto as a reaction accelerator if necessary. Examples of said suitable ligands are

2,2'-Bis(diphenylphosphino)-1,1'-binaphthalene(BINAP), Tri-t-butvl phosphine(P(t-Bu)3), 1,1'-bi s(diphenylphosphino)ferrocene (dppf), 2-Dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl (x-phos),

23 4,5-bis(diphenylphosphino)-9,9-dimethyl xanthene(Xantphos), tri-tert-butylphosphine tetrafluoroborate and Tri(o-toIyl)phosphine (P (o-tolVI)3). Method 3: The method comprises the step to obtain the compound of formula (VII) or a salt thereof by the amidation reaction of the compound of formula (VI) or a salt thereof with the compound of formula (III) compound or a salt thereof, followed by the reduction step to give a compound of formula (I), as shown in Reaction Formula 3

L CI L - C) H 0 N N -R3

+ HOOC-L (G E E R2 R ---- Reaction R2IR(R2Formula 3 ( VI)K D SB D S D S (VII) (I)

wherein, ring Q L, A, B, D, E, R1 , R2 and R3 are defined and prefered as hereinbefore. The amidation reaction can be performed in two ways. The first amidation method is conducted in the presence or absence of a catalyst, by activating the carboxyl group of the compound of formula (VI) followed by the ammonolysis reaction with the compound of formula (III). The activator may be one or more selected from the group consisting of thionyl chloride, oxalyl chloride, thionyl bromide, phosphorus oxychloride, phosphorus pentachloride, pivaloyl chloride, ethyl chloroformate, isobutyl chloroformate, carbonyl diimidazole (CDI), methanesulfonyl chloride, p-toluenesulfonyl chloride, p-nitrobenzenesulfonyl chloride and the like. The catalyst may be one or more selected from the group consisting of N, N-dimethyiformamide (DMF), diethylaniline, dimethylaniline, N-methylmorpholine and the like. The solvent for the carboxyl group activation reaction is not particularly limited, for example, may be one or more selected from the group consisting of dichloromethane, dichloroethane, dimethylsulfoxide, tetrahydrofuran, benzene, toluene, chloroform, carbon tetrachloride, xylene, N, N-dimethylformamide, N, N dimethylacetamide and the like. The aminolysis reaction is conducted in the presence of a base in an appropriate solvent. Said base may be one or more selected from the group consisting of pyridine, piperidine, pyrrolidine, morpholine, N-methylmorpholine, quinoline, 4-dimethylaminopyridine (DMAP), triethylamine, diethylamine, tri-n-butyl amine, tripropylamine, diisopropylamine, dii sopropyl ethylami ne, sodium methoxide, sodium ethoxide, potassium t-butoxide, butyl lithium, 1,8-diazabicyclo[5,4,0 ]undec-7-ene (IDBU), sodium hydride, sodium hydroxide, potassium hydroxide. lithium hydroxide, sodium hy drogencarbon ate, potassium hydrogen carbonate, sodium carbonate and potassium carbonate. The ammonolysis

24 reaction solvent is one or more selected from the group consisting of aromatic hydrocarbon solvents, ether solvents, halogenated hydrocarbon solvents and other solvents. Wherein said aromatic hydrocarbon solvents may be one or more selected from the group consisting of benzene, toluene, xylene and the like; said ether solvents may be one or more selected from the group consisting of tetrahydrofuran (THF), diethyl ether, methyl t-butyl ether , ethylene glycol dimethyl ether, diethylene glycol dimethyl ether, ethylene glycol monomethyl ether, 1,4-dioxane and the like; said halogenated hydrocarbon solvents may be one or more selected from the group consisting of dichloromethane, chloroform, carbon tetrachloride, dichloroethane, and the like; said other solvents may be one or more selected from the group consisting of methanol, ethanol, ethylene glycol, hexane, cyclohexane, N, N-dimethylformamide DMF), N, N-dimethylacetamide, dimethylsulfoxide (DMSO), N-methyl pyrrolidone, acetone, acetonitrile, ethyl acetate, and the like; but the present invention is not limited to the above solvents.The temperature for the ammonolysis reaction is not particularly limited, but preferably is -30 C ~ 150 'C, more preferably is -10 'C ~ 120 'C. The reaction time for the ammonolysis reaction is not particularly limited, but preferably is 10 minutes to 24 hours. The second amidation method is conducted in the presence of a condensing agent, with or without a catalyst, with or without a base. Said condensing agent can be one or more selected from the group consisting of N, N'-dicyclohexyl carbodiimide (DCC), 1-ethyl-3

(3-dimethylaminopropyl) carbodiimide (EDCI), N, N'-diisopropyl carbodiimide (DIC), 0-(Benzotriazol- 1-i)-N,N,N',N'-tetramethyl uroniurm tetrafluoroborate (TBTU), o-(7-Azabenzotriazol- I -yl)-N,N,N,N'-te-tramethyluronium hexafluorophosphate (HATU), o-Benzotriazol- I -yl -N,N,N', N'-tetramethyluronium hexafluorophosphate (J-[BTU), (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP) and Benzotriazol e-I -yl -oxytri pyrrol idin ophosp honium hexafluorophosphate (PyBOP). Said catalyst may be one or more selected from the group consisting of I-hydroxy-benzotriazole (HOBt) and 4-dimethylaminopyridine (DMAP). Said base may be one or more selected from the group consisting of triethylamine, diethylamine, n-butylamine, tripropylamine, diisopropylamine, diisopropylethyi amine, trimethylamine, pyridine, 2,6-dimethyl pyridine, 4-dimethylaminopyri dine, piperidine, pyrrolidine, quinoline, morpholine, N-methyl morpholine, N-ethyl morpholine, 1,8-diazabicyclo[5,4,0]undecene-7 (DBU) or 1,5-diazabicyclo[4.3 .0]non-5-ene (DBN) and the like. The solvent of the second amidation method may be selected from the group consisting of hydrocarbons, such as benzene, xylene, toluene, dichloromethane or chloroform; ethers such as tetrahydrofuran, diethyl ether, dipropyl ether, or 1,4-dioxane; amides such as N, N-dimethylformamide, N. N-diethylformamide or N, N-dimethlvacetamide; nitriles such as acetonitrile; others such as dimethyl sulfoxide; these solvents may be used singly or in combination with two or more. Preferably, the reaction

25 solvent is selected from the group consisting of tetrahydrofuran, acetonitrile, dichloromethane, N. N-dimethyiformamide, N, N-dimethylacetamide or dimethyl sulfoxi de. The reaction temperature of the second amidation method is not particularly limited, but preferably is -20 'C ~ 80 'C, more preferably is 0 'C ~ 50 'C.

Said reducing agent is one or more selected from the group consisting of borne, hydrogen/palladium on carbon, lithium aluminum tetrahydride, triacetoxy sodium borohydride, diisobutyl aluminum hydride, boron trifluoride, boron tribromide, sodium borohydride and potassium borohydride. Method 4: The compound of Formula (I) was obtained by the reductive amination reaction of the compound of Formula (VIII) or a salt thereof and the compound of formula (III) or a salt thereof, as shown in Reaction Formula 4:

H L N N

-R3 R3

E OHC-L E 2 RR2 R ~~~~~~ Reaction Formula4 (ViIllI

D S D S (III) (I)

wherein, ring C, L, A, B, D, E, R1 , R2 and R 3 are defined and preferred as hereinbefore. The reductive amination reaction is carried out in the presence of a reductant, the reductant included but not limited to: sodium borohydride, potassium borohydride, sodium triacetoxy borohydride (NaBH(OAc) 3), Tetramethylammonium Triacetoxyborohydride and sodium cyanoborohydride.

Said reaction solvent is selected from the group consisting of water; ethers such as dioxane, tetrahydrofuran, diethyl ether, methyl t-butyl ether, diisopropyl ether, diglyme, ethylene glycol dimethyl ether; aromatic hydrocarbons such as benzene, toluene, xylene, nitrobenzene, chlorobenzene; alcohols such as methanol, ethanol, isopropanol, butanol, tert-butanol, ethylene glycol; ketones such as acetone, methyl ethyl ketone, 4-methyl-2-pentanone; aides such as N, N-dimethylformamide, N, N-di methylacetami de, 1i-methyl-2-pyrrolidinone; halogenated hydrocarbons such as chloroform, dichloromethane, dichloroethane, carbon tetrachloride; esters such as ethyl acetate, ethyl formate, methyl acetate, isopropyl acetate; nitriles such as acetonitrile; others such as dimethyl sulfoxide. These solvents may be used singly or in combination with two or more. The reaction temperature is generally 100C to 100C, preferably from 20"C to 50C. The reaction time is generally 1 hour to 30 hours. Method 5: The compound of Formula (I) was obtained through the functional group 26 conversion from the product obtained by method 1-4. e.g., by the oxidation reaction, the Grignard reaction, the hydrolysis reaction, the fluorination reaction, the chlorination reaction or the thiosulfate reaction. Said oxidation reaction is carried out in the presence of an oxidant, the oxidant included but not limited to: Dess-Martin reagent, Jones reagent, Swern reagents (DMSO and oxalyl chloride) or 2,3 -Dichloro-5,6-dicy ano-1,4-benzoqiinone (DDQ) and the like. Said Grignard reaction is carried out in the presence of a Grignard reagent, the Grignard reagent included but are not limited to: Methylmagnesium chloride, Methylmagnesium bromide, Methylmagnesium iodide or Ethylmagnesium bromide and the like. Said hydrolysis reaction may be carried out in the presence of an acid or a base, the acid or base included but are not limited to: hydrochloric acid, sulfuric acid, sodium hydroxide or potassium hydroxide and the like. Said fluorination reaction is carried out in the presence of a fluorinated agent, the fluorinated agents included but are not limited to: diethylamino sulfur trifluoride (DAST), sulfur tetrafluoride or iodine pentafluoride and the like. Said chlorination reaction is carried out in the presence of a chlorinated agents, the chlorinated agents included but are not limited to: thionyl chloride, phosphorus pentachloride or N-chlorosuccinimide (NCS) and the like. Said thiosulfate reaction is carried out in the presence of a thiosulfate reagent, the thiosulfate agents included but are not limited to: phosphorus pentasulfide or Lawesson reagent and the like. The compounds of Formula (II), formula (III), formula (IV), Formula (V), formula (VI), and formula (VIII) are commercially available or are prepared according to the reported mthods or are prepared according to the reported mthods of their analogs. The starting compounds used in the above reaction may be in the form of suitable salts, the suitable salts include alkali metal salts and alkaline earth metal salts such as sodium, potassium, calcium, magnesium salt and the like; organic base salts such as pyridine salt, triethylamine salt and the like; inorganic acid salts such as hydrochloride, hydrobromide, hydroiodide, sulfate, nitrate, phosphate and the like; organic acid salts such as formate, acetate, propionate, glycolate, oxalate, mnalonate, succinate, fumarate, mnaleate, lactate, malate, citrate, tartrate. pirate, glutamate, methanesulfonate and benzene sulfonate; Further, the starting compound used in the above reactions may be in the form of solvates, e.g. hydrates, alcoholates and the like. The heterocyclic compounds represented by the general formula (I) and stereoisomers thereof in the present invention also include compounds in the form of solvate, such as hydrates, alcoholates, and the solvates are included within the scope of the present invention. The Pharmaceutically acceptable salt of the heterocyclic compound represented by

27 formula (I) or its stereoisomer refers to converting the heterocyclic compound represented by formula (I) or its stereoisomer to non-toxic addition salt forms with therapeutic activity with suitable acid. Specific examples of said salts include hydrochloride, hydrobromide, hydroiodide, sulfate, bisulfate, nitrate, phosphate, acid phosphate, perchlorate, formate, acetate, trifluoroacetate, 5 propionate, pyruvate, glycolate, oxalate, malonate, succinate, glutarate, maleate, fumarate, lactate, malate, citrate, tartrate, picrate, glutamate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, salicylate, ascorbate, camphor acid salt or camphorsulfonic acid salt. Conversely, the acid addition salt can also be converted to the free base form with a base. The term "pharmaceutically acceptable salts" used above also includes solvates thereof, and 10 the solvates are included within the scope of the present invention. Examples of solvates include the hydrates, alcoholates and the like. The compounds prepared by the above reaction formula may be isolated and purified from the reaction mixture by the following methods: the reaction mixture was cooled and filtered or extracted or concentrated to give a crude, then the crude was purified by chromatography, 15 recrystallization or slurrying process. The present invention also provides a use of the heterocyclic compounds of the general fonnula(I) in the present invention, stereoisomers or a pharmaceutically acceptable salt thereof in the manufacture of medicament for the prevention and/or treatment of central nervous system disease. 20 The present invention also provides a method for the treatment or prevention of the central nervous system disease. Such method comprises administering to a human or animal the heterocyclic compound represented by formula (I), stereoisomer or a pharmaceutically acceptable salt thereof. The present invention also provides a pharmaceutical composition comprising a therapeutically effective amount of the heterocyclic compound represented by formula (I), 25 stereoisomer or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable carrier. The pharmaceutical composition is very useful in the treatment or prevention of central nervous system disease. The present invention further provides a process for preparing a pharmaceutical composition comprising mixing the heterocyclic compound represented by formula (I), stereoisomer or a 30 pharmaceutically acceptable salt thereof with one or more pharmaceutically acceptable carrier. In the pharmaceutical compositions of the present invention, various forms of pharmaceutical preparations can be selected according to the treatment purpose, generally include: tablets, pills, capsules, granules, suspensions, solutions, creams, ointments, powders, suppositories, aerosols and injections.

28 Said central nervous system disease is selected from the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar I type disorder; bipolar II type disorder; depression; endogenous depression; major depression; refractory depression; dysthymic disorder; cyclothymic disorder; panic attack; panic disorder; social phobia; obsessive-compulsive disorder; impulse disorder post-traumatic stess disorder; anxiety disorder; acute stress disorder; hysteria; anorexia nervosa; sleep disorder; adjustment disorder; cognitive disorder; autism; neuropathic headache; mania; Parkinson's disease; Huntington's disease; Alzheimer's disease; dementia; memory disorder; hyperkinetic syndrome; attention deficit/hyperactivity disorder, tic disorder and the like. The groups in the general formula (I) are defined as follows: The term halogen generally refers to fluorine, chlorine, bromine and iodine; preferably fluorine, chlorine or bromine; more preferably fluorine or chlorine; Cl~C6 alkyl group refers to a linear or branched alkyl group having I to 6 carbon atoms, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-ethylpropyl, isopentyl, neopentyl, isohexyl, 3-methylpentyl or n-hexyl group and the like, preferably methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl or tert-butyl group; Halogenated C I ~C6 alkyl group refers to a linear or branched alkyl group having I to 6 carbon atoms that was substituted with one or more identical or different halogen atoms, for example, trifluoromethyl, fluoromethyl, difluoromethyl, chloromethyl, bromomethyl, dichlorofluoromethyl, chloroethyl, bromopropyl, 2-chloro-butyl or pentafiluoroethyl group; CI-C6 alkoxy group refers to a linear or branched alkoxy group having I to 6 carbon atoms, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, sec-butoxy, n-pentyloxy, isopentyloxy, neopentyloxy, isohexyloxy, 3-methylpentyloxy or n-hexyloxy group and the like, preferably methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy or tert-butoxy group; Halogenated C I ~C6 alkoxy refers to a linear or branched alkoxy group having 1 to 6 carbon atoms that was substituted with one or more identical or different halogen atoms, for example, -OCF3, -OC-CH2Cl, -OCHi3rC-Clor -OCF 2CF 3 and the like; Cl~C6 alkylthio group refers to a linear or branched alkylthio group having I to 6 carbon atoms, for example, methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, isobutylthio, tert-butylthio, sec-butylthio, n-pentylthio, isopentylthio, neopentylthio or n-hexylthio and the like, preferably methylthio, ethylthio, n-propylthio, isopropylthio, n-butylthio, iso-butylthio or tert-butylthio group; C2-C6 alkenyl refers to an unsaturated linear or branched alkyl group having I to 3 double bonds and 2 to 6 carbon atoms, including both cis and trans configuration, for example, vinyl, I-propenyl, 2-propenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 2-methyl-2-propenyl, I-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1.3-butadienyl,

29 1,3-pentadienyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 3,3-dimethyl-I-propenyl or 2-ethyl-1-propenyl group and the like; C2~C6 alkynyl refers to a linear or branched alkynyl group having 2 to 6 carbon atoms, for example, ethynyl, 2-propynyl, 2-butynyl, 3-butynyl., 1-methyl-2-propynyl, 2-pentynyl or 2-hexynil group and the like; Phenyl C1~C6 alkyl refers to a saturated linear or branched hydrocarbon group having I to 6 carbon atoms was linked with phenyl group through carbon atoms, for example, benzyl, phenylethyl or phenylpropyl group and the like;Phenyl-C1~C6 alkoxy refers to a linear or branched alkoxy group having I to 6 carbon atoms was linked with phenyl group through carbon atoms, for example, benzyloxy, -OCH(C1 3)Ph, phenylethoxy or phenylpropoxy group and the like; Phenvl CI-C6 alkanoyl group refers to a linear or branched alkanoyl group having I to 6 carbon atoms was linked with phenyl group through carbon atoms, for example, benzoyl, phenylacetyl or phenylpropionyl and the like: C2~-C6 alkenyloxy group refers to a linear or branched alkenyloxy group containing I to 3 double bonds and 2 to 6 carbon atoms, such as vinyloxy, 1-propenyloxy, 1-methyl-I-propenyloxy, 2-methyl-I-propenyloxy, 1-pentenyloxy, 1,3-pentadienyloxy or 2-pentenyloxy group and the like; C2~-C6 alkynyl group refers to a linear or branched alkynyl group having 2 to 6 carbon atoms, for example, ethynyloxy, 2-propynyloxy, 2-butynyloxy, 3-butynyloxy, I-methyl-2-propynyloxy, 2-pentynyloxy or 2-hexynyloxy group and the like CI-C6 alkanoyl group refers to a linear or branched alkoxy group having I to 6 carbon atoms, for example, formyl, acetyl, propionyl, butyryl, isobutyryl, pentanoyl, t-butyryl or hexanoyl group and the like; Halogenated Cl-C6 alkanoyl group refers to a linear or branched alkanoyl group having I to 6 carbon atoms that was substituted with one or more identical or different halogen atoms, for example, trifluoroacetyl group and the like; ClC6 alkyl-substituted carbamoyl group refers to an carbamoyl group substituted with one or two identical or different Cl~-C6 alkyl group, for example, -CONI-Me, -CON(Me)Et,

-CONEt2 or -CONMe 2 and the like; Hydroxy C1-C6 alkyl group refers to a linear or branched alkyl group having I to 6 carbon atoms was linked with a hydroxyl group through a carbon atom, for example, -CH 2OH,

-CH 2CH2IOH, -CH(OH)CH 3, -CH 2CH 2CH2IOH, -CH 2CH 2CH2CH 2OH or -CH 2CH(CH3)CH 2 OH and the like; Amino C1~C6 alkyl refers to a linear or branched alkyl group having I to 6 carbon atoms was linked with an amino group through a carbon atom, for example, -CH 2NHI2 , -CH 2C-1 2N1 2,

-CH(NH 2 )CH 3I, -CH[CH2CH2NIH or -CH 2 CH2 CH NH2 and the like;

30 C1~C6 alkyl-substituted amino C1 ~--C6 alkyl group refers to an amino C1 ~ C6 alkyl group whose hydrogen atom on the amino part is replaced by one or two identical or different

Cl (~C6 alkyl group, for example, -CHJ2 NIMe or -CHI2 CH2NEt2 and the like Carbamoyl C1-C6 alkyl refers to a linear or branched alkyl group having I to 6 carbon atoms was linked with a carbarnoyl group through a carbonyl carbon atom, for example,

-CH 2 CON1 2, -CH 2CH 2 CONH 2, -CH(CONI-H 2)CH 3 or -CH 2 CH 2CH 2CONH 2 and the like C1~"C6 alkyl-substituted carbamoyl C1~C6 alkyl group refers to an carbamoyl C1~C6 alkyl group whose hydrogen atoms on the carbamoyl part is replaced by one or two identical or different C1~C6 alkyl group, for example, -CH 2CONHMe, -CH-12CH 2CONHEt,

-11 2CH1-2 CONMe2 or -CH 2CONEt 2 and the like; Cyano CI ~(6 alkyl refers to a linear or branched alkyl group having I to 6 carbon atoms was linked with a cyano group through a carbon atom, for example, cyanomethyl, 2-cyanoethyl, 1-cvanoethyl, 3-cyanopropyl, 4-cyanobutyl or 5-cyano-pentyl group and the like; Carboxy CI~-C6 alkyl group refers to a linear or branched alkyl group having I to 6 carbon atoms was linked with a carboxyl group through a carbon atom, for example, carboxymethyl, 2-carboxyethyl, I-carboxyethyl, 3-carboxypropyl, 4-carboxybutyl or 5-carboxy-pentyl group and the like; C1~C6 alkylsulfonyl group refers to a linear or branched alkylsulfonyl group having I to 6 carbon atoms, for example, methylsulfonyl, ethylsulfonyl or propylsulfonyl and the like 1-alogenated (1~,'C6 alkylsulfonyl group refers to a linear or branched alkylsulfonyl group having I to 6 carbon atoms that was substituted with one or more identical or different halogen atoms, for example, trifluoromethylsuilfonyl group; C1-C6 alkyl-substituted amino group refers to an amino group substituted with one or two identical or different C 1C6 alkyl group, for example, -NHMe or -NEtz and the like; C3~"C 10 cyclohydrocarbyl refers to a saturated or unsaturated cycloalkyl group having 3-10 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclobutenyl, cyclohexenyl, cyclohexadienyl, cyclopentenyl, or cyclopentadienyl group and the like;

3-10 memb ered heteromonocyclic group refers to a 3-10 membered monocyclic group containing at least one hetero atom selected from N, S and 0, such as oxiranyl, azetidinyl, furanyl, dihydrofuranyl, tetrahydrofuranyl, thienyl, dihydrothienyl, tetrahydrothienyl, pyrrolyl, dihydro-pyrrolyl, pyrrolidinyl, pyrazolyl, dihydro-pyrazolyl, pyrazolidinyl, triazolyl, dihydro-triazole, triazolidinyl, thiazolyl, dihydro-thiazolyl, thiazolidinyl, isothiazolyl, dihydro-isothiazolyl, isothiazolidinyl, oxazolyl, dihydro-oxazolyl, oxazolidinyl, isoxazolyl, dihydro-isoxazolyl, isoxazolidinyl, pyranyl, dihydro-pyranyl, tetrahydropyranyl, pyrazinyl, dilhydro-pyrazinyl, tetrahydro-pyrazinyl, piperazinyl, pyridazinyl, dihydro-pyridazinyl, 31 tetrahydro-pyridazinyl,

N N N N N N N N N H H H H

HN N HN 1 N HN NN, N HN N N N N N N N N N ) ) H H H H H H H

H

N

N

HN N HN HN HN HN j HN HN N

HN HN- 0 0 H N H N H H O OO H N HN NJ / D HN --- ND H H N HN N HN- N N N H H

0 N H , N Oz N O N, O N, O'NH, O'NH HN HNH

N'' N H H N H Nzz N ) N N and (NN( N) \ N N-x% NK H W N) N- N H H N H H H H H

The compounds of this invention have the following advantages: 1) The compounds of the present invention show good activities for the serotonin IA (5-1-1TIA) receptor and/or dopamine D2 receptor and/or serotonin 2A (5--1T2A) receptor, especially for 5-HTIA receptor, the EC50 value of some compounds even reach 1 ~ 0. 1M level. 2) The compounds of the present invention have multi-target effect and simultaneously act on multiple subtypes of dopamine/serotonin receptors, specifically, they have high activity on

5 dopamine D 2 receptor, 5-HTiA receptor and -HT2A receptor. As seen from the results of pharmacological experiments, most of the compounds have D2 receptor antagonism/5-HTIA receptor agoni sm/5-HT2A receptor antagonism activities or D2 receptor partial agonism/ 5-HT1A receptor agonism/5--T2A receptor antagonism activities. In particular, some compounds have extremely potent D 2 receptor antagonisn/5-1-ITIA receptor agonism/5--IT2A receptor antagonism activities and the IC50/EC50 values reached 10- ~ 10-"M level. The multi-target effect characteristic is helpful to maintain receptor-balance in the brain, especially the balance of 5-HT and DA system, so as to treat central nervous system disease effectively.

32 3) Since the compounds of the present invention are multi-target modulators for the central nervous system receptors, they are devoid of side effects associated with D2 receptor antagonists or D2/5-HT2A receptor antagonists, such as extrapyramidal symptom (E PS) and metabolic disorders. 4) The compounds of the present invention are highly potent, orally active, and endowed with low effective dose and low toxicity. They are extremely effective for the treatment of central nervous system disorders, especially for major depressive disorder (IDD), anxiety disorder, negative symptoms in schizophrenia, cognitive impairment, Parkinson's disease, ADHD and the like. In summary, the compounds of the present invention have advantages of multi-target effect, lower effective dose, fewer side effects, better safety and tolerability compared with conventional antipsychotics and show good clinical prospect.

Example Hereinbelow, the present invention will be further made clear with reference to Reference Examples, Examples and Pharmacological Experimental Examples. It should be understood, the following examples are only used for illustration of the present invention without intended to limit the scope of the invention. Reference Example 1 Preparation of 1-(benzo[blthiophen-4-yl)piperazine hydrochloride

O Bocc N O O

F Cl- N CI- Boc N N S

1-a 1-b 0 1-c Boc, N OH Boc' N- , HN r \ N ---- '--N N N S

d' e HC 1-d I -e Step 1: 2-chloro-6-fluorobenzaldehyde 1-a (500mg, 3.15mmol) and 1-boc-piperazine (646 mg, 3.47 mmol) were dissolved in N, N-dimethylformamide (5ml), potassium carbonate (2.18 g, 15.77mmol) was added thereto at room temperature under a nitrogen atmosphere. The mixture was stirred at 80 0C for 4 hours, cooled and filtered. The mixture was extracted with ethyl acetate (5 ml x 3) and water (20ml), washed with IN hydrochloric acid (3mi) and saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate and concentrated. The residue was slurried in petroleum ether (50ml) for I hour, filtered to give compound 1-b as a pale yellow solid(1 .0 g, yield: 90%) . (300Hz, DMSO-d-): 6 ppm 10.19(s, 1H1NMR1H), 7.52(t,

33 1H), 7.18(d, 2H4), 3.46(t, 4H), 2.94(t, 4H), 1.39(s, 9H).

Step 2: Compound 1-b (5g, 15.3 mmol), ethyl thioglycolate (1 8g, 15.3mmol), potassium carbonate (6.2 g, 44.9 mmol) were added to N, N-dimethylformamide (50ml) at room temperature under a nitrogen atmosphere. The mixture was stirred at 80 'C for 5 hours, cooled, filtered after ethyl acetate (50m]) was added. The filtrate was extracted with ethyl acetate and water (200ml). The organic phase was dried and concentrated to give a red-brown oil, which was slurried in petroleum ether, filtered to give compound 1-c (5.9 g, yield: 98%). ESI-MS

(m z): 391.4 [M+H]v. 1H-NR (300Hz, CDCl3): 6 ppm 8.10(s, IH), 7.52(d, IH), 7.37(t, iH), 6.88(d, 11). 4.40(q, 211), 3.68(t. 41i), 3.10(t, 4H), 1.49(s, 91H), 1.41(t, 3H). Step 3: Compound 1-c (1.0 g, 2.5 mmol) was dissolved in 1,4-dioxane (5ml), 4N aqueous sodium hydroxide (1.8ml, 7.2 mmol) was added and the mixture was stirred at 80 'C for 3 hours. The reaction mixture was cooled to room temperature and extracted with ethyl acetate (10ml) and water (5ml). The pH value of the aqueous phase was adjusted with IN hydrochloric acid to 4.0, the resulting solid was filtered, dried to give compound 1-d as a pale yellow solid (0.83g, yield:

90%) . 'H-NM\R (300Hz, DMSO-d 6): 6 ppm 13.51(brs, IH), 7.96(s, iH), 7.65(d, 1H), 7.40(t, 111), 6.95(d, 11H), 3.55(s, 411), 3.00(s, 4H), 1.41(s, 911). Step 4: Compound I-d (20g, 54mmol) and cuprous oxide (lg) were dissolved in quinoline (50ml). The mixture was stirred at 140 'C overnight and filtered after cooling. The mixture was extracted with ethyl acetate and water, washed with IN hydrochloric acid and saturated sodium bicarbonate solution sequentially, dried over anhydrous sodium sulfate, filtered, concentrated and purified by column chromatography to give a crude. The crude was scurried in petroleum ether and then filtered to give compound I-e as a white solid (10 g). ESI-MS (m z):

319.2 [M+H]. 'H-NNIR (300Hz, CDCl 3): 6 ppm 7.57(d, 1H), 7.41(s, 2H), 7.27(t, IH), 6.88(d, 111), 3.66(t, 411), 3.09(t, 411), 1.50(s, 911). Step 5: Compound 1-e (lg, 3.14mmol) was added into hydrochloric acid-methanol solution (5ml) and the mixture was stirred at 50 'C for half an hour. The reaction mixture was concentrated to dryness, slurried in acetonitrile and filtered to give an off-white solid (800 mg, yield: 100%). ESI-MS (m / z): 219.2 [M + H]

Reference Example 2 Preparation of 5-(2-oxo-1,2,3,4-tetrahvdroquinolin-7-yl)pentyI methanesulfon ate 34 HO -C N O TfO N 0 OO HH H 2-a H 2-b 2-c

HO MsO " ~N 0 ;r -"0 0 2-d H H Step 1: The reaction flask was charged with 7-hydroxy-3,4-di hydro-quinolin-2(111)-one 2-a (10g, 61.3mmol), chloroform (100m]) and pyridine (10.6g, 134mmol) were added thereto. The mixture was stirred at room temperature for 10 minutes and then cooled to 0 'C. Trifluoromethanesulfonic anhydride (17.2g, 60.99mmol) was slowly added dropwise under ice bath followed by stirring for 30 minutes. The reaction was stirred at room temperature for I hour, filtered, the filtrate was washed with aqueous potassium bisulfate(iM) and water twice, dried over anhydrous sodium sulfate, concentrated, subjected to column chromatography to give 2-b as a pale yellow solid (12g, yield: 67%).

Step 2: Compound 2-b (18g, 61LOmmol), bis(triphenylphosphine) palladium dichloride (3.6g, 5.12mmol) and cuprous iodide (3.96g, 20.8mmol) were added into the reaction flask under a nitrogen atmosphere. 4-pentyn-1-ol (5g, 59.5mmol), triethylamine (26g, 25.7mmol) and N, N dimethylformamide (100ml) were injected and the mixture was stirred at 80 'C overnight. The reaction was cooled to room temperature, ethyl acetate (300ml) was added. The insoluble solid was filtered off, the filtrate was washed twice with IN hydrochloric acid and water, dried over anhydrous sodium sulfate, concentrated and the residue was purified by column chromatography to give compound 2-c as a white solid(5.5g, yield:39%).

Step 3:

A single-necked flask was charged with compound 2-c (5.5g, 24.0mmol), methanol (55 ml) and 10% Pd/C (1 50mg) were added and the mixture was stirred at 55 'C under a hydrogen atmosphere for 15 hours. The mixture was cooled, filtered, concentrated and subjected to column chromatography to give 2-d as a white solid (3.3g, yield: 60%). Step 4: Compound 2-d (0.5g, 2.14mmol) was dissolved in dichloromethane (5ml) and triethylamine (0.6ml, 4.28mmol) was added. Methanesulfonyl chloride (0.2ml, 2.56mmol) was slowly injected into the above solution under ice bath condition in 15 minutes. Then the mixture was stirred at room temperature for 2 hours. The reaction mixture was extracted with dichloromethane and water. The organic phase was washed with brine, dried over anhydrous sodium sulfate and concentrated to give the target compound as a white solid (0.6 g, yield:

35 90%). ESI-MS (m z): 312.1 [M-H].

Reference Example 3 Preparation of 5-(2-oxo-1,2-dihydroqiinolin-7-vl)pentyl methanesulfonate

MsO ------MsO-N N O H H 1,4-dioxane (5ml) and 2,3 -dichl oro-5,6-di cyano- 1,4-benzoquinone (0.875mg, 3.85mmol) were added into the product of Reference Example 2(0.8g, 2 57mmol) and the mixture was stirred at 95 'C for 3 hours. The reaction mixture was cooled, filtered, the filtrate was extracted with dichloromethane, washed with saturated sodium bicarbonate solution, saturated sodium thiosulfate solution, and brine sequentially, then dried over anhydrous sodium sulfate, concentrated and the residue was subjected to column chromatography to give a white solid (0.6 g, yield: 75%). ESI-MS (mnz): 310.1 [M-H].

Reference Example 4 Preparation of 4-(2-oxo-1,2,3,4-tetrahvdroquinolin-7-yl)butyl methanesulfonate

MsO N 0 H By a similar method as in Reference example 2, 4-(2-oxo-1,2,3,4-tetrahyrdroquinolin-7-yl)butyl methanesulfonate was prepared from

3 -butyn-1-ol as pale yellow oil, yield 34%. ESI-MS (m z): 298.1 [M+H]'. 1H-NVIR (300Hz,

CDC 3): 6 ppm 8.43(s, IH), 7.07(d, iH), 6.79(d, iH), 6.60(s, 1H), 4.23(t, 2H), 3.00(s, 3H), 2.93(t, 2H), 2.62(m, 4H), 1.75(m, 4H).

Reference Example 5 Preparation of 4-(2-oxo-1,2-dihydroquinolin-7-yl)butyl methanesulfonate

MsO N 0 H By a similar method as in Reference example 3, 4-(2-oxo- 1,2-dihydroquinolin-7-yl)butyl methanesulfonate was prepared from the product of Reference example 4 as grey solid, yield

61%. ESI-MS (mn ): 296.1 [M-HF]. IH-NMR (300Hz, CDCI3 ): 6 ppm 12.37(s, 1H), 7.85(d, IH), 7.52(d, 11-), 7.26(s, 1H), 7.09(d, 11-), 6.72(d, 1-I), 4.25(t, 2H1-), 3.00(s, 31-), 2.78(t, 2H), 1.79(m, 411)

Reference Example 6 36 Preparation of 2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl methanesulfonate

TfO N 0 N 0 N 0 H H O H 2-b 6-a 6-b

HO N 0 MsO N 0 6-c H H Step 1: Lithiurn chloride(8.7g., 203.1 mmol), bis(triphenyl phosphine)pailladiurm dichloride (5.7g,

8.12mmol) and N, N-dimethyl formamide (200ml) were added into compound 2-b (20g, 67.7mmol). Tributylvinyltin (21ml, 74.4mmol) was injected thereto under a nitrogen atmosphere followed by stirring at 100 cC overnight. The mixture was filtered, extracted with dichloromethane and water, the organic phase was washed with brine, dried, concentrated, and subjected to column chromatography to give compound 6-a (8.0g, yield: 68%). Step 2: Potassium peroxornonosuilfate (Oxone, 43.6g, 69.3mmol), sodium bicarbonate (29.2 g) and acetone-water (400ml: 400ml) solution were added into compound 6-a (8g, 46.2mmol) and the mixture was stirred at room temperature for 2 hours. The mixture was filtered, extracted with dichloromethane and water. The organic phase was washed with brine, dried, concentrated, and subjected to column chromatography to obtain the target 6-b (5.7g, yield: 65 %). ESI-MS (mz): 190.1 [M+I]. 'H-NMR (300Hz, CDCL3): 6 ppm 8.42( brs, 1-1), 7.16(.d, IH) 6.94(dd, 1-1), 6.71(d, 11-1), 3.85(dd, I H), 3.15(dd, IH), 2.98(t, 21-1), 2.78(dd, IH), 2.66(t, 21-1) Step 3:

A mixture of compound 6-b (3.6g, 19.Ommol), ammonium formate (3.0g, 47.6mmol), ethyl acetate (I 00ml), methanol (I00ml) and 10% Pd/C (460mg) was stirred at reflux under a nitrogen atmosphere overnight. The mixture was filtered, concentrated, subjected to column chromatography to obtain the compound 6-c (1.5g, yield: 41%). ESI-MS (mz): 192.0 [MiH]-.

H-NMR (300Hz, CDCIs): 6 ppm 8.87(brs, 1H), 7.07(d, 1H), 6.84(d, 1H), 6.69(s, 1H), 3.84(t, 21-), 3.78(s, 11-), 2.90(t, 21-), 2.80(t, 21H), 2.59(t, 211). Step 4: Compound 6-c (1.5g, 7.85mmol) was dissolved in dichloromethane (60ml) and triethylamine (3ml, 23.55mmol) was added. Methanesulfonyl chloride (0.92ml, 11.77mmol) was added dropwise under ice bath followed by stirring at room temperature for 3 hours. The mixture was extracted with dichloromethane and water, the organic phase was dried, concentrated, subjected to column chromatography to obtain a white solid (1.3g, yield: 61%).

37 'H-NMR (300Hz, CDCi: 6 ppm 8.97(brs, 1H), 7.11 (d, IH), 6.86(dd, 1H), 6.69(d, 1 H), 4.39(t, 2H), 3.00(t, 2H), 2.94(t, 2H), 2.93(s, 31H), 2.63(t, 2H).

Reference Example 7 Preparation of 2-(2-oxo-1,2-dihvdroquinolin-7-yl)ethyl methanesulfonate

MsO 0 H By a similar method as in Reference example 3, 2-(2-oxo-1,2-dihydroquinoiin-7-yi)ethyI methanesulfonate was prepared from the product of Reference example 6 as a white solid, yield

75%. ESI-MS (m z): 268.1 [M+H]'. 'H-NM1R (300Hz, DMSO-d6 ): 6 ppm 11.74(brs, iH), 7.87(d, 11-), 7.61(d, 11-), 7.18(s., I-H, 7.12(d, 11-1), 6.45(d, 111), 4.44(t, 211), 3 13(s, 31-1), 3.07(t, 21-).

Reference Example 8 ]reparation of 1-(2-fluorobenzo[bIthiophen-4-yl)piperazine Boc Boc H N N N) N N N

F F s 6s F 1-e 8-a Step 1: Compound I -e (Ig, 3.14mmol) was dissolved in dry tetrahydrofuran, stirred at -78 'C under a nitrogen atmosphere for 30 minutes. 2.5M n-butyllithium in n-hexane (1.65ml, 4.08mmol) was added dropwise and the mixture was stirred at the same temperature for 3 hours. N-Fluorobenzenesulfonimide (1.5g, 4.71 mmol) dissolved in tetrahydrofuran (5nil) was added dropwise into the system. The mixture was maintained at -78 'C for one hour and then stirred at room temperature overnight. The reaction was quenched with saturated ammonium chloride solution. The mixture was extracted with dichloromethane and water. The organic phase was washed with brine, dried over anhydrous sodium sulfate, concentrated, subjected to column chromatography to obtain 8-a as an oil (600 mg, yield: 57 %). Step 2: Compound 8-a (600mg) was dissolved in dichloromethane (imi) and trifluoroacetic acid (1ml), the mixture was stirred at room temperature for 1 hour. The reaction mixture was concentrated and saturated sodium bicarbonate solution (5ml) was added. The precipitated solid was filtered, dried to obtain a pale yellow solid (400mg, 95% yield). ESI-MS (n z): 237.1

38 [M+-H]F.

Reference Example 9

Preparation of 1-(2-chlorobenzo[blthiophena-4-yl)piperazine Boc Boc N) N H

N N . N

CI 1-e 9-a Step 1: Compound I-e (900mg, 2.83mmol) was dissolved in tetrahydrofuran (3ml) in a three-necked flask under a nitrogen atmosphere. The mixture was cooled to -78 'C, 2.5M n-butyllithium in n-hexane (1.47 ml, 3.67mmol) was injected and the mixture was stirred at -78 C for 3 hours. N-chlorosuccinimide (677mg, 5.09mmol) dissolved in tetrahydrofuran (3ml) was slowly injected into the reaction system in 0.5 h. Then the mixture was stirred at room temperature overnight and quenched with saturated ammonium chloride solution. The mixture was extracted with dichloromethane and water. The organic phase was washed with brine, dried over anhydrous sodium sulfate, concentrated, subjected to column chromatography to obtain 9-a as an oil (540mg, yield: 54%). Step 2: Compound 9-a (540mg, 1.53mmol) was dissolved in dichlioromethane (Imi) and trifluoroacetic acid (1ml), the mixture was stirred at room temperature for 3 hours. The reaction mixture was concentrated and saturated sodium bicarbonate solution was added (3 ml). The precipitated solid was filtered, slurried in acetonitrile to give a white solid (210mg, yield: 54%).

ESI-MS (mn): 253.2 [M+H]. HNM[R (300MHz, DMSO-d6 ): 6 ppm 8.19(brs, iH), 7.46-7.68(m, 2H), 7.32(t, 1H-), 6.98(d, 11-), 3.25(s, 4H), 3.16(s, 411).

Reference Example 10

Preparation of 3-(2-chloroethyl)-2-niethyl-6,7-dihvdro-41-pyrido[1,2-a pyrinidin-4-oie OH OMs N N NN CI4 N N N CI CI 0 0 O 10-a 10-b Step 1: 39 Triethylamine (0.85ml, 6.19mmol) and dichloromethane (10mi) were added into compound 10-a (1g., 4.13mmol), then methanesulfonyl chloride (0.38m], 4.95mmol) was added dropwise under ice bath condition. The mixture was stirred at room temperature for 30 minutes and extracted with dichloromethane and water. The organic phase was washed with brine, dried, and concentrated to give 10-b as an oil (1.23g, yield: 93%). Step 2:

Lithium bromide (418mg, 4.86mmol), lithium carbonate (358mg, 4.86mmol) and N, N-dimethylformamide (5ml) were added into compound 10-b (520mg, 1.62mmol), the mixture was stirred at 115 'C for 2 hours and extracted with dichloromethane and water. The organic phase was washed with brine, dried and concentrated to give a yellow solid (400mg, yield:

100%). ESI-MS (m z): 225.1 [M+H] H-NMR (300Hz, CDC 3): 6 ppm 2.35(s, 3H), 2.54(m, 211), 3.01(t, 21H), 3.76(t, 21-1), 4.14(t, 211), 6.35(dt, 11), 6.64(m, 11).

Reference Example 11 Preparation of 6-(5-chloropentyl)-2-methylquinazolin-4(3H)-one

0 0 0 0 Ci HOH OMe T OMe NO ... N'02O NO 2 11-a 11-b 11-c 11-d 0 0 0 HO OOMe HO OMe- NH

NO 2 NH 1-e 11-f 2 N

Step 1: Potassium hydroxide aqueous solution (13.8g, 248mmol, 40ml) was added into 5-chlioro-2-nitrobenzoic acid 11-a 5g, 24.8mmol) and the mixture was stirred at reflux for 24 hours. The pH value of the reaction mixture was adjusted to 2 with concentrated hydrochloric acid under ice-cooling, the precipitated solid was filtered and dried to give I1-b as a white solid (4.lg, yield: 90%).

Step 2:

Thionyl chloride (26.8 mmol) and methanol (Oml) were added into compound 11-b (4. 1g, 22.4mmol) and the mixture was stirred at reflux for 5 hours. The reaction solution was concentrated, extracted with ethyl acetate and water, washed with brine, dried, and concentrated to give the target 11-c (3. 19g, yield: 72%). Step 3: Pyridine (67.5 mmol) and dichloromethane (10ml) were added into compound 11-c (2.66g, 13.5mmol). Trifluoromethanesulfonic anhydride (20.2mmol) was slowly added dropwise

40 thereto under ice-cooling followed by stirring at room temperature for 6 hours. The mixture was diluted with dichloromethane (100ml), washed with IN hydrochloric acid (70ml) and brine, the organic phase was dried over anhydrous sodium sulfate and concentrated to give 11-d as a tan solid (3.86g., yield: 87%) Step 4: A mixture of compound 11-d (2.83g, 8.6mmol), 4-pentyn-1-ol (789mg, 9.4mmol), bis (triphenylphosphine) palladium dichloride (603mg, 0.86mmol), cuprous iodide (245mg, 1.29mmol), triethylamine (5.9ml, 43mmol) and N, N-dimethylformamide (1Oml) was stirred at room temperature overnight. The reaction mixture was diluted with dichloromethane, washed twice with dilute hydrochloric acid, the organic phase was dried, concentrated, subjected to column chromatography to obtain 1 -e as an oil (2.2g, yield: 97%). I--NMR (300Hz, CDCI3 ): 6 ppm 7.88(d, 1H), 7.67(d, 1H), 7.57(dd, 11), 3.92(s, 311). 3.80(q, 21), 258(t, 2H), 1.87(m, 2H-), 1.49(t, 1H). Step 5: Ethanol (5ml) and Pd/C (150 mg) were added into compound 11-e (1.04g, 3.95mmol) and the reaction mixture was stirred at 50 'C under a hydrogen atmosphere for 24 hours. The mixture was filtered and the filtrate was concentrated. Hydrogen chloride-ethanol solution was added, the resulting hydrochloride salt was slurried in acetone/methyl tert-butyl ether system, filtered, and dried to give I1-f as a yellow solid (840mg, yield: 89%). ESI-MS (n z): 238.1 [M+ihH]7. Step 6: Compound 11-f (455mg, 1.91mmol) was dissolved in acetonitrile (3ml) and hydrogen chloride/1,4-dioxane solution (3 ml) in a sealed tube and the mixture was stirred at 70 'C overnight. The reaction mixture was concentrated, the pH value thereof was adjusted to be around 7 with saturated sodium bicarbonate solution. The mixture was extracted with ethyl acetate, the organic phase was dried, concentrated and subjected to silica gel column chromatography to give the title compound (280mg, yield: 55%). ESI-MS (m z): 265.1 [MH-1]. 1 -- NMR (300Hz, DMSO-d6): 6 ppm 12 11 (brs, 11-), 7.86(d, 11-1), 7.60(dd, I -I), 7.48(d, 1-1), 3.61(t, 211), 2.69(t, 211), 2.32(s, 311), 1.73(i, 211), 1.62(m, 2H), 1.39(m, 211).

Reference Example 12 Preparation of 1-(2,3-dihydrobenzo[blthiophen-4-yl)piperazine hydrochloride

41 F F F OH OH

6 cCI C1 12-a 12-b o .s 12-c

CI C1(N) * HCI 12-d N H Step 1: Lithium aluminium hydride (4.6g, 121mmol) was added to a flask containing dry tetrahydrofuran (20ml). Compound 12-a (10g, 53.2mmol) dissolved in tetrahydrofuran (100ml) was added dropwise under ice bath condition. The mixture was stirred for 20 minutes at room temperature, then at reflux for 3 hours. Sodium sulfate decahydrate was added slowly until no bubbles appear. The mixture was filtered, the filtrate was dried, concentrated, subjected to column chromatography to obtain the product 12-b (7.8g, yield: 85%).

Step 2: Compound 12-b (6.7g, 38.5mmol), triethylamine (4.66g, 46.2mmol) and dichloromethane (80ml) were added to the flask, p-toluenesulfonyl chloride (7.34g, 38.5mmol) in dichloromethane (20n1) was added dropwise at room temperature and the mixture was stirred. After the reaction is complete, water and IN hydrochloric acid was added, the mixture was extracted with dichloromethane. The organic phase was washed with water and saturated sodium bicarbonate solution, dried and concentrated to give the product 12-c (10g, yield: 80%).

Step 3: Compound 12-c (10g, 30.4mmol), sodium sulfide nonahydrate (8. 7 5g, 36.4mmol) and N methylpyrrolidinone (50ml) were added to the flask and the mixture was stirred at 150 cC for 4 hours. The mixture was extracted with methyl t-butyl ether (80mnlx2) and water (100ml). The organic phase was washed with saturated brine (100mlx2), dried, concentrated, subjected to column chromatography to obtain the product 12-d (1.8g, yield: 35%) Step 4: Compound 12-d (500mg, 2.94mmol), anhydrous piperazine (379mg, 4.41mmoil), sodium tert-butoxide (423mg, 4.41mmol), 2,2-bis( diphenylphosphino-1,1'-binaphthyl) (83mg, 0.13mmol), palladium acetate (10mg, 0.044mmol) and dry toluene (10ml) were added to the flask under a nitrogen atmosphere and the mixture was stirred at 115 'C for 24 hours. The reaction mixture was concentrated, and subjected to column chromatography to obtain an oil. Hydrogen chloride-ethanol solution was added, the resulting hydrochloride salt was slurried in

42 acetonitrile, filtered to give a white solid (280mg, yield: 43%). ESI-MS (i z): 221 1 [+H]7.

Reference Example 13 Preparation of 4-(piperazin-1-yl)thieno[2,3-dpyrimidine trifluoroacetate Boc

0 / OH CI N

N N CF 3C0 2H

13-a 13-b 13-c

13-d

Step 1: Methyl 2-Amino-thiophene-3-carboxylate (2.0g, 12.7mmol) was dissolved in formamide (60ml) and the mixture was stirred at 190 'C for 4 hours. The mixture was cooled, poured into water (200ml) and extracted with n-butanol (50ml - 4). The combined organic phase was dried over anhydrous sodium sulfate, concentrated and subjected to column chromatography to give 13-b as a pale yellow solid (1.2g, yield: 63%). ESI-MS (mi z): 153.0 [M+1-]. 'H-NMR (300Hz,

DMSO-d6 ): 6 ppm 7.39(d, 1H), 7.57(d, 1H), 8. 12(s, IH), 12.49(brs, iH). Step 2:

Phosphorus oxychloride (10ml) was added into compound 13-b (500mg, 3.23mmol) followed by stirring at reflux overnight. The reaction mixture was cooled to room temperature, poured into a vigorously stirred ice-water mixture and stirring was continued for 30 minutes.

The mixture was extracted with dichloromethane (50ml x 3). The combined organic phase was washed with brine, dried over anhydrous sodium sulfate, and concentrated to give 13-c as a yellow solid (600mg, yield: 100%). ESI-MS (mil ): 170.9 [M-H]. IH-NMR (300Hz, CDCl3): 6 ppm 7.46(d, IH), 7.64(d, 1H), 8.87(s, iH). Step 3: Compound 13-c (600mg, 3.53 mmol) was dissolved in tetrahydrofuran (20ml), 1-boc-piperazine (984mg, 5.3mmol) and N, N-diisopropylethylamine (910mg, 7.06mmol) were added thereto followed by stirring at reflux for 2 hours. The reaction mixture was cooled to room temperature, concentrated, subjected to column chromatography to obtain 13-d as a white solid (900mg, yield: 79.4%). ESI-MS (i/z): 321.2 [M+H]I. 1H-NMR (3001Hz, CDCi;): 6 ppm 1.48(s, 911), 3.61(m, 411), 3.92(m, 411), 7.32(m, 211), 8.50(s, 11). Step 4: Compound 13-d (900mg) was dissolved in dichloromethane (10ml), trifluoroacetic acid (ml) was added at 00C and the mixture was stirred overnight at room temperature. The

43 reaction mixture was concentrated to dryness under reduced pressure, the residue was slurried in methyl t-butyl ether/methanol system(V:V=15ml :Iml), filtered, and dried to give a yellow solid (606mg, yield: 98%).

Reference Example 14 Preparation of 4-(benzo [b]thiophen-4-yl)- 1,2,3,6-tetrahydropyridine hydrochloride Br Br Br Br CHO (: COOEt \ COOH L F K. F S- 14-a 14-b 14-c 14-d Boc H N N Br MgBr OH HCI

14-e 14-f S s 14-g Step 1: A 500mL three-necked flask was charged with tetrahydrofuran (250ml) and diisopropylamine (28ml), n-butyllithium (78 ml) was added dropwise at -10 'C 0 0C under a nitrogen atmosphere. The mixture was stirred at 0 0C for 30 minutes and then cooled to -78 0 C. 3-Bromofluorobenzene (21ml) was added dropwise, after stirring at -78'C for 1 hour, N, N-dimethylformamide (I 7ml) was added followed by stirring 20 minutes at the same temperature. Then glacial acetic acid (28m]) and water (200ml) was quickly added and the mixture was warmed to 15 'C. The mixture was extracted with ethyl acetate (500ml 2), the organic phase was washed with water (300ml x 2) and brine (200ml x 1), dried over anhydrous sodium sulfate, concentrated and subjected to column chromatography to obtain the target 14-b (32g, yield: 81%). Step 2: A three-necked flask was charged with N, N-dimethylformamide (250ml) and potassium carbonate (51.5g., 373mmol). Ethyl thioglycolate (13.7 ml) was added dropwise at room temperature under a nitrogen atmosphere followed by rapid addition of compound 14-b (25.2g, 124mmol). The mixture was stirred at 60 'C overnight, diluted with ethyl acetate (300ml), filtered, and the filtrate was washed with water and saturated brine, dried, concentrated and subjected to column chromatography to obtain compound 14-c (23g, yield: 66%). Step 3: A 500mL single-neck flask was charged with compound 14-c (20g, 70.4mmol), tetrahydrofuran (120ml) and water (100ml). 4N aqueous sodium hydroxide solution (40m]) was

44 added under stirring followed by stirring at 70 0C for 1 hour. The reaction mixture was extracted with ethyl acetate (70ml x 2), the p-I of the aqueous phase was adjusted with concentrated hydrochloric acid to I - 2, the precipitated solid was filtered and dried to give compound 14-d (16g, yield: 88%). Step 4: Compound 14-d (14g, 54.6mmol) and dimethyl sulfoxide (140ml) were placed in a 25mL single neck flask, silver carbonate (15g, 54.3mmol) and acetic acid (163mg) were added thereto under stirring. The mixture was stirred at 120 'C overnight, cooled to room temperature, filtered after ethyl acetate (100ml) was added. The filtrate was extracted with ethyl acetate (200ml x 3) and water, the organic phase was dried, concentrated, subjected to column chromatography to obtain 14-e as a colorless transparent oil (I Ig, yield: 95%). Step 5: Magnesium debris (113mg, 4.7mnmol) was added to tetrahydrofuran (5mil) under a nitrogen atmosphere, the mixture was stirred for 5 min and then heated to 60 'C. Part of the tetrahydrofuran solution (1.0 g, 4.7mmol, 5ml) of compound 14-e (2ml) was added dropwise to the above systems and stirred at 60 C. The Grignard reaction began as the system turned cyan blue. The remaining tetrahydrofuran solution of the compound 14-e was added dropwise under refux and the system turned pale yellow. The reaction was continued at reflux until disappearance of magnesium debris(about 2 hours), which indicated the end of the Grignard reaction. Step 6: Tert-butyl 4-oxopiperidine- I-carboxylate (1.0g, 5mmol) in tetrahydrofuran (5ml) was added dropwise into the fresh Grignard reagent 14-f at 0 -C followed by stirring at room temperature for 1 hour. The reaction was cooled to 0 cC and saturated ammonium chloride solution was added. The mixture was extracted with ethyl acetate, washed with brine, dried, concentrated and subjected to column chromatography to obtain compound 14 -g (700mg, 44% yield by two steps). Step 7: Compound 14-g (120 mg, 0.36mnmol) was dissolved in toluene (5ml) and 6N hydrochloric acid (5ml) and the mixture was stirred at 100 'C overnight. The reaction was cooled to room temperature, the pH value of the aqueous phase was adjusted to 9.0 with 10% sodium hydroxide solution at 0 'C. The mixture was extracted with dichloromethane, dried, concentrated, the residue was dissolved in ethyl acetate and added with hydrogen chloride-ethanol solution. The resulting salt was filtered to give the target (50 mg, yield: 65%). ESI-MS (mn) 216.1 [MH] 1-- NMR (300H1z, MeOH-d4): 6 ppm 7.89(d, IH), 7.64(d, U-1), 7.56(dd, 11H), 7.37(t, 1H), 7.28(dd, 1H), 5.96(m, 1H), 3.93(m, 2H), 3.55(t, 2H), 2.85(m, 21-1).

45 Reference Example 15 Preparation of 5-(2-chloroethyl)in dolin-2-one 0

N= 'N -~N H H H 15-a 15-b Step 1:

Indolin-2-one 15-a (2g, 15.03mmol) was dissolved in dichloromethane (10ml), aluminum trichloride (7g, 52.60mmol) was added, then chloroacetyl chloride (2.26ml, 30.06 mmol) dissolved in dichloromethane (10ml) was slowly added dropwise tinder ice bath, the mixture was stirred at this temperature for 1 hour and at reflux for 2 hours. The mixture was cooled, poured into ice water, the aqueous layer was adjusted to be strongly acidic, the precipitated solid was filtered and dried to give a light gray white solid (2.811g, yield: 90%).

Step 2: Compound 15-b (Ig, 4.78mmol) was dissolved in trifluoroacetic acid (10ml), triethylsilane (1.5mi) was added dropwise under ice-cooling followed by stirring at room temperature for 2 hours. The reaction solution was poured into water, extracted twice with ethyl acetate. The organic phase was washed with saturated sodium bicarbonate solution and brine, dried and concentrated to give a khaki solid (0.9g, yield: 96%). ESI-MS (n z): 195.9 [M-1f IFI-NMR

(300Hz, CDC 3): 6 ppm 7.69(brs, 1H), 7.10(s, 1H). 7.07(d, 1H-), 680(d, 1H), 3.68(t, 2H), 3.52(s, 21), 3.02(t, 2H).

Reference Example 16 Preparation of 2-(6-chloro-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl methanesulfonate C1

MsO N 0 H N, N-dimethylformamide (8ml) and N-chlorosuccinimide (228mg, 1.7 Immol) were added into the product of Reference Example 6 (440mg, 1.63mmol) and the mixture was stirred at 100 'C for 4 hours. The mixture was extracted with dichloromethane and water, the organic phase was washed with brine, dried over anhydrous sodium sulfate, concentrated and subjected to column chromatography to give a white solid (330 mg , yield: 67%). ESI-MS (n Z): 304.0 [M+-1].

Reference Example 17 Preparation of 46 3-(2-chloroethyl)-9-fluoro-2-methyl-6,7,8,9-tetrahvdro-4H-pyrido [1,2-al pyrimidin-4-one 0 0 CI CI N N-r OH 10-a F

3 -(2-chloroethlv)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-pyrido[ 1,2-a] pyrimidi n-4-one 10-a (500mg, 2.06 mmol) was dissolved in dichloromethane (10ml), diethlvaminosulfur trifluoride (0.32ml, 2.47mmol) dissolved in dichloromethane (8ml) was added dropwise thereto under ice bath followed by stirring at room temperature for 3 hours. The mixture was quenched with water, saturated sodium bicarbonate solution was added to adjust pH to 7. The mixture was extracted with dichloromethane, dried over anhydrous sodium sulfate, concentrated and subjected to column chromatography to obtain the product as white crystal (370mg, yield: 74%).

ESI-MS (m z): 245.1 [M+H]-. 'H-NMR (300Hz, DMSO-d6 ): 6 ppm 1.92(m, 2-1), 2.15(m, 2H), 2.29(s, 31H), 2.90(t, 21), 3.55(m, 11-1), 373(t, 214), 4.00(dt, 1H), 5.26-5.47(dt, lfH).

Reference Example 18 Preparation of 5-(2-chloroethyl)-4-methylthiazole

HO S CI s N N 18-a 2-(4-methyl-thi azoI-5-yI) ethanol 18-a (500mg, 3.49mmol) was added into thionyl chloride (4ml) and the mixture was stirred at reflux for 3 hours. The mixture was concentrated to dryness to give a pale yellow solid (680 mg, yield: 98%). ESI-MS (nz): 162.0 [M+H].

Reference Example 19 Preparation of 5-(2-chloroethyl)-1 H-benzo[dIimidazol-2(3H)-one

H H H SN> o N>= N = N CI N CI N HH H 19-a 0 19-b

Step 1: 1H-benzimidazol-2(3H)-one 19-a (500mg, 3.73mmol) was added into anhydrous aluminum chloride (1.98g, 14.9mmol) and tetrachloroethane (3ml). Chloroacetyl chloride (843mg, 7.46mmol) dissolved in tetrachloroethane (3ml) was added dropwise thereto under ice

47 bath followed by stirring at 100 'C for 1 hour. The mixture was cooled to room temperature, ice and 4N hydrochloric acid 20ml) were added sequentially followed by stirring for 6 hours, the precipitated solid was filtered, the filter cake was slurried in isopropanol, filtered, and dried to give 19-b as an off-white solid (730mg, yield : 93%). EI-MS (ml z): 210. Step 2:

Compound 19-b (350mg, 1.67mmol) was dissolved in trifluoroacetic acid (5ml), triethylsilane (0.66ml, 4. 17mmol) was added dropwise under ice-cooling followed by stirring at room temperature overnight. The reaction mixture was concentrated, saturated sodium bicarbonate solution was added, the precipitated solid was filtered, the filter cake was washed three times with ice water and dried to give a pale yellow solid (3 10mg, yield: 95%). EI-MS (n '): 196.

Reference Example 20 Preparation of 6-(2-chlIoroethyl)benzo[d thiazol-2(3HI)-one

H H H N = >=N S S CI S 20-a 0 20-b Step 1: Benzothiazole-2(3H)-one 20-a (500mg, 3.307mmol) was suspended in carbon disulfide (8ml), anhydrous aluminum chloride (2.65g, 19.841mmol) was added portionwise under ice bath, then chloroacetyl chloride (324ul, 4.299mmol) was slowly added dropwise. The reaction mixture was stirred at room temperature for 10 minutes and at reflux for 1.5 hours. The reaction was quenched with ice water and concentrated. Ice water (1 5mil) and 4N hydrochloric acid (10ml) was added thereto. The mixture was stirred for 2 hours at room temperature, filtered, the filter cake was washed with ice water twice, dried to give 20-b as a pink solid (740mg, yield:

98%). ESI-MS (n z): 227.9 [M+H] . 'H-NMR (300Hz, DMSO-d6 ): 6 ppm 12.35(s, 1H), 8.25(d, 1H), 7.89(dd, 1H), 7.20(d, 1H), 5.13(s, 2H). Step 2: Compound 20-b (360mg, 1.586mmol) was dissolved in trifluoroacetic acid (5ml), triethylsilane (630ul, 3.965mmol) was added dropwise followed by stirring at 10 'C overnight. The reaction mixture was concentrated, extracted with di chloromethane and water. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to give a crude(385ig), which was purified by column chromatography to obtain the target (280mg, yield: 82.5%).

48 Reference Example 21 Preparation of 6-(2-chlIoroethyl)-2H1-beizo[b][1,4]oxazin-3(4[H)-one

0 CI N I O H O H H 21 -a 21-b

Step 1: 2H-1,4-benzoxazin-3(4H)-one 21-a (500mg, 3.356mmol) was suspended in dichloromethane (8ml). Anhydrous aluminum chloride (895 mg, 6.712mmol) was added portionwise under ice bath, then chloroacetyl chloride (330ul, 4.363mmol) was added slowly dropwise. The reaction mixture was stirred at room temperature for 10 minutes, then at reflux for 5 hours. The reaction was quenched with water, concentrated. The residue was added with ice water (10ml), 4N hydrochloric acid (5ml) and stirred for 2 hours at room temperature, then filtered, the filter cake was washed with ice water twice, dried to give 21-b as a pale yellow solid (690mg, yield: 91%).

Step 2: Compound 21-b (370mg, 1.637mmol) was dissolved in trifluoroacetic acid (4ml), triethylsilane (640ul, 4.093mmol) was added dropwise under ice-bath followed by stirring at 10 'C overnight. The reaction solution was concentrated and extracted with dichloromethane and water. The organic phase was dried over anhydrous sodium sulfate, filtered and concentrated to give a crude (375mg). The crude was slurried in petroleum ether, filtered and dried to give a pale yellow solid (316mg, yield:91%). 'H-NVR (300Hz, DMSO-d6 ): 6 ppm 10.68(brs, 1H), 6.86(d, 11), 68 1(dd, 1H-), 6.74(d, 1-1), 4.51 (s, 2H), 3.75(t, 2H), 2.90(t, 2H).

Reference Example 22 Preparation of 6-(2-chloroethyl)-2H-benzo[b][1,4]thiazin-3(4H)-one

ICs S1 o CI N I N H 0 H H 22-a 22-b

Step 1: Anhydrous aluminum trichloride (1.62g, 12.15mmol) was added portionwise into chloroacetyl chloride (912ul, 12.1lmmol) dissolved in methylene chloride (6ml) under ice bath followed by stirring for 10 minutes at this temperature. Then 2H-,4-benzothiazine-3(41-)-one 22-a (500mg, 3.027mmol) was added portionwise thereto, the reaction was stirred under ice 49 bath for 4 hours and at room temperature overnight. Ice water (10ml) and 4N hydrochloric acid (10ml) was added sequentially. The mixture was stirred at room temperature for 2 hours. The precipitated solid was filtered, the filter cake was washed twice with ice water, dried to give

22-b as a pale yellow solid (700mg, yield: 95.6%). H-NMR (300Hz, DMSO-d6 ): 6 ppm 10.76(brs, 111), 7.57(dd, 1H), 7.50(m, 211), 5.11(s, 2H), 3.54(s, 21H). Step 2: Compound 22-b (350mg, 1.446mmol) was dissolved in trifluoroacetic acid (4ml). triethylsilane (578ul, 3.615mmol) was added dropwise thereto under ice bath condition followed by stirring at 30 'C overnight. The reaction mixture was poured into ice water, extracted with dichloromethane, the organic phase was dried over anhydrous sodium sulfate, filtered, concentrated and subjected to column chromatography to give a pale yellow solid (285mg, yield: 86.8%). EI-MS (ml z): 227.

Reference Example 23 Preparation of 5-(4-oxo-3,4-dihvdroquinazolin-6-yl)pentyl methanesulfonate

COOMe 0 HO HO : ~NH 11-f NH2 HN 23-a N MsO NH

NY

Step 1: A mixture of compound 11-f (395mg, 1.66mmol), ammonium formate (1.04g, 16.6mmol) and formamide (5ml) was stirred at 135 'C for 60 hours. The reaction mixture was poured into ice water and extracted with ethyl acetate three times. The combined organic layer was washed with brine, dried over anhydrous sodium sulfate, concentrated and subjected to column chromatography to obtain the target 23-a (150mg, yield: 38%). ESI-MS (i z): 233.2 [M +H].

tH-NMR (300Hz, DMSO-d 6): 6 ppm 12.17(brs, 111), 8.03(s, 11-), 7.90(d, 11-), 7.65(dd, FI), 7.57(d, 1H), 4.36(t, 1H), 3.37(m, 211), 2.70(t, 211), 1.60(in, 2H), 1.43(n, 21). 1.30(m. 2H). Step 2: Triethylamine (125ul, 0.87mmol) was added to the compound 23-a (100mg, 0.43mmol) in dichloromethane (5ml). Methanesulfonyl chloride (51ul, 0.65mmol) was added thereto under ice-bath followed by stirring at room temperature for 2 hours. The reaction was diluted with dichloromethane, washed with saturated ammonium chloride solution, the organic phase was dried, concentrated and subjected to column chromatography to obtain a white solid (71mg, yield: 53%). ESI-MS (m z): 311.1 [M--f

50 Reference Example 24 Preparation of 2-(2-chloroethyl)quinazolin-4(3H)-one 0 0 O' HN

NH2 CI N 24-a o-aminobenzoate 24-a (1.0g, 6.62mmol), acrylonitrile (0.88ml, 13.24nmol) were dissolved in 1,4-dioxane, hydrogen chloride-1,4-dioxane (10ml) solution was slowly added thereto under ice bath condition. The mixture was stirred in a sealed tube at 80 0 C overnight and concentrated. Water and dichloromethane was added thereto and the pH value of the aqueous layer was adjusted to 7-8 with ammonia. The mixture was filtered, the filter cake was slurried in methyl t-butyl ether, filtered and dried to give a pale yellow solid (660mg, yield: 52%). ESI-MS (m z): 209 1 [M-+-H]7

Reference Example 25 Preparation of 3-(2-oxoindolin-5-yl)propyl methanesulfonate 0

O CI-- O- CI O H H H 15-a 25-a Step 1: 3-chloropropionyl chloride (53 8ul, 5.63mmol) was added dropwise to anhydrous aluminum chloride (2g, 15.02mmol) suspended in carbon disulfide under ice bath condition and stirred for 10 minutes, indolin-2-one 15- a (500mg, 3.75mmol) was added thereto. The mixture was stirred at room temperature for 15 minutes and at reflux for 3 hours. Carbon disulfide was removed, the reaction mixture was added with ice and 4N hydrochloric acid (5ml) under stirring. The resulting solid was filtered, the filter cake was washed 3 times with ice water, dried to give a crude. The crude was scurried in ethyl acetate, filtered and dried to give 25-a as a pale

1 pink solid (777mg, yield: 92.4%). HNMR (300MHz, DMSO-d 6): 6 ppm 10.77(s, 1H), 7.86(d, 1lH), 7.81(s, 1H), 6.89(d, 11), 3.89(t, 21), 3.54(s, 2H), 344(t, 2H). Step 2: Triethylsilane (900u], 5.58mmol) was added dropwise to compound 25-a (500mg, 2.32mmol) dissolved in trifluoroacetic acid and the mixture was stirred at 30 'C overnight. The reaction mixture was poured into ice water, and extracted three times with dichloromethane, the combined organic phase was dried and concentrated. The residue was slurried in petroleum 51 ether/acetone system(V: V=30: 1), filtered and dried to give a light pink solid (430mg, yield: 92%).

Reference Example 26 Preparation of 4-(piperaziii-1-vI)thieno[2,3-cIpyridine trifluoroacetate

Br Br Br Br

NHO N COOEt --- 0 N B.Br Br Nzz.. s 0~.OH 26-a 26-b 26-c 26-d BocN N Br N N CF3 CO 2 H

26-e N , N.0S. 26-f Step 1: Diisopropylamine (2.4g, 24 Ommol) was dissolved in dry tetrahydrofuran (20ml) under a nitrogen atmosphere, n-butyllithium in n-hexane(9.6ml, 24.Ommol) was added dropwise thereto at 0 C followed by stirring at this temperature for 30 minutes, dry tetrahydrofuran (30ml) was added and the mixture was cooled to -78 C, 3,5-dibromo-pyridine 26-a (4.7g, 20mml) in dry tetrahydrofuran (50ml) was added dropwise thereto followed by stirring for 30 minutes. Methyl formate (2.4g, 40mml) was added followed by stirring for 30 minutes, The mixture was warmed to room temperature, extracted with saturated sodium bicarbonate (100ml) and ethyl acetate

(50ml x 3). The combined organic phase was dried over anhydrous sodium sulfate, concentrated and subjected to column chromatography to give 26-b as a pale yellow solid (4.0 g, yield: 75%). 'HNMR (300MHz, DMSO-d 6): 6 ppm 10.06(s, 1H), 8.87(s, 2H). Step 2: Compound 26-b (2.0g, 7.5mmol) was dissolved in tetrahydrofuran (10ml), ethyl thioglycolate (0.68ml, 7.5mmol) was added thereto at 0 'C and the mixture was stirred for 1 hour. Cesium carbonate (2.46g, 7.5mmol) was added thereto followed by stirring at room temperature overnight. The reaction mixture was filtered, concentrated and subjected to column chromatography to give 26-c as a white solid (1 6g, yield: 74%). ESI-MS (n z): 286. 1 M-+H].

HNMR (300MHz, DMSO-d 6): 6 ppm 9.36(s, 11-), 8.71(s, 111), 8.01 (s, 111), 4.39(q, 21-), 1.34(t, 3 H). Step 3: Compound 26-c (2.0g, 7.0 mmol) was dissolved in tetrahydrofuran(40ml), lithium hydroxide monohydrate (588mg, 14.Ommol) and methanol (5ml) were added thereto followed

52 by stirring at room temperature for 2 hours. The pH value of the mixture was adjusted to 4 with 2N hydrochloric acid. The mixture was concentrated to remove tetrahydrofuran and methanol, filtered, and dried in vacuum to give 26-d as a white solid (1.0g, yield: 55%). 1HNIMR

(300M1z, DMSO-d 6): 6 ppm 9.33(s, 1H), 8.69(s, 11) 7.94(s, 1H). Step 4: Compound 26-d (500mg, 1.9mol) was added into diphenyl ether (6ml) and stirred at 230 'C for 2 hours. The mixture was cooled to room temperature, concentrated and subjected to silica gel column chromatography to obtain 26-e as a white solid (300mg, yield: 73%). ESI-MS

(mz): 213.8 [M+H]i. 'HNMR (300MHz, CDCl 3): 6 ppm 9.10(s, 1H), 8.60(s, 1H), 7.89(d, 11), 7.54(d, 1H). Step 5: Compound 26-e (1.5g, 7.0 mmol), 1-boc-piperazine (2.6g, 14.0mml), 2,'-bis(diphenylphosphino-1,1'-binaphthyl) (436mg, 0.7mml), tris(dibenzylideneacetone) dipalladium (320.3mg, 0.35mmol) and sodium tert-butoxide (1.34g, 14.Omml) were dispersed in anhydrous toluene (50ml) and stirred at 100 cC overnight under a nitrogen atmosphere. The reaction was cooled to room temperature, filtered, concentrated and subjected to silica gel column chromatography to obtain 26-f as a pale yellow solid (1.7g, yield: 77%). ESI-MS (m z): 320.3 [M+1 Step 6: Compound 26-f (687mg) was dissolved in dichloromethane (10ml), trifluoroacetic acid (3.0 ml) was added thereto under 00C followed by stirring at room temperature overnight. The reaction mixture was concentrated to dryness under reduced pressure, the residual oil was slurried in methyl t-butyl ether/methanol (V: V=1 5ml :1 ml) system, fi altered, and dried to give a 1 yellow solid (941 mg , yield: 98%). HNMR (300MHz, CDCl 3): 6 ppm 8.90(s, 1H), 8.06(s, 111), 7.89(d, 1H), 7.51(d, 11-), 3.68(t, 411), 3.21(t, 411). 1.49(s, 911).

Reference Example 27 Preparation of 3-(2-oxo-1,2,3,4-tetrahydroq uinolin-7-yl)propyl methanesulfonate

TfO N 0 N 0 H HO0, H 2-b 27-a

HO N 0 MsOOMS N 0 H H 27-b Step 1: Compound 2-b (10.g, 33.9mmol), Bis(triphenylphosphine) palladium dichloride (1.2g,

53 1.7mmol), triphenylphosphine (888.2mg, 3.39mmol), cuprous iodide (644mg, 3.39mol) and diisopropylamine (17.17g, 170.Ommol) were dispersed in N, N-dimethyiformamide (100ml) and the mixture was heated to 80 'C under a nitrogen atmosphere. Propargyl alcohol (9.5 g, 170.0mmol) was added dropwise followed by stirring for 4 hours. The reaction mixture was cooled, concentrated, subjected to column chromatography to give a pale yellow solid (4.0 g, yield: 58%). ESI-MS (n z): 202.1 [M+H]. IHNMR (300-MHz, DMSO-d): 6 ppm 10.14(s, 1H), 7.14(d, 1H), 6.93(dd, 1H), 6.85(d, 1H), 5.30(t, 1H), 4.25(d, 2H), 2.85(t, 2H), 2.42(t, 2H). Step 2: Compound 27-a (2.0g, 10.0 mmol) was dissolved in methanol (50m]), 10% Pd / C (200mg) was added and the mixture was stirred under a hydrogen atmosphere overnight. The reaction mixture was cooled, filtered, concentrated and subjected to column chromatography to give 27-b as a white solid (1 2 g, yield: 58%). ESI-MS (ml '): 206.2 [M1H]*. 'HNMR (300MIz, 9 DMSO-d6 ): 6 ppm 9. 8(s, 1H),-7.02(d, 1H), 6.71(dd, 1H), 6.64(d, 1H), 4.44(t, 1H), 337(q, 2H), 2.78(t, 2H), 2.49(t, 2H), 2.39(t, 2H), 1.63(m, 2H). Step 3. Compound 27-b (600mg, 2.93mmol) was dissolved in dichloromethane (10ml) and trimethylamine (443.9mg, 4.4mmol) was added. Methanesulfonyl chloride (404mg, 3.51mmol) was added dropwise under ice bath condition followed by stirring at room temperature for 2 hours. Di chloromethane (100ml) was added thereto, the organic phase was separated, washed with IN hydrochloric acid and saturated sodium bicarbonate solution, dried over anhydrous sodium sulfate, concentrated and the residue was purified by column chromatography to give a 1 white solid (745mg, yield: 90.5%). ESI-MS (nvz): 284.1 [M+I]7. HNMR (300MHz, CDCl 3): 6 ppm 8.76(s, 1H), 7.08(d, 1H), 6.81(d, 1H), 6.63(s, 1H), 4.21(t, 2H), 3.01(s, 3H), 2.93(t, 2H), 2.70(t, 2H), 2.63(t, 2H), 2.04(m, 2H).

Reference Example 28 Preparation of 3-(2-oxo-1,2-dihydroquinolin-7-yl)propyl methanesulfonate

MsO NO O H By a similar method as in Reference Example 3, 3-(2 -oxo-1,2-dihydroquinolin-7-yl)propyI methanesulfonate was prepared from the product of Reference Example 27 as a gray solid, yield 37.5%. ESI-MS (m ): 282.2 [M+H]. HNMR

(300MHz, DMSO-de): 6 ppm 11.67(s, 1H), 7.83(d. 11-), 7.56(d, 1H). 7.10(s. 11-1), 704(d, 1H). 6.40(d, 11), 4 19(t, 21-1), 3.16(s, 31-), 2.71 (t, 2H), 1.96(m, 21-).

Reference Example 29 54 Preparation of 7-(2-chloroethyl)-4,5-dihydro-1H1-benzo[blazepin-2(311)-one 0 CI CI N N N HO H O H O 29-a 29-b Step 1: Chloroacetyl chloride (470pl, 6.20mrnmol) was added dropwise into anhydrous aluminum chloride (2.48g, 18.60mmol) suspended in carbon disulfide under ice bath condition and stirred for 10 minutes. 4,5-dihydro-benzo-iH-azepine-2(3H)-one 29-a (500mg, 3.10mmol) was added and the mixture was stirred at room temperature for 15 minutes and at reflux for 3 hours. Carbon disulfide was removed, ice and 4N hydrochloric acid (5ml) was added sequentially under stirring. The precipitated pale yellow solid was filtered, washed 3 times with ice water, dried to give a crude. The crude was recrystallized in water-methanol system(1 Imil: 1l) to give the product as tan needles (640mg, yield: 86.7%). 'HNMR (300MHz, CDC): 6 ppm 8.31(s, 11), 7.86(d, 11), 7.84(dd, 11), 7.07(d, 11), 4.67(s, 2H), 2.88(t, 214), 241(t, 2H), 2 29(m, 21H).

Step 2:

Triethylsilane (840iL, 5.25mmol) was added dropwise into compound 29-b (500mg, 2. 10mrnol) dissolved in trifluoroacetic acid (5ml) and the mixture was stirred at 50 'C overnight. The reaction mixture was poured into ice water, extracted three times with dichloromethane. The combined organic phase was dried and concentrated. The residue was slurried in isopropyl ether, filtered and dried to give a pale yellow solid (430 mg, yield: 91.4%).

Reference Example 30 Preparation of 2-(2-oxoindolin-6-yl)ethyl methanesulfonate

O 2 OH OE EOEt

Ho Eto EtO K 30-a 30-b 30-c 0 1O EtO HO MNIIsO N 30-d 30-e H H Step 1:

The reaction flask was charged with 2,2'-(1,4-phen ylene)diacetic acid 30-a (9.2g, 47.4mmol) and ethanol (50ml), concentrated sulfuric acid (5m], 94.8mmol) was slowly added dropwise under stirring. The mixture was stirred at 80 'C overnight and then concentrated

55 tinder reduced pressure to remove ethanol. Dichloromethane was added and the pH- value of the aqueous layer was adjusted to 8 with saturated sodium bicarbonate solution. The aqueous phase was separated and extracted again with dichloromethane.The combined organic phase was dried and concentrated to give 30-b as solid (10.3g, yield: 87%). ESI-MS (m z): 251 2 [M111. Step 2: The reaction flask was charged with compound 30-b (10g, 40mmol) and concentrated sulfuric acid (30ml), fuming nitric acid (1 7ml, 40.4mmol) was added dropwise thereto at 0 'C followed by stirring at room temperature for 1 hour. The reaction mixture was poured into ice water, the precipitated solid was filtered, washed with water and dried to give 30-c as solid(1 1g, yield: 93%). Step 3: Ethanol ('25ml) and 10% Pd/C (850mg) were added into compound 30-c (4.7g, 15.9mmol) and the mixture was stirred at 40 'C under a hydrogen atmosphere overnight. The mixture was filtered at 40 'C, the filtrate was concentrated to give a crude(3.lg). The crude was scurried in petroleum ether/ethyl acetate (V:V=6: 1) system, filtered to obtain 30-d (24g, yield: 71%). EI-MS (ml ): 219. 11-NMR (300MHz. CDCls): 6 ppm 8.80(brs, 1H),7.17(d, 1H), 6.93(d, 111). 6.86(s, 11), 4.17(q, 211), 3.60(s. 2H), 3.52(s, 21), 1 28(t, 31H). Step 4: The reaction flask was charged with compound 30-d (2.86g, 13.Ommol) and tetrahydrofuran (200m]), lithium aluminum hydride (2.5g, 65.3mmol) was added portionwise at 0 'C followed by stirring for 30 minutes. Water (1.24ml), 15% aqueous sodium hydroxide solution (1.24ml) and water (3.72 ml) were slowly added dropwise successively. The mixture was filtered and concentrated. The residue was slurried in dichloromethane, filtered to give a crude(1 28g). The crude was scurried in petroleum ether/dichloromethane system, filtered and dried to give 30-c as a white solid (1. 17g, yield: 50%). ESI-MS (n :): 178.1 [M+H-1-1]v. 'THNMR

(300MHz, DMSO-d 6): 6 ppm 10.3 1(brs, lH1), 7.07(d, IH), 6.76(d, 11), 6.68(s., lH1), 4.64(t, 1H), 3.57(q, 2H), 3.39(s, 2H), 2.67(t, 2H). Step 5: Compound 30-e (200mg, 1.Immol) and pyridine (0.24, 3.3mmol) were suspended in dichloromethane. Methanesulfonyl chloride (0.12ml, 1.21mmol) was slowly added thereto dropwise under ice bath followed by stirring at room temperature for 4 hours. The reaction mixture was poured into water, washed with IN hydrochloric acid and saturated brine, the organic phase was dried, filtered and concentrated to give the target (220 mg, yield: 76%). ESI-MS (i z): 256.0 [M1HI]v.

Reference Example 31 Preparation of 4-(benzo[bithiophen-4-yl)piperidine trifluoroacetate 56 Boc Boc Boc Br Br N N N

CHO - -- F F CHO CHO : OH ~ H 31-a 31-b F F F 31-c 31-d 31-e Boo Boc BocH N N N N

CF 3C0 2H

COOEt -- COOH

-. S -.- S S~ 31-f 31-g 31-h

Step 1: Diisopropylamine (5.14g, 50.8mrnmol) was dissolved in dry tetrahydrofuran (50ml) under a nitrogen atmosphere, n-butyllithium in hexane (20.3ml, 50.8mml) was added dropwise thereto at 0 'C followed by stirring for 30 minutes. The reaction mixture was cooled to -78 'C, 1-bromo-3-fluorobenzene 31-a (10.0g, 42.4mml) in dry tetrahydrofuran (100ml) solution was added dropwise thereto followed by stirring for 30 minutes. Methyl formate (7.63g, 127.2mml) was added dropwise thereto followed by stirring for 30 minutes. The mixture was warmed to room temperature, extracted with ethyl acetate(100ml x 3) and IN hydrochloric acid (100ml). The combined organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, subjected to column chromatography to give 31-b as a white solid (8.0 g, yield: 93%).

Step 2: Compound 31-b (4.1 g, 20.4mmol), tert-butyl

4-(4,4,5, 5-tetramethyl- 1,3 ,2-di oxaborolan-2-yl)-5,6-dihy dropyri dine-I (2H)-carboxylate (6.3g, 20.4mmol), 1, '-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride-dichloromethane complex

(Pd(dppf )Cl 2.CH 2Ci 2, 1.7g, 2.04mmol) and potassium carbonate (7.04g, 51.Ommol) were dispersed in anhydrous N, N-dimethylformamide (80ml) and stirred at 80 'C under a nitrogen atmosphere overnight. The reaction was cooled to room temperature, poured into water (200ml) and extracted with ethyl acetate(100ml x 3). The combined organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated, subjected to column chromatography to give 31-c as a colorless oil (3.5 g, yield: 55.5%). lHNMR (300MHz, CDCi;):

6 ppm 10.26(s, 1H), 7.50(m, 1-1), 7.09(t, 111), 7.03(d, 1-1), 5.55(s, 11), 4.05(m, 21), 3.67(m, 2H), 2.33(s, 2H), 1.49(s, 91-1). Step 3: Compound 31-c (3.5g, Il.5mmol) was dissolved in ethyl acetate (50ml), 10% Pd / C (1 Og)

57 was added and the mixture was stirred at room temperature under a hydrogen atmosphere for 5 hours. The mixture was filtered, the filtrate was concentrated to give 31-d as a colorless oil

(3.5g, 100%). ESI-MS (m z): 310.1 [MH11-1]. .-IN MR (300MHz, DMSO-d 6): 6 ppm 7.26(dd, 111), 7.04(d, 114), 6.93(t, 114), 4.80(s, 214), 4.24(d. 2H), 3.08(t, 1-I), 2.84t, 21-), 1.78(d, 21H), 1.72-1.53(m, 411), 1.47(s, 911). Step 4: Compound 31-d (3.5g, 11.5 mmol) was dissolved in dichloromethane (50ml), pyridinium chlorochromate (PCC, 3.0g, 13.8mmol) was added thereto at room temperature followed by stirring for 1 hour. The mixture was filtered, concentrated and subjected to column chromatography to obtain 31-e as a white solid (3.0g, yield: 85%). ESI-MS (iz): 308.1 [M+H]4. 1HNMR (300MHz, CDCI;): 6 ppm 10.54(s, 11), 7.51(dd, ll), 7.16(d, IH), 7.02(t, 114), 4.23(d, 21), 3.78(t, 111), 2.86(t, 211), 1.78(d, 21), 1.57(m., 211), 1.47(s, 911). Step 5: Compound 31-e (3.0g, 9.4 mmol) was dissolved in acetonitrile (50ml), potassium carbonate (1.95g, 14.1mmol) and ethyl thioglycolate (0.85ml, 9.4mmol) were added thereto followed by stirring at 80 'C overnight. The mixture was filtered, concentrated and subjected to column chromatography to give 31-f as a white solid (3.3g, yield: 90.1%). ESI-MS (nl ): 390.0 [M+!H]. 1HNMR (300MHz, CDCi;): 6 ppm 8.20(s, 1[1), 7.71(d, 114), 7.41(t, 11-1), 7.22(d, 1H-), 4.41(q, 214), 4.30(d, 2H), 3.22(m, 1H), 2.90(t, 214), 1.91(d, 2H), 1.75(m, 214), 1.49(s, 91). 1.42(t, 3 1-) Step 6: Lithium hydroxide monohydrate (698mg, 16.6mmol) and methanol (10ml) were added into compound 31-f (3.24g, 8.3mmol) dissolved in tetrahydrofuran (60ml) and the mixture was stirred at room temperature for 5 hours. The pH of the reaction mixture was adjusted to 4-5 with IN hydrochloric acid, the precipitated solid was filtered, dried in vacuo to give 3 1-g as a white solid (2.8g, yield: 96.5%). Step 7: Cuprous oxide (966mg, 0.676mml) was added into compound 31-g (2.44g, 6.76mmol) dispersed in quinoline (30ml) and the mixture was stirred at 140 'C for 5 hours, then cooled to room temperature. The pH value of the mixture was adjusted to 4-5 with 1N hydrochloric acid. The mixture was extracted with ethyl acetate (100ml x 3). The combined organic phase was dried over anhydrous sodium sulfate, filtered, concentrated, subjected to column chromatography to give 31-h as a white solid (1.0g, yield : 46.7%). ESI-MS (m/lz): 318.2 [M+H-1]. H1{NMR (300MHz, CDCI-): 6 ppm 7.76(d, 1H), 7.47(s, 214), 7.32(t, 1H), 7.19(d, 1H), 4.31(s, 21), 3.20(t, 114), 2.89(t, 2H), 1.93(d, 2H), 1.77(m, 2H), 1.49(s, 9H). Step 8: Compound 31-h (400mg, 1.26mmol) was dissolved in dichloromethane (iml), 58 trifluoroacetic acid (I ml) was added followed by stirring at room temperature overnight. The reaction mixture was concentrated to dryness, the residual oil was scurried in methyl tert-butyl ether/methanol (V:V=: 15ml:1ml) system, filtered, and dried to give a yellow solid (219 mg, yield: 80%). ESI-MS (m z): 218.0 [M+H].

Reference Example 32 Preparation of 2-(6-chloro-2-oxo-1,2-dihydroquinolin-7-yl)ethyl methanesulfonate

MsO O MsO N 0 H H A reaction flask was charged with the product of Reference Example 16 2-(6-chloro-2-oxo- 1,2,3,4-tetrahydro-quinolin-7-yl) ethyl methanesulfonate (330mg, 1.09mmol) , 1,4-dioxane (5ml) and 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ, 740mg, 3.26mmol) were added thereto followed by stirring at reflux overnight. After completion of the reaction, the mixture was concentrated and di chloromethane (25ml) was added. The mixture was washed with saturated sodium bicarbonate solution, saturated sodium thiosulfate solution and brine sequentially. The organic phase was dried, concentrated and purified by column chromatography to obtain the target (180mg, yield: 55%). ESI-MS (m ): 301.9 [M+H]7.

Reference Example 33 Preparation of 6-(2-chloroethyl)-3-methyl-3,4-dihydroq uinazolin-2(1H)-one 0

H H H 33-a 33-b Step 1:

Chloroacetyl chloride (460L, 6.16mmol) was added into anhydrous aluminum chlioride(l.03g, 7.7mmol) suspended in 1,2-dichloroethane under ice bath condition and stirred for 10 minutes. 3-methyl 3,4-dihydro-quinazolin2(H1-L)-one 33-a (500mg, 3.08mmol) was added and the mixture was stirred at room temperature for 15 minutes and at 48 0C for 3 hours. The reaction mixture was cooled to room temperature and poured into ice. The precipitated pale yellow solid was filtered, the filter cake was washed 3 times with ice water, dried to give compound 33-b as a pale yellow solid (710mg, yield: 97%) 'FINMR (300MHz, DMSO-d 6)' a ppm 9.72(s, 1H), 7.82-7.73(m, 2H), 6.84(d, 1H), 5.06(s, 2H), 4.47(s, 2H), 2.87(s, 3H). Step 2:

59 Tri ethylsilane (587i 1, 3.68mmol) was added dropwise into compound 33-b (350mg, 1.47mmol) dissolved in trifluoroacetic acid (4ml) and the mixture was stirred at 35 'C for 2.5 hours. The reaction solution was poured into ice water, the precipitated solid was filtered, the filter cake was washed 3 times with ice water, dried to give a pale yellow solid (320mg., yield: 97%).

Reference Example 34 Preparation of 2-(1H-indol-3-yI)ethyl methanesulfonate OH OMs

~~CN [ N H H 34-a Compound 34-a (200mg, 1.24mmol) was dissolved in dichloromethane (5ml), triethylamine (0.206m], 1.49mmol) was added, methanesulfonyl chloride (0.105ml, 1.36mmol) was added dropwise under ice bath condition and the mixture was stirred at room temperature for 3 hours.The mixture was extracted with dichloromethane and water. The organic phase was washed with brine, dried and concentrated to give the target (260mg, yield: 87%). ESI-MS (mz): 240.0 [M+H].

Reference Example 35 Preparation of 6-(2-chloroethyl)-3,4-dihvdroquin olin-2(111)-one 0 CI CI

-0 CI"AN 0 :' N 0 H H H 35-a 35-b Step 1: Chloroacetyl chloride (640pd, 8.49mmol) was added to anhydrous aluminum chloride (2.72g, 20.38mmol) suspended in carbon disulfide (10ml) under ice bath. The mixture was stirred for 10 minutes and 3,4-di hydroquinoline-2(1H)-one 35-a (500mg, 3.40mmol) was added. The system was stirred at room temperature for 15 minutes and at reflux for 9 hours. Carbon disulfide was removed, ice and 4N hydrochloric acid (5ml) were added under stirring. The precipitated solid was filtered, dried to give a crude. The crude was slurried in ethyl acetate, filtered, dried to give an off-white solid (710mg, yield: 93%). 'ININMR (300MHz. DMSO-d6): 6 ppm 10.46(s, 11-), 7.81(d, lH1), 7.78(dd, 1H-), 6.92(d, 1H-), 5.07(s, 2H), 2.93(t, 21H), 2.48(t, 214). Step 2: Triethylsilane (900ptL, 5.58mmol) was added dropwise into compound 35-b(500mg, 60 2.32mmol) dissolved in trifluoroacetic acid (5ml) and the mixture was stirred at 30 'C overnight. The reaction mixture was poured into ice water (15ml x 3) and extracted with dichloromethane. The combined organic phase was dried, filtered and concentrated. The residue was scurried in petroleum ether, filtered, dried to give the target product as a brown solid (417mg, yield: 89%).

Reference Example 36 Preparation of 2-(2-oxoindolin-4-yI)ethyl methanesulfonate

HO MsO

0 - 0 N 'N H H 36-a

4-(2-hydroxyethlv)indolin-2-one 36-a (500mg, 2.822mmol) was dissolved in dichloromethane (151mi) and pyridine (335mg, 4. 233mmol) was added. Methanesulfonyl chloride (356mg, 3.104mmol) was added dropwise thereto at 0cC followed by stirring at room temperature overnight. The mixture was diluted with dichloromethane (15 ml), washed with IN hydrochloric acid, water, and brine sequentially. The organic phase was dried over anhydrous sodium sulfate, concentrated and subjected to column chromatography to obtain a yellow solid (460mg, yield: 64%). ESI- MS (mnX): 256.0 [M+H17.

Reference Example 37 Preparation of tert-butyl 4,5-diethyl-2-(2-((methylsulfoiiyl)oxy)ethyl)-6-oxopyrimidine-1(6H)-carboxylate O 0 0 HO NH -- O .HCIt ODI* ' 5 NH2 37-a 37-b HO N CAH5 0 0 37-c

BocN C2 H5 BocN C2H5 N ------A.N 1

HO N CH 5 MsO N CH5 37-d Step 1:

A mixture of compound 37-a (2.0g, 16.3mmol), ethyl 2-ethyl-3-oxopentanoate 37-b (6.0g, 19.5mmol), potassium carbonate (9.4g, 48.9mmol) and ethanol (20ml ) was stirred at reflux for 15 hours, then cooled and filtered. The filtrate was concentrated and subjected to column chromatography to obtain the target (198mg). 1H-NMR (300Hz, DMSO-d 6): 6 ppm 12.09(brs,

61 I H), 4.75(brs, 11-1), , 2.61(t, 2H), 2.45(q, 2H), 2.37(q, 2H), 1.11(t, 31), 0.98(t, 31H). Step 2: Di-tert-butyl dicarbonate (317mg, 1.45mmol) was added into compound 37-c (250mg, 1.32mmol) suspended in tetrahvdrofuran(15ml) and the reaction mixture was stirred at 25 30 C overnight. The mixture was concentrated and subjected to column chromatography to obtain a pale yellow oil (494mg). Step 3: Compound 37-d (494mg, 1.667mmol) was dissolved in dichloromethane (20ml) and triethylamine (253mg, 2.5mmol) was added. Methanesulfonyl chloride (210mg, 1.834mmol) was added thereto under 0 ~ 5 C followed by stirring at room temperature for 1 hour. The reaction mixture was washed with water and brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated and subjected to column chromatography to obtain the target (520mg). E'S1-MS (m, z): 374.3 [M+-H].

Reference Example 38 Preparation of tert-butyl 2-(2-((methylsulfonvl)oxy)ethyl)-6-oxopyrimidine-1(6H)-carboxylate

0 Boc~~

MsO N

By a similar method as in Reference Example 37, tert-butyl

2-(2-((n ethyl sulfonyl)oxy)ethyl )-6-oxopyrimidi ne-I (61-1)-carboxyl ate was prepared from Ethyl propiolate. ESI-MS (m z): 319.1 [M-H-].

Example

Example I

6-chloro-5-(2-(4-(2,3-dihydrobenzo[blthiophen-4-yl)piperazin-1-yl)ethyl)indolin-2-one 6-chloro-5-(2-chloroethyl)indolin-2-one (120mg, 0.52mmol), the product of Reference Example 12 (115mg, 0.52mmol), potassium carbonate (215mg, 1.56mmol), potassium iodide (86mg, 0.52mmol) and acetonitrile (5ml) were added to the flask and the mixture was stirred at 85 'C overnight. The reaction mixture was concentrated and subjected to column chromatography to obtain a white solid (120 mg, yield: 56%). IHNMR (300MIz, DMSO-d6 ): 6 ppm 10.42(brs, 11-1), 7.21(s, IlH), 7.07(t, 111), 6.90(d. IH)., 6.80(s, 11-1), 6.69(d, 11), 3.45(s, 211), 3.30(t, 2H), 3.14(t, 2H), 2.74-2.95(m, 61H), 2.59(brs, 4H), 2.50(t, 2H).

62 ESI-MS (mnX): 414.2 [M+H].

Example 2

3-(2-(4-(2,3-dihydrobenzo[bithiophen-4-yl)piperazin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,

9-tetrahydro-4-pyrido[1 ,2-alpyrimidin-4-one 3-(2-chloroethlv)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1I ,2-a]pyrimidin-4-on e 10-a (120mg, 0.49 mmol), the product of Reference Example 12 (109mg, 0.49mmol), potassium carbonate (202mg, 1.47mmol), potassium iodide (81mg, 0.49mmol) and acetonitrile (5ml) were added to the flask and the mixture was stirred at 85 'C overnight. The reaction mixture was concentrated and subjected to column chromatography to give a pale yellow solid

(120mg, yield: 56%). 'HNMR (300MHz, DMSO-d6): 6 ppm 7.07(t, 1H), 6.89(d, 1H), 6.69(d, 1H), 5.68(d, 1H), 4.44(m, 1H), 3.89(m, 1H), 3.66(m, 1H), 3.30(t, 2H), 3.14(t, 2H), 2.87(brt, 41-1), 2.53-2.67(m, 61-), 2.39(t, 2H), 2.26(s, 3H1), 1.73-2.06(m, 4H). ESI-MS (i z): 427.2

[M+H]H.

Example 3 3-(2-(4-(benzo [b] thiop hen-4-yl)piperazin-1 -yl)ethyl)-2-m ethyl-6,7,8,9-tetrahydro-4 H-py rid o11,2-alpyrimidin-4-one 3-(2-chl oroethyl)-2-methyl-67, 8,9-tetrahydro-4N-pyrido[ I,2-a]pyrimidin-4-one (120mg, 0.53mmol), the product of Reference Example 1(116mg, 0.53mmol), potassium carbonate (219mg., 1.59mmol), potassium iodide (88mg, 0.53mmol) and acetonitrile (5ml) were added to the flask and the mixture was stirred at 85 'C overnight. The reaction mixture was concentrated and subjected to column chromatography to obtain a white solid (120 mg, yield: 55%). 'HNMXR

(300MHz, DMSO-d 6): 6 ppm 7.69(d, 1H), 7.61(d, 1H), 7.40(d, 1H), 7.27(t, 1H), 6.89(d, 1H), 3.78(t, 2H), 3.07(brs, 4H), 2.75(t, 2H), 2.68(brs, 4H), 2.63(t, 2H), 2.42(t, 2H), 2.22(s, 3H), 1.85(m, 2H), 1.76(m, 2H). ESI-M S (n z): 409.1 [M+11].

Example 4 3-(2-(4-(beiizo[bithiophei-4-yl)piperazin-1--yl)ethvI)-9-hydroxy-2-m ethyl-6,7,8,9-tetrahydr o-4H-pyrido[1,2-a]pyrimidin-4-one A mixture of 3-(2-chloroethyli)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyri do[1,2-a]pyrimidin-4-one 10-a (ig, 4.13mmoil), the product of Reference Example 1 (1.05g, 4.13mmol), potassium carbonate (1.7g, 12.3mmol), potassium iodide (0.68g, 4.13mmol) and acetonitrile (10ml) was stirred at 85 'C overnight, the reaction was concentrated and subjected to column 63 chromatography to obtain a pale yellow solid (1g, yield: 58%). 'HNMR (300MHz, DMSO-d6 ): 6 ppm 7.69(d, 111), 7.61(d, I H), 7.40(d, 1H), 7.27(t, 11), 6.90(d, 1H-), 5.69(d, I H), 4.44(q, 1H), 3.91(m, 1H-), 3.68(m, 1H1-), 3.08(brs, 4H-), 2.69(brs, 4H-), 2.66(t, 2H-), 2.45(t, 2H-), 2.28(s, 3H4), 1.74-2.04(m, 411). ESI-MS (m z): 425.3 [M+H]v. A single isomer 4a and 4b was obtained respectively by HPLC chiral separation, the retention time is 13.2 minute and 16.3 minute respectively. Column type: AY-H 4.6 x 250mm; mobile phase: ethanol: hexane = 30: 70 (v / v); flow rate: 1.0ml / min; detection wavelength: 277nm. Comound 4a: (+ )-3-(2-(4-(benzo[b]thiophen-4-yl)piperazin--I-ylethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydr 0 o-4fH-pyrido[1,2-a]pyrimidin-4-one, specific rotation: +8.82 (C=0 17, CH 2Cl 2). Comound 4b: (-)-3 -(2-(4-(benzo[b]thi ophen-4-yl)piperazin-I -yl )ethyl)-9-hydroxy-2-methyl-6,7,8, 9-tetrahydro

-411-pyrido[1,2-a]pyrimidin-4-one, specific rotation: -7.98'(C= 0 17, CH-12Cl 2).

Example 5 3-(2-(4-(benzo b] thiophen-4-yl)piperazin-1 -yl)ethyl)-2-m ethyl-7,8-dihydro-4H-pyridoji,2 a]pyrimidine-4,9(6H)-dione The product of Example 4 (120mg, 0.28mmol) was dissolved in dichloromethane (5ml), Dess-Martin reagent (3 59mg, 0.84mmol) was added portionwise thereto and stirred at room temperature for 5 hours, then saturated sodium bicarbonate solution (2nl) and sodium thiosulfate solution (Iml) were added followed by stirring for 10 minutes. The mixture was extracted with dichlorornethane, washed with brine, dried over anhydrous sodium sulfate, concentrated and subjected to column chromatography to give a pale yellow solid (70 mg., yield:

58%). 'HNMR (300MHz, CDCl3): 6 ppm 7.54(d, 1H), 7.39(m, 2H), 7.27(t, 1H), 6.89(d, 1H), 4.20(t, 2H), 3.20(brs, 4H), 2.92-2.74(m, 8H), 2.62(t, 2H), 2.48(s, 3H), 2.33(m, 2H). ESI-MS (mz): 423.2 [M+H].

Example 6 3-(2-(4-(benzolbithiophen-4-yl)piperazin-1-yl)ethyl)-9-hydroxy-2,9-dimethyl-6,7,8,9-tetrah ydro-4H-pyrido[1,2-aIpyrimidin-4-one hydrochloride

The product of Example 5 (120mg, 0.28mmol) was dissolved in dry tetrahydrofuran (3ml), methyl magnesium bromide (2ml, 1.99mmol, IM in THF) was added dropwise thereto under ice-cooling condition followed by stirring at room temperature for 3 hours. The reaction was quenched with saturated amn oniurn chloride, concentrated, extracted with dichloromethane,

64 washed with brine, dried over anhydrous sodium sulfate, concentrated and subjected to column chromatography to give an oil. Hydrogen chloride-ethanol solution was added thereto under stirring, the resulting salt was slurried in acetonitrile, filtered to give a pale yellow solid (40mg, 1 yield: 32%). HNMR (300M1-z,MeOH-d 6 ): 6 ppm 7.65(d, 114), 7.58(d, 1H), 7.48(d, 11), 7.3 (t, 114), 7.02(d, 11), 4.37(d, 11), 3.83(m, 11), 3.66(m, 3H1), 3.41(m, 2H), 3.19 (m, 41-1), 2.93-2.49(m, 4H), 2.22-1.60(m, 6H), 1.52(s, 31-1).

Example 7 3-(2-(4-(benzo[bithiophen-4-yl)piperazin-I -yl)ethyl)-9-fluoro-2-m ethyl-6,7,8,9-tetrahydro 4-pyrido[1 ,2-aipyrimidin-4-one The product of Reference Example 17 (125mg, 0.51mmol), the product of Reference Example 1 (112mg, 0.51mmol), potassium carbonate (213mg, 1.54mmol), potassium iodide (85mg, 0.5 immol) and acetonitrile (5ml) were added to the flask and the mixture was stirred at 85 'C overnight. The reaction mixture was concentrated and subjected to column chromatography to obtain a pale yellow solid (150 mg , yield: 68%). 'HNMR (300MHz, CDCi;): 6 ppm 7.54(d, 1I), 7.36-7.43(m, 2HF1), 7.27(t, 11-1), 6.90(d, IH), 5.25-5.46(dt, 1H-), 4.18(dt, 1-), 3.75(m, 1-), 3.21(brt, 4H), 2.82(m, 61-), 2.60(t, 21), 2.30-2.46(m, 1H), 2.39(s, 3H11), 1.96-2.25(m, 31-1). ESI-MS (w z): 427.2 [M+H-]

Example 8 5-(2-(4-(benzo [b] thio phen -4-yi)piperazin- I-yl)ethyl)indolin-2-one The product of Reference Example 15 (79mg, 0.40mmol), the product of Reference Example 1 (104mg, 0.40mmol), sodium carbonate (108mg, 0.81mmol), sodium iodide (60mg, 0.40mmol) and water (3ml) were added to the flask and the mixture was stirred at 100 0C overnight. The mixture was extracted with dichloromethane and water, the organic phase was dried over anhydrous sodium sulfate, concentrated and subjected to column chromatography to give a crude. The crude was scurried in acetonitrile, filtered to give a white powder (90 Ing yield: 58%). 'TINMR (300M-fz, DMSO-d 6): 6 ppm i10.28(brs, 1H), 7.69(d, 111), 7.61(d, 111). 7.40(d, 11), 7.27(t, 11-1), 7.10(s, 1H-), 7.04(d, 11H), 6.90(d, 11-1), 6.72(d, 1-1), 3.44(s, 2H-I), 3.07(brs, 41), 2.72(t, 21-), 2.70(brs, 41), 2.57(t, 2[1). ESI-MS (n z): 378.3 [M+H]f.

Example 9 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)quinolin-2(1IH)-one The product of Reference Example 7 (440mg, 1.64mmol), the product of Reference Example 1 (418mg, 1.64mmol), potassium carbonate 682mg, 4. 9 4mmol), potassium iodide

65 (272mg, 1.64mmol) were dissolved in acetonitrile (10ml) and stirred at reflux overnight. The reaction mixture was poured into ice water and extracted twice with ethyl acetate, the combined organic layer was washed with brine, dried over anhydrous sodium sulfate, concentrated to give a crude which was further purified by column chromatography to obtain a white solid (200mg, vield: 31%). i-INNIR (400Mf-z, DMSO-d 6): 6 ppm 11 .70(brs, 1-1), 786(d, 1H), 7.70(d, 1-1), 7.61(d, 1H), 7.57(d, 1H), 7.40(d, 1H), 7.27(t, IH), 7.17(s, IH), 7.09(dd, 1H), 6.90(d, 1H), 6.42(dd, 1H), 3.08(brs, 4H), 2.85(t, 2H), 2.71(brs, 4H), 2.64(t, 2H). ESI-MS (m z): 390.2

[M+H]-.

Example 10 7-(5-(4-(benzo[bithiophen-4-yl)piperazin-1-yl)pentyl)-3,4-dihvdroquinolin-2(1H)-one The product of Reference Example 2 (250mg, 0.80mnol), the product of Reference Example 1 (140mg, 080mmol), potassiumn carbonate (221mg., 1.6mmnol), potassium iodide (132mg, 0.80mmoil) and acetonitrile (5ml) were added to the flask and the mixture was stirred at 85 'C overnight. The reaction mixture was concentrated, and the residue was purified by column chromatography to obtain a white powder (270 mg, yield: 77%). 'HNvR (300M-Hz,

DMSO-d6 ): 6 ppm 9.98(brs, 1H), 7.68(d, 1H), 7.60(d, 1H), 7.38(d, 111), 7.26(t, 111), 7.04(d, 1H), 6.88(d, 1H), 6.74(d, 1H), 6.67(s, 1H), 3.05(brs, 411), 2.80(t, 2H), 2.58(brs, 411), 2.49(t, 2H), 2.40(t, 2H1), 2.34(t, 2H), 1.51(m, 41-1), 1.30(m, 211). ESI-MS (m z): 434.3 [M+H]y.

Example 11 7-(5-(4-(benzo [b] thiophen-4-yl)piperazin-1 -yl)pentvl)quinolin-2(1 H)-one The product of R.eference Example 3 (180mg, 0.58mmol), the product of Reference Example 1 (148g, 0.58mmol), anhydrous potassium carbonate (241mg, 1.74mmol), potassium iodide (96mg, 0.58mmol) and acetonitrile (5ml) were added to the flask and the mixture was stirred at 85 'C overnight. The reaction mixture was concentrated, and the residue was purified by column chromatography to obtain a white powder (200mg, yield: 79%). 'HNMR (300MHz,

DMSO-d 6 ): 6 ppm 11.65(s, 111), 7.84(d, 1-1), 7.68(d, lH), 7.60(d, 1H), 7.55(d, 111), 7.38(d, 1H), 7.26 (t, 11), 7.11(s, 1H). 7.03(dd, 111), 6.87(d, 111), 6.41(d, 111), 3.03(brs, 41H), 2.65(t, 214), 2.57(brs, 41), 2.34(t, 214), 1.62(m, 21-1), 1.49(m, 21-1), 1.33(m, 211). ESI-MS (n z): 432.3 [M+ H].

Example 12 7-(5-(4-(2-chlorobenzo[b thiophen-4-yl)piperazin-1-l)pentyl)quinolin-2(1H)-one A mixture of the product of Reference Example 3 (108mg, 0.35mmol), the product of

66 Reference Example 9 (90mg, 0.35mmol), potassium carbonate (147mg, 1.07mmol), potassium iodide (58mg, 0.35mmol) and acetonitrile (5ml) was stirred at 85 'C overnight. The reaction solution was concentrated, and subjected to column chromatography to obtain a white powder

(75mg, yield: 45%). 'HNMR (500MHz, DMSO-d6 ): 6 ppm 11.66(brs, 111), 7.84(d, 111), 7.55(m, 21), 7.36(s, 1H-), 7.29(t, 11-1), 7.10(s, 111), 7.03(d, 1H4). 6.91(d, 1H-), 6.41(d. 1H-). 3.00(brs, 411), 2.64(t, 2H), 2.56(brs, 4H), 2.33(t, 2H), 1.61(m, 2H), 1.49(m, 2H), 1.32(m, 2H). ESI-MS (n z): 466.2 [M1H].

Example 13

7-(5-(4-(2-fluorobenzoIbltlhiopheni-4-yI)piperazin-1-yl)pentyl)quinolin-2(1H)l-one hydrochloride A mixture of the product of Reference Example 3 (104mg, 0.33mmol), the product of Reference Example 8 (80mg, 0.33mmol), potassium carbonate (140mg, l.Ommol), potassium iodide (56mg, 0.33mmol) and acetonitrile (5ml) was stirred at 85 'C overnight. The reaction mixture was concentrated, subjected to column chromatography to obtain an oil Hydrogen chloride-ethanol solution was added thereto under stirring, the resulting salt was filtered to give a white solid (95mg, yield:62%). 'HNMR (400MHz, DMSO-d6): 6 ppm 11.70(s, 11), 10.67(brs, IH), 7.85(d, IH), 7.61(d, 1H), 7.57(d, 1H), 7.31(t, 1H-), 7.15(d, 1H-), 7.12(s, ILH), 7.05(d, 1H), 7.01(d, 1H), 6.42(d, 1H1), 3.55(d, 1H), 3.44(d, 1H1), 3.05-3.29(m, 6H), 2.67(t, 2H), 1.77(m, 2H), 1.64(m, 2H), 1.35(m, 2H-). ESI-MS (n z): 450.2 [M+H]

Example 14

7-(5-(4-(benzo bthiophen-4-yl)-5,6-dihydropyridin-1(2H)-yl)pentyl)qinolin-2 (1 H)-one A mixture of the product of Reference Example 3 (114mg, 0.37mmol), the product of Reference Example 14 (80mg, 0.37mmol), potassium carbonate (154mg, 1.11mmol), potassium iodide (61mg, 0.37mmol) and acetonitrile (5m]) was stirred at 85 'C overnight. The reaction mixture was concentrated, and subjected to column chromatography to obtain a white powder

(66mg, yield: 60%). H1NMR (500MHz, DMSO-d6 ): 6 ppm I .65(brs, 11), 7 88(d, 11-), 7.84(d, IH), 7.73(d, iH), 7.55(d, iH), 7.48(d, 1H), 7.32(t, IH), 7.21(d, iH), 7.11(s, 1H), 7.04(d, 1H), 6.41(d, 1H), 5.86(s, 1H1), 3.09(s, 2H), 2.65(m, 4H), 2.49 (t, 2H), 2.40 (t, 2H) , 1.63(m, 211), 1.53(m, 2H), 1.35(m, 2H). ESI-MS (m z): 429.3 [M1H]

Example 15

5-(2-(4-(benzo[bjthiopheii-4-yl)piperazin-1-yl)ethyl)-6-chloroindoliii-2-one hydrochloride

67 A mixture of 6-chloro-5-(2-chloroethyl)indolin-2-one (332mg, 1.45 mmol), the product of Reference Example 1 (370mg, 1.45 mmol), sodium carbonate (461mg, 4.35mmol), iodine sodium (216mg, 1.45mmol) and water (5ml) was stirred under reflux for 24 hours. The reaction was cooled to room temperature, extracted with methylene chloride and water. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated and subjected to column chromatography to obtain an oil. Hydrogen chloride-ethanol solution was added thereto under stirring, the resulting salt was slurried in isopropanol, filtered to give a pale yellow solid

(308mg, yield: 51%). 'HNMR (400MHz, DMSO-d6 ): 6 ppm 11.04(brs, 1H), 10.55(s, iH), 7.77(d, 1H), 7.71(d, 1H), 7.50(d, 11-), 7.32(t, 1H-), 7.29(s, 1H), 6.98(d, 11), 6.88(s, 111), 3.71(d,

2H), 3.57(d, 2H), 3.50(s, 2H), 3.38(m, 4H), 3.21(m, 4H). ESI-MS (m z): 412.2 [M+H]F

Example 16

3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-2-methyl-6,7-dihydro-4H-pyrido[1,2 alpyrimidin-4-one hydrochloride

A mixture of the product of Reference Example 10 (100mg, 0.44 mmol), the product of

Reference Example 1 (113mg, 0.44 mmol), potassium carbonate (184mg, 1.33mmol), potassium iodide (74mg, 0.44mmol) and acetonitrile (5ml) was stirred at 85 'C overnight. The reaction was cooled to room temperature, extracted with methylene chloride and water. The organic phase was dried over anhydrous sodium sulfate, filtered, concentrated and subjected to column chromatography to obtain an oil. Hydrogen chloride-ethanol solution was added thereto under stirring, the resulting salt was slurried in isopropanol, filtered to give a white powder(60mg, yield: 33%). 'HNMR (300MHz, DMSO-d6 ): ( ppm 11.34(brs, 1H), 7.77(d, 1H), 7.70(d, 1-), 7.50(d, 1H), 7.32(t, 1-1), 7.00(m, 21), 6.60(d, 1H), 4.04(t, 21-1), 3.71(d, 211), 3.56(d,

2H), 3.14-3.47(m, 6H), 3.02(m, 2H), 2.61(m, 2H), 2.42(s, 3H). ESI-MS (in z): 407.1 [M+].

Example 17

3-(2-(4-(benzolbithiophen-4-yl)piperazin-1-yl)ethyl)-9-(benzyloxy)-2-methyl-4H-pyrido[1,

2-alpyrimidin-4-one hydrochloride The product of Reference Example 1 (155mg, 0.60mmoil), 9-(benzyloxy)-3 (2-chloroethyl)-2-methvl-4H-pyrido [1,2-a] pyrimidin-4-one (200mg, 0.60mmol), potassium carbonate (673mg, 4.87mmol), potassium iodide (101mg, 0.60mmoil) and acetonitrile (5ml) were added to the flask and the mixture was stirred at 85 "C for 24 hours. The reaction mixture was cooled to room temperature, extracted with dichloromethane and water. The organic layer 68 was dried over anhydrous sodium sulfate, filtered, concentrated and subjected to column chromatog raphy to obtain an oil. Hydrogen chloride-ethanol solution was added thereto under stirring, the resulting salt was filtered to give a white powder (200mg, yield:64%). 'FINMR

(300MHz, CDCl 3 ): 6 ppm 8.61(dd, 1H), 7.54(d, 11), 7.24-7.49(m, 8H), 6.86-6.93(m, 3H), 5.39(s, 2H), 3.23(brs, 4H-), 3.01(t, 2H4), 2.87(brs, 4H), 2.69(t, 2H1-), 2.64(s, 3H1). ESI-MIS (ml z): 511.3 [M+H].

Example 18

3-(2-(4-(benzo[bithiophen-4-yl)piperazin-1-yl)ethyl)-9-hydroxy-2-methyl-41-pyrido[1,2-a] pyrimidin-4-one The product of Example 17 (180mg, 0.3 5mmol) was added into concentrated hydrochloric acid (5mil) and stirred at 80 'C for 2 hours. The reaction mixture was cooled and isopropanol (5ml) was added dropwise thereto. The precipitated solid was filtered to give a pale yellow solid (130 mg, yield 87%). 'HNMR (300MHz, DMSO-d 6): 6 ppm 11.64(brs, 1H), 8.63(d, 1H), 7.88(m, 111), 7.77(d, 1H), 7.69(d, 111), 7.57(td, 111), 7.50(d, IFl 7.31(t, 1H), 6.96(d, 1-1), 3.75(d, 1H), 3.56(d, 11), 3.50-3.12(m, 8H), 2.70(s, 3H). ESI-MS (m z): 421.2 [M+H].

Example 19

7-(2-(4-(benzo[bithiophei-4-yl)piperazin-I-yl)ethyl)-3,4-dihydroquinolin-2(IH)-one The product of Reference Example 6 (100mg, 0.37mmol), the product of Reference Example 1 (95mg, 0.37mmol), potassium carbonate (153mg, 1.11 mmol), potassium iodide (61mg, 0.37mmol) were dissolved in acetonitrile (10ml) and the mixture was stirred at reflux overnight. The reaction mixture was concentrated, the residue was subjected to column chromatography to obtain a white solid (70 mg, yield 48%). 'HNIR (400MHz, DMSO-d 6): 6 ppm 10.02(brs, 11H), 7.70(d, IH), 7.62(d, 1H), 7.41(d, 11H), 7.28(t, 1H), 7.07(d, 1 H), 6.91(d, 11H), 6.80(dd, 1H), 6.74(d, 1H), 3.08(brs, 4H), 2.82(t, 2H), 2.69(m,6H), 2.58(t, 2H), 2.43(t, 2H). ESI-MS (i z): 392.1 [H1 ]

Example 20

9-hydroxy-2-m ethyl-3-(2-(4-(thieno [2,3-dI pyrim idin-4-yl)piperazin-I-yl)ethyl)-6,7,8,9-tetr ahydro-4H-pyrido[1,2-alpyrimidin-4-one The product of Reference Example 13 (77mg, 0.30mmol), 3 -(2-chloroethyli)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-41--pyrido[ I ,2-a]pyrimi din-4-one

10-a (73mg, 0.30 mmol), potassium carbonate (145mg, 1.05mmol), potassium iodide (50mg, 69 0.30mmol) were dissolved in acetonitrile (7.5 ml) and the mixture was stirred at reflux overnight. The reaction mixture was concentrated and subjected to column chromatography to obtain a white solid (53mg, yield: 41%). KHINMR (300M-z, DMSO-d6 ): 6 ppm 8.40(s, 1-1), 7.63(s, 2H), 5.71(d, 1H), 4.44(m, 1H), 3.87(brs, 5H), 3.66(m, 1H), 2.53-2.70(m, 6H), 2.39(t, 2H), 2.26(s, 31), 1.73-2.06(m, 4H). ESI-MVIS (i z). 427.2 [M+H]-.

Example 21 2-methyl-3-(2-(4-(thieno[2,3-d]pyrimidin-4-yl)piperazin-1-yl)ethyl)-6,7,8,9-tetrahydro-4H pyrido[1,2-alpyrimidin-4-one The product of Reference Example 13 (93mg, 0.36mmol), 3-(2-chloroethyl)-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[ 1,2-a]pyrimidin-4-one (82mg, 0.36mmol), potassium carbonate (173mg., 1.26mmol), potassium iodide (60mg, 0.36mmol) were dissolved in acetonitrile (7.5 ml) and the mixture was stirred at reflux overnight. The reaction mixture was concentrated and subjected to column chromatography to obtain a white solid (80mg, yield: 54%). INMR (300M-z, DMSO-d 6): 6 pmm 8.40(s, 1H), 7.62(s, 2-),

3.87 (brs, 4H) , 3.77(t, 2H), 2.74(t, 2H), 2.58(brs, 6H), 2.38(t, 2H), 1.84(m, 2H), 1.74(m, 2H). ESI-MS (n z): 411.1 [M+H]f.

Example 22 7-(4-(4-(benzo[blthiophen-4-yl)piperazin-1-yl)butyl)-3,4-dihydroquinolin-2(1HI)-one The product of Reference Example 4 (154mg, 0.52mmol), the product of Reference Example 1 (133mg, 0.52mmol), potassium carbonate (21 5mg, 1.56mmol) and potassium iodide (86mg, 0.52mmol) were dissolved in acetonitrile (7.5 ml) and the mixture was stirred at reflux overnight. The reaction mixture was concentrated and subjected to column chromatography to obtain a yellow solid (110 mg, yield: 50%). 'HNMR (300MHz, DMSO-d6 ): 6 ppm 10.02 (brs,

IH) , 7.69(d, 1H), 7.61(d, 11), 7.39(d, 1H),7.27(t, 1H4), 7.05(d, 1H), 6.88(d, 1[H), 6.74(d, iFl), 6.68(s, IH), 3.05(brs, 4H), 2.81 (t, 21-), 2.58(brs, 411), 2.50(t, 2H), 2.41 (t, 41-1), 1.39-1.64(in, 4H). ESI-MS (m z): 420.2 [M+H].

Example 23 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-6-chloro-3,4-dihydroquinolin-2(1H)-o ne The product of Reference Example 16 (100mg, 0.33mmol), the product of Reference

70 Example 1 (84mg, 0.33mmol), potassium carbonate (114mg, 0.82mmol), potassium iodide (55mg, 0.33mmol) were dissolved in acetonitrile (10ml) and the mixture was stirred at reflux overnight. The mixture was concentrated and subjected to column chromatography to obtain a white solid (45mg, yield: 32%). IHNIR (300MHz, DMSO-d6): 6 ppm 10.17(brs, 1H), 7.69(d, 1H), 7.62(d, 1H), 7.41(d, IFl), 7,20-7.33(m, 2H)l, 6.90(d, IFl), 6.84(s, 1H), 3.08(brs, 4H) 2.83(m, 4H), 2.70(brs, 4H), 2.56(t, 2H), 2.42(t, 2H). ESI-MS (m z): 426.3 [M+H]v.

Example 24 6-(5-(4-(benzo[bithiophen-4-yl)piperazin-1-yl)pentyl)-2-methylquinazolin-4(3 H)-one The product of Reference Example 11 (77mg, 0.29mmol), the product of Reference Example 1 (74mg, 0.29mmol), potassium carbonate (120mg, 0.87mmol), potassium iodide (48mg, 0.29mmol) were added to acetonitrile (3ml) and the mixture was stirred at reflux for 50 hours. The reaction mixture was concentrated and subjected to column chromatography to give a pale yellow solid (35mg, yield: 27%). I-NMR (300Hz, CDC 3 ): 6 ppm 10.84(brs, H), 8.05(s, 1H), 7.51-7.63(m, 3H) 7.38(m, 2H), 7.27(t, IH), 6.91(d, IFl), 3.27(brs, 4H), 2.83(brs, 411), 2.77(t, 211), 2.57(t, 211), 2.54(s, 3H), 1.72(m, 4H), 1.41(m, 211). ESI-MS (n ): 447.3 [M-+ H]-.

Example 25

7-(2-(4-(2,3-dihydrobenzo[bithiophen-4-yl)piperazin- 1-yI)ethyl)quinolin-2(1 H)-one The product of Reference Example 12 (85mg, 0.38mmol), the product of Reference Example 7 (103mg, 0.38mmol), potassium carbonate (157mg, 1.14mmol), potassium iodide (63mg, 0.38mmol) and acetonitrile (5ml) were added to the flask and the mixture was stirred at 85 'C overnight. The reaction mixture was concentrated and subjected to column chromatography to obtain a crude. The crude was slurried in acetonitrile, filtered to give the product as a white solid (70mg, yield: 46%). 'H-NMR (3001-z, DMSO-d 6): 0 ppm 11.67(brs, 1H), 7.85(d, 1H), 7.56(d, I H), 7.16(s, 1H), 7.07(m, 21-1), 6.90(d, IH), 6.69(d, 1-), 6.42(d, I1H), -3.30(tI,2H-), 3.14(t, 2H-), 2.88(brs, 4H4), 2.83(tI, 2H-), 2.61 (ml, 6H-). ESI-MS (m,11): 392.2 [M+H]-11.

Example 26

5-(2-(4-(benzo[bithiophen-4-yl)piperazin-1-yl)ethyl)-4-methylthiazole hydrochloride The product of Reference Example 18, The product of Reference Example 1, potassium carbonate (836mg, 6.058mmol), potassium iodide (87mg, 0.529mmol) were added to acetonitrile (6ml) and the mixture was stirred at reflux overnight. The reaction mixture was concentrated and extracted with dichloromethane and water. The organic layer was dried, concentrated and subjected to column chromatography to give an oil (140mg). Hydrogen

71 chloride-ethanol solution was added thereto under stirring, the resulting salt was filtered and dried to give a white solid (78mg, yield:39%). 1H-NMR (300Hz, [)MS()-d): 6 ppm 8.79(s, 1H), 7.70(d, 11), 7.62(d, 1H), 7.40(d, 114), 7.28(t, 11), 6.91(d, lH), 3.09(brs, 41), 2.95(t, 21-) 2.70(brs, 4H), 2.60(t, 214), 2.33(s, 311). ESI-MS (w z): 344.2 [M+H]

Example 27 5-(2-(4-(benzo[bithiophena-4-yl)piperazinI-1-yl)ethyl)-1 H-benzo[dlimidazol-2(31)-one The product of Reference Example 19 (150mg, 0.76mmol), the product of Reference Example 1 (178mg, 0.61mmol), potassium carbonate (42mg, 3.04mmol), potassium iodide (126mg, 0.76mmol) were added to N, N- dimethylformamide (6ml) and the mixture was stirred at 105 'C overnight. The reaction mixture was extracted with dichloromethane and water. The organic phase was dried, concentrated and subjected to column chromatography to give a pale yellow solid (59mg, yield: 20%). 'H-NMR (300Hz, DMSO-d6): 6 ppm 10.53(s, 11-1), 10.49(s, 11-), 7.70(d, 111), 7.62(d, I-i), 7.40(d, 11-), 7.28(t, 11H). 6.90(d, 11-1), 6.81(m, 31-1), 3 .08(brs, 41-), 2.75(t, 2H), 2.69(brs, 4H), 2.58(t, 2H). ESI-MS (m z): 379.2 [M+H]*.

Example 28 3-(2-(4-(benzo[bthiophen-4-yl)piperazin-1-yl)ethyl)-9,9-difluoro-2-methvl-6,7,8,9-tetrahy dro-4H-pyrido[1,2-alpyrimidin-4-one hydrochloride The product of Example 5 (120mg, 0.28mmol) was dissolved in dichloromethane (3ml), diethylaminosulfur trifluoride (0.079ml, 0.59mmol) dissolved in dichloromethane (3ml) was added dropwise thereto under ice bath condition followed by stirring at room temperature overnight. The mixture was extracted with dichloromethane and saturated sodium bicarbonate solution. The organic phase was washed with brine, dried over anhydrous sodium sulfate, filtered, concentrated and the residue was purified by column chromatography to obtain a crude. Hydrogen chloride-ethanol solution was added thereto under stirring, the resulting salt was filtered to give a pale yellow solid (50mg, yield: 39%). !HNMR (300MHz, DMSO-d6 ): 6 ppm 10.91(brs, 1H), 7.77(d, 1H), 7.71(d, 1H), 7.51(d, 111), 7.32(t, 1H), 6.98(d, 1H), 3.88(t, 2H), 3.73(d, 2-1), 3.58(d, 21-1), 3.40(m, 2H), 3.23(m, 41-1), 3.02(m, 2I), 2.43(m, 21), 2.40(s, 31-1), 2.07(m, 21-1). ESI-MS (m,). 445.3 [M+H].

Example 29 6-(2-(4-(benzo [b] thiophen-4-yl)piperazin-1-yl)ethyl)benzo [d] thiazol-2(3H)-on e hydrochloride The product of Reference Example 1 (228mg, 0.784mmol), the product of Reference Example 20 (186mg, 0.869mmol), sodium carbonate (333mg, 3.142mmol), sodium iodide (5mg)

72 were added to 4-methyl-2-pentanone ( M[BK, 6ml) under a nitrogen atmosphere and the mixture was stirred at reflux for 24h. The reaction mixture was concentrated and the residue was purified by column chromatography to obtain a yellow oil. Hydrogen chloride-ethanol solution was added thereto under stirring. The resulting hydrochloride salt was slurried in acetone/isopropyl ether system(V:V=:1 1), filtered, and dried to give the product as a pale yellow solid (58mg, yield: 17%). !H-NMR (400Hz, DMSO-d6): 6 ppm 11.98(s, 1H), 11.05(brs, 11), 7.78(d, 1H), 7.72(d, 11), 7.53(s, 1H-), 7.50(d, 11H). 7.33(t, 11), 7.23(dd, 11H), 7.12(d, 11), 6.99(d, 1H), 3.68(d, 2H), 3.57(d, 2H), 3.39(m, 4H), 3.24(t, 2H), 3.14(m, 2H). ESI-MS (m/z): 396.2 [M+H] .

Example 30

6-(2-(4-(benzo[bithiophen-4-yl)piperazin-I -yl)ethyl)-2H1-benzo[b] [1,4]oxazin-3(4H)-one hydrochloride

The product of Reference Example 1 (224mg, 0.77mmol), the product of Reference

Example 22 (196mg, 0.925mmol), sodium carbonate (328mg, 3.094mmol), sodium iodide (5mg) were added to N- methylpyrrolidone (NTTNMP, 6ml) under a nitrogen atmosphere and the mixture was stirred at 120 'C for 11 hours. The reaction solution was poured into ice water, the precipitated red-brown solid was filtered. The filter cake was washed three times with ice water, dried and subjected to silica gel column chromatography to give a crude (112mg). Hydrogen chloride-ethanol solution was added thereto under stirring, the resulting salt was slurried in acetone, filtered and dried to give a pale yellow solid (105mg, yield: 31.7%). 'H-NMR (300Hz,

DMSO-d6 ): 6 ppm 10.67(s, 1H), 7.69(d, IH), 7.62(d, 1H), 7.40(d, 1H), 7.28(t, 1H), 6.90(d, 1H), 6.88-6.76(m, 31-), 4.52(s, 21), 3.08(brt, 41-), 2.69(m. 61H), 2.56(t, 2H). ESI-MS (m z): 394.3

[M+H]; .

Example 31

6-(2-(4-(beiizo[blthiophen-4-yl)piperazin-1-yl)ethyl)-2HI-benlzo[b] [1,4]thiazin-3(4RH)-one The product of Reference Example 1 (204mg, 0.701mmol), the product of Reference Example 22 (200mg, 0.881mmol), sodium carbonate (300mg, 2.83mmol), sodium iodide

(132mg, 0.881mmol) were added to N-methylpyrrolidone (NMP , 6ml) tinder a nitrogen atmosphere and the mixture was stirred at 120 'C overnight. The reaction mixture was poured into ice water under stirring, the precipitated tan solid was filtered, the filter cake was washed three times with ice water, dried, subjected to silica gel column chromatography to give an oil. 73 The oil was slurried in ethyl acetate, filtered, and dried to give a pale yellow solid (43mg, yield:

15%). TH-NMR (300Hz, DMSO-d 6): 6 ppm 10 .54(brs, 111), 7.71(d, 111), 7.64(d, 1H), 7.43(d, 11), 7.27(m, 211), 6.90(m, 311), 3.44(s, 2H), 3.11 (brt, 4H), 2.74(m, 6H), 2.50(t, 2H). ESI-MS (n z): 410.2 [M+H].

Example 32 7-(2-(4-(thieno [2,3-dl pyrim idin-4-yl)piperazin- 1-yl)ethyl )q u inol in-2(1 H)-one The product of Reference Example 7 (40mg, 0.15mm ol), the product of Reference Example 13 (50mg, 0.15mmol), potassium carbonate (41mg, 0.3mmol), potassium iodide (25mg, 0.15mmol) were suspended in water (3ml) and stirred at 80 'C overnight. The reaction mixture was cooled to room temperature and filtered. The filter cake was washed with water and dried to give a gray solid (30mg, yield: 51%). 'H-NMR (300Hz, DMSO-d6): 6 ppm 11.68(s, 114), 8.41(s, 114), 7.85(d, I1H), 7.63(m, 211), 7.56(d, 11H), 7.17(s, 114), 7.08(d, lH), 6.42(d, 1-1), 3.89(brt, 411), 2.84(t, 21), 2.60(m, 6H). ESI-MS (mz): 392.3 [M1I1]+.

Example 33 7-(4-(4-(benzo[blthiophen-4-yl)piperazin-1-yl)butyl)quinolin-2(1HI)-one The product of Reference Example 5 (100mg, 0.34mmol), the product of Reference Example 1 (87mg, 0.34mmol), potassium carbonate (117mg, 0.85mmol), potassium iodide (56mg, 0.34mmol) were suspended in acetonitrile (7.5 ml) and the mixture was stirred at reflux overnight. The reaction mixture was concentrated and subjected to silica gel column chromatography to give a crude. The crude was slurried in methyl tert-butyl ether, filtered, and dried to obtain the product as an off-white solid (40mg, yield: 28%). 11H-NMR (DMSO-d6) : 6 ppm 11.70(brs, 114), 7.86(d, 111), 7.73(d, 111), 7.66(d, 1H), 7.58(d, IH), 7.44(d, H), 7.29(t, 1H), 7.12(s, 111), 7.06(d111), 6.93(d, iH), 6.43(d, 111), 3.33(t, 211), 3.07(m., 61H). 2.70(brs, 411), 1.64(m, 411). ESI-MS (mi z): 418.4 [M+H]

Example 34 6-(5-(4-(benzo[bithiophen-4-yl)piperazin-1-yl)pentyl)quinazolin-4(3H)-one hydrochloride The product of Reference Example 1 (60mg, 0.206mmol), the product of Reference Example 23 (71mg, 0.229mmol), potassium carbonate (95mg, 0.688mmol) were added to acetonitrile (3ml) and the mixture was stirred at reflux overnight. The reaction mixture was concentrated and subjected to silica gel column chromatography to give an oil(60mg). Hydrogen chloride-ethanol solution was added thereto under stirring. The resulting hydrochloride salt was slurried in acetone, filtered, and dried to give a pale yellow solid (55mg, yield: 56.9%). 1-I-NMR (300Hz, DMSO-d): 6 ppm 12.15(brs, 1H), 8.03(s, 1-1), 7.93(d, 1H), 74 7.68(d, 1H), 7.66(d, 1H), 7.61(d, 1H), 7.58(d, 11), 7.38(d, 1H), 7.27(t, 11), 6.87(d, 1H), 3.03(brs, 411), 2.74(t, 211), 2.58(brs, 411), 2.35(t, 211), 1.65(m, 211), 1.51(m, 2H), 1.33(m, 211). ESI- MS (mnX): 433.4 [M-+-1].

Example 35 2-(2-(4-(benzo[bithiophen-4-yl)piperazin-1-yl)ethyl)quinazolin-4(3H)-one The product of Reference Example 24 (120mg, 0.57mmol), the product of Reference Example I (145mg, 0.57mmol), potassium carbonate (236mg, 1.71mmol), potassium iodide (95mg, 0.57mmol) and water (1Oml) were added to the flask. The mixture was stirred at reflux overnight, concentrated and the residue was purified by column chromatography to give the product (100mg. yield: 44%). 11-NMR(4001-z, DMSO-d,): 6 ppm 12.29(s, 111), 8.09(dd, 111), 7.79(td, 111), 7.70(d, 111), 7.62(d, 211), 7.47(t, 111), 741(d, 111). 7.27(t, 111), 6.90(d, 11-), 3.07(brs, 4H), 2.87(m, 4H), 2.73(brs, 4H). ESI-MS (n z): 391.3 [M+H]'.

Example 36 3-(2-(4-(benzo[bithiophen-4-y)piperidin-1-yl)ethyl)-9-hydroxv-2-methvI-6,7,8,9-tetrahydr o-4H-pyrido I1,2-alpyrimidin-4-one 3-(2-chloroethlv)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-411-pyrido[1, 2-a]pyrimidin-4-on e 10-a (133mg, 0.55rmmol), the product of Reference Example 31 (120mg, 0.55mmol), potassium carbonate (229mg, 1.65mnmol), potassium iodide (92mg, 0.55mmoil) and acetonitrile (51ml) were added to the flask. The mixture was stirred at reflux for 12 hours, concentrated, and the residue was purified by column chromatography to obtain a white solid (115mg, yield: 49%). 'H-1 4NM4R (400Hz, DMSO-d6): 6 ppm 7.84(d, 1H), 7.76(d, 1H), 7.62(d, 1H), 7.33(t, 1H), 7.26(d, 11), 5.71(d, 1H), 4.45(q, IH), 3.91(m, 1H), 3.68(m, IH), 3.08(m, 311), 2.65(m, 2H), 2.41(t, 211), 2.28(s, 3H), 2.2 1(t, 2H), 2.06-1.70(m, 811). ESI-MS (n z): 424.4 [M+-H]F.

Example 37 5-(2-(4-(benzo [b]thiophen -4-yl)piperidin-1-yl)ethyl)-6-chloroindolin-2-one

The product of Reference Example 31 (120mg, 0.553mmol), 6-chloro-5-(2-chloroethyl)indolin-2-one (150mg, 0.663mmol), potassium carbonate (230mg, 1.66mmol), potassium iodide (90mg, 0.553mmol) and water (5mil) were added to the flask The mixture was stirred at 105 'C for 12 hours, cooled, filtered. The filter cake was slurried in acetonitrile and filtered to give the product (155mg, yield: 58%). 'H-NMR (400Hz, DMSO-d6): 6 ppm 10.43(s, 1H), 7.84(d, 1H), 7.76(d, 1H), 7.62(d, 1H), 7.33(t, 1H), 7.26(d, 11), 7.23(s, 1H), 6.81(s, 111), 3.47(s, 211), 3.08(d, 311), 2.84(t, 211), 2.51(m, 211), 2.23(t, 2H), 1.79(m, 411).

75 ESI-MS (m z): 411.3 [M+H1-1

Example 38

4-(2-(4-(benzo[bithiophen-4-yl)piperazinl-1-yl)ethyl)indolin-2-one The product of Reference Example 36 (180mg, 0.706mmol), the product of Reference Example 1 (180mg, 0.706mmol), potassium carbonate (243mg, 1.77mmol), potassium iodide (176mg., 1.06mmol) were added to acetonitrile (7.5 ml) and the mixture was stirred at 80 'C overnight. The reaction mixture was concentrated and the residue was purified by column chromatography to obtain a yellow solid (126mg, yield: 47%). 'H-NMR (300Hz, DMSO-d): 6 ppm 10.35(s, IH), 7.69(d, 1H), 7.61(d, IH), 7.40(d, IH), 7.27(t, 1H), 7.10(t, 1H), 6.89(d, IH), 6.82(d, 1H), 6.66(d, 1H), 3.49(s, 2H), 3.07(brs, 4H), 2.70(m, 6H), 2.60(t, 2H). ESI-MS (m z): 378.4 [M+H]Y.

Example 39

6-(2-(4-(benzo[bithiophen-4-yl)piperazin-1-yl)ethyl)indolin-2-one hydrochloride

The product of Reference Example 30 (110mg, 0.41 2mmol), the product of Reference

Example 1 (100mg, 0.344mmol), potassium carbonate (200mg, 1.376mmol), potassium iodide

(73mg, 0.344mmol) were suspended in acetonitrile (5ml) and the mixture was stirred at reflux overnight. The reaction solution was concentrated, and the residue was purified by column chromatography to obtain a crude. Hydrogen chloride-ethanol solution was added thereto under stirring, the resulting salt was filtered to give an off-white solid (100mg, yield: 61%). 'H-NMR

(400Hz, DMSO-d6 ): 6 ppm 11.05(brs, 1H), 10.52(s, 1H), 7.79(d, 1H), 7.72(d, 1H), 7.50(d, 1H),

7.33(t, 1H), 7.19(d, 1H), 6.99(d, 1H), 6.87(dd, 1H), 6.77(d, 1H), 3.69(d, 2H), 3.58(d, 2H), 3.46(s, 2H), 3.38(m, 4H), 3.24(t, 2H), 3.09(m, 2H). ESI-MS (i z): 378.2 [M+H]

Example 40 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-6-chloroquinolin-2(1H)-one The product of Reference Example 32 (24mg, 0.079mmol), the product of Reference Example 1 (20mg, 0.079mmol), potassium carbonate (22mg, 0.158mmol), potassium iodide (13mg) were suspended in water (3m]) and the reaction was stirred at 80 'C overnight. The reaction mixture was cooled to room temperature, filtered, the filter cake was washed with water and dried to give a gray solid (23mg, yield: 69%). 'H-NMR (300Hz, DMSO-d6 ): 6 ppm ll.77(brs, lH), 780(m, 211), 7.67(d, lH), 7.59(d, 1H). 7.39(d, 1H), 7.26(m, 2H), 6.88(d, 1K),

76 6.48(d, IH), 3.08(brs, 4H), 2.94(t, 2H), 2.71(brs, 4H), 2.63(t, 2H). ESI-MS (mz): 424.2 [M+-H].

Example 41 9-hydroxy-2-m ethyl-3-(2-(4-(thieno[2,3-clpvridin-4-yl)piperazin-1-yl)ethyl)-6,7,8,9-tetrahy dro-4H-pyrido[1,2-alpyrimidin-4-one The product of Reference Example 26 (200mg, 0.632mmol), 3-(2-chloroethlv)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyri do[I ,2-a]pyimi din-4-one 10-a (158mg, 0.695mmol), potassium carbonate (218mg, 1.58mmol), potassium iodide (157mg, 0.948mmol) were added to acetonitrile (7.5 ml) and the mixture was stirred at 80 'C overnight. The reaction mixture was concentrated and subjected to column chromatography to obtain a 1 yellow solid (125mg, yield: 46.6%). H-NMR (300Hz, DMSO-d6 ): 6 ppm 8.91(s, 1H), 8.06(m, 2H), 7.53(d, 1H), 5.71(d, 1H), 4.45(q, 1H), 3.91(m, 1H), 3.68(m, 1H), 3.21(brs, 41H), 2.95-2.61(m, 6H), 2.50(t, 2-), 2 29(s, 3H), 2.10-1.70(m, 41H). ESII-MS (in z): 426.3 [M-+-I]

Example 42 6-chloro-5-(2-(4-(tliieiio[2,3-clpyridin-4-yl)piperazin-1-yl)ethyl)iiidolin-2-one The product of Reference Example 26 (200mg, 0.632mmol), 6-chloro-5-(2-chloroethyl)indolin-2-one (160mg, 0.695mmol), potassium carbonate (218mg, 1.58mmol), potassium iodide (157mg, 0.948mmol) were added to acetonitrile (7.5 ml) and the mixture was stirred at 80 'C overnight. The reaction mixture was concentrated and subjected to column chromatography to obtain a white solid (25mg, yield: 8.7%). 'H-NMR (300Hz,

I)MSO-d6 ): 6 ppm 10.41(s, 11), 8.89(s, 1H), 8.04(m, 21-1), 7.51(d, 1IH), 7.23(s, 1H), 6.81(s, 11H), 3.46(s, 21-), 3.18(brs, 4H), 2.85(t, 211), 2.71(brs, 4H), 2.56(t, 21-1). ESI-MS (mI z): 413.3 [M--1].

Example 43 7-(2-(4-(thieno[2,3-clpyridin-4-yI)piperazin-1-vl)ethyl)quinolin-2(i1)-one The product of Reference Example 26 (177mg, 0.56mmol), the product of Reference Example 7 (150mg, 0.56mmol), potassium carbonate (271mg, 1.96mmol), potassium iodide (140mg, 0.84mmol) were added to acetonitrile (7.5 ml) and the mixture was stirred at 80 'C overnight. The reaction mixture was concentrated and subjected to column chromatography to give a white solid (75mg, yield: 34.4%). 'H-NMR (DMSO-d,): 6 ppm 11 68(s, U-1, 8.90(s, 1-1), 8.05(s, 2H-1l), 7.85(d, 1I). 7.54(m, 21-1), 7.18(s, 1H-), 7.0 9 (m, 1I), 6.42(d, Ili), 3.19(brs, 41H), 2.86(t, 21-I), 2.74(brs, 61-). ESI-MS (ml z): 391.3 [M1H]4.

77 Example 44 7-(3-(4-(benzo[blthiophen-4-y)piperazin-1-yl)propyl)quinolin-2(1HiI)-one The product of Reference Example 28 (100mg, 0.355mmol), the product of Reference Example 1 (91mg, 0.355mmol), potassium carbonate (172mg, 1.24mmol), potassium iodide (88mg, 0.53mmol) were added to acetonitrile (7.5 ml) and the mixture was stirred at 80 'C overnight. The reaction mixture was cooled to room temperature, poured into water (30ml). The precipitated solid was filtered, washed with water and dried to give a crude. The crude was slurried in ethyl acetate 2.0ml), filtred, dried to give the product as an off-white solid (88mg, yield: 61.5%). 1H-NMR (DMS()-d 6): 6 ppm 11.68(s, 1H), 7.85(d, I H), 7.69(d, 1H), 7.61(d, 1H), 7.56(d, 1H-), 7.38(d, 11), 7.27(t, 1H), 7.14(s, 111), 7.06(d, 1H), 6.89(d, 11). 6.42(d, 1H), 3.07(brs, 4H), 2.69(t, 2H), 2.60(brs, 4H) 2.38(t, 2H), 1.79(m, 21). ESI-MS (miz): 404.4 [M+H] .

Example 45 7-(3-(4-(benzo[bithiophen-4-yl)piperazin-1-yl)propyl)-3,4-dihydroquinolin-2(1IH)-one The product of Reference Example 27 (120mg, 0.424mmol), the product of Reference Example 1 (108mg, 0.424mmol), potassium carbonate (205mg, 1.484mmol), potassium iodide (106mg, 0.636mmol) were added to acetonitrile (7.5 ml) and the mixture was stirred at 80 'C overnight. The reaction mixture was cooled to room temperature, poured into water (30ml). The precipitated solid was filtered, washed with water and dried to give a crude. The crude was slurried in petroleum ether-ethyl acetate system, filtered, dried to give the product as an off-white solid (58mg, yield: 34%). 'H-NMXR (DMSO-d6 ): 6 ppm 10.01(s, IH), 7.69(d, IH), 7.61(d, IH), 7.39(d, 1I), 7.27(t, IH), 7.05(d, IH), 6.89(d, IH), 6.76(d, 1HI), 6.70(s, 1H), 3.07(brs, 4H), 2.81(t, 2H), 2.59(brs, 4H), 2.54(t, 21H), 2.39(m, 4H), 1.72(m, 2H). ESI-MS (m z): 406.3 [M+H]f.

Example 46 3-(2-(4-(beizo[bjtliiophen-4-yl)piperazin-1--yl)ethyl)- IH-indole The product of Reference Example 34 (200mg, 0.83mmol), the product of Reference Example 1 (1 82mg, 083mmol), potassium carbonate (347mg, 2.5mmno), potassium iodide (139mg, 0.83mmol) were added to acetonitrile (5ml) and the mixture was stirred at 80 'C overnight. The reaction mixture was concentrated and subjected to column chromatography to give a white solid (120 mg, yield: 39%). 'H-NMR (DM SO-d6): 6 ppm 10.85(s, IH), 7.71(d, IH), 7.63(d, 1HI), 7.56(d, 1H)', 7.43(d, 1HI), 7.35(d, 1HI), 7.29(t, 1H), 7.20(s, 1HI), 7.07(t, 1H), 6.98(t, 11-1), 6.92(d, 111), 3.16(brs, 4H), 3.04-2.63(m, 8H). ESI-MS (m z): 362.1 [M--1].

78 Example 47 6-(2-(4-(benzo [b] th iop hen -4-y l)piperazin-1I-yl)eth yl)-3,4-di hydroq uinolIin-2(1-H)-one hydrochloride The product of Reference Example 35 (120mg, 0.57nmol), the product of Reference Example 1 (163mg, 0.56mmol), sodium carbonate (238mg, 2.23mmol), sodium iodide (2mg) were added to N, N-dirnethylformamide ( 3ml) under a nitrogen atmosphere and the mixture was stirred at 120 'C for 9 hours. The reaction mixture was poured into ice water. The precipitated pale yellow solid was filtered, washed three times with ice water, dried, subjected to column chromatography to give a crude. -Iydrogen chloride-ethanol solution was added thereto under stirring. The resulting hydrochloride salt was slurried in acetonitrile/methanol system, filtered, and dried to give a pale yellow solid(80mg, yield: 33%). 11--NMR (30Hz,

DMSO-d6 ): 6 ppm 9.99(s, 1H), 7.69(d, IH), 7.61(d, 1I), 7.40(d, iH), 7.27(t, IH), 7.05(d, 1I), 7.01(d, 111), 6.90(d, 1H), 6.76(d, 1H, 3.07(brt, 41). 2.83(t, 21). 2.69(n, 611). 2.56(t, 211), 2.42(t, 21H). ESI-MS (m z): 392.1 [M+H]

Example 48 5-(3-(4-(benzo[bIthiopheii-4-yl)piperazin-1-yl)propyl)indolin-2-one hydrochloride The product of Reference Example 25 (100mg, 0.48mmol), the product of Reference Example 1 (136mg, 0.47mmol), sodium carbonate (198mg, 1.87mmoil), sodium iodide (71mg, 0.48mmol) were added to water (4ml) under a nitrogen atmosphere and the mixture was stirred at reflux for 9 hours. The reaction mixture was extracted twice with dichloromethane.The combined organic layer was dried, concentrated, subjected to column chromatography to obtain a crude. Hydrogen chloride-ethanol solution was added thereto under stirring. The resulting hydrochloride salt was scurried in ethyl acetate- methanol system, filtered, dried to give a white solid (135mg, yield: 68%). 'I-NMv/R (300Hz, DMSO-d6): 6 ppm 10.27(s, 1H), 7.69(d, 1H), 7.61(d, 1H). 7.39(d, 1H), 7 27(t, 111), 7.07(s, 111), 7.00(d. 11), 6.89(d, 11), 6.71(d, 111), 3.43(s.

2H), 3.07(brs, 4H), 2.59(brs, 4H), 2.55(t, 2H), 2.37(t, 2H), I.73(m, 21H). ESI-MS (m z): 392.2

[M+H] -.

Example 49 7-(2-(4-(benzo[bithiophen-4-yl)piperazin-1-yl)ethyl)-4,5-dihydro-1H-benzo[biazepin-2(3H )-one hydrochloride The product of Reference Example 29 (100mg, 0.45mmol), the product of Reference

Example 1 (130mg, 0.45mmo), potassium carbonate (246mg, l.79mmol), potassium iodide (74mg, 0.45mmol) were added to acetonitrile (4ml) and the mixture was stirred at reflux for 20

79 hours. The reaction mixture was extracted with dichloromethane and water. The combined organic layer was dried, concentrated, subjected to column chromatography to obtain a crude. -Iydrogen chloride-ethanol solution was added thereto tinder stirring. The resulting hydrochloride salt was scurried in ethyl acetate, filtered, dried to give a pale yellow solid (90 mg , yield: 45.6%). 'H-NMR (300Hz, DMSO-dr): 6 ppm 9.45(s, 11), 7.69(d, 1-1), 7.61(d, 11), 7.40(d, 1H), 7.27(t, 1H), 7.11(m, 2H), 6.89(m, 2H), 3.08(brs, 4H), 2.80-2.54(m, 10H), 2.11(m, 41-). ESI-MS (n z): 406.3 [M+H]Y.

Example 50 3-(2-(4-(benzo[bithiophen-4-yl)piperazin-I -yl)ethyl)-2-methyl-411-pyrido[1,2-alpyrim idin 4-one hydrochloride The product of Reference Example 1 (50mg, 0. 17mmol), 3-(2-ch oroethyl)-2-methyl-4H-pyridoI 1,2-a]pyrimidin-4-one (40mg, 0.18mmol), potassium carbonate (82mg, 0.60mmol), potassium iodide (2mg) were added to acetonitrile (2ml) and the mixture was stirred at reflux overnight. The reaction mixture was extracted with dichloromethane and water. The organic layer was combined, dried, concentrated, subjected to column chromatography to obtain a crude. Hydrogen chloride-ethanol solution was added thereto under stirring. The resulting hydrochloride salt was slurried in ethyl acetate/n-hexane

1 system, filtered, dried to give a white solid (40mg, yield: 49%). H-NMR (300Kz, DMSO-d6 ): 6 ppm 8.89(d, 1H), 7.85(t, lH), 7.69(d, IFl), 7.60(t, 21-1), 7.42(d, IH), 7.28(t , 2H), 6.91(d, 1H), 3.09(brs, 4H), 2.85(t, 2H), 2.73(brs, 4H), 2.54(t, 2H), 2.50(s, 3H). ESI-MS (m z): 405.3 [M+l-H]7.

Example 51 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-3-methyl-3,4-dihydroquinazolin-2(1H )-one The product of Reference Example 33 (180mg, 0.80mmol), the product of Reference Example 1 (230mg, 0.79mmol), sodium carbonate (335mg, 3.16mmol), sodium iodide (4mg) were added to N, N-dimethylformamide (4ml) under a nitrogen atmosphere and the mixture was stirred at 120 'C for 16 hours. The reaction mixture was poured into ice water, the precipitated solid was filtered, washed 3 times with ice water, dried, subjected to column chromatography to give a crude (110mg). The crude was scurried in ethyl acetate, filtered, dried 1 to give a pale yellow solid (80mg, yield: 25%). H-NMR(300Hz, DMSO-d6 ): 6 ppm 9.12(S, 111), 7.69(d, 1H), 7.61(d, 1H), 7.40(d, 1H), 7.27(t, 1H), 7.00(d, 1H), 6.96(s, 1H), 6.89(d, 1H), 6.68(d, 1H), 4.36(s, 2H), 3.07(brs, 4H), 2.84(s, 3H), 2.67(m, 6H), 2.55(t, 2H). ESI-MS (nz): 407.3

80 [M-H]F.

Example 52 3-(2-(4-(beiizo[bithiophei-4-yl)piperazin-1--yl)ethvl)-9-chloro-2-methvl-6,7,8,9-tetrahydro 4H-pyrido[1,2-a pyrimidin-4-one Thionyl chloride (6.8ul, 0.094mmol) in dichloromethane was added dropwise to the product of Example 4 (20mg, 0.047mmol) dissolved in dichloromethane under ice bath followed by stirring at 10 'C for 1 hour. The reaction solution was diluted with dichloromethane, washed with saturated aqueous sodium bicarbonate solution. The organic phase was dried, concentrated and subjected to column chromatography to obtain the target (19mg, yield: 91%). H-2NMR (300Hz, MeOH-d4): 6 ppm 7.66(d, 1H), 7.60(d, 1H), 7.50(d, 1H), 7.33(t, 1H), 7.03(d, IH), 5.18(m, 1H), 4.30(m, IH), 3.71(m, 1H), 3.49(brs, 4H), 3.41(brs, 4H), 3.21(t, 2H), 3.03(m, 2H), 2.43(s, 3H), 2.35(m, 31H), 2.14(m, IH). ESI-MS (nz): 443.3 [M+H]7.

Example 53 5-(2-(4-(beiizo[bithiophei-4-yl)piperazin-1--yl)ethvl)indoliie-2-thione hydrochloride

The product of Example 8 (500mg, 1.325mmol) was suspended in toluene (15ml),

Lawesson's reagent was added (642mg, 1.59mmol) and the mixture was stirred at 80 'C overnight. The reaction solution was concentrated, and the residue was purified by column chromatography to obtain a crude. Hydrogen chloride-ethanol solution was added thereto under stirring, the resulting salt was slurried in isopropyl ether/methanol system, filtered to give a yellow solid (40mg, yield: 7.6%). 'H-NMR (300Hz, DMSO-d6 ): 6 ppm 12.66(s, 11-), 10.96(brs, IH), 7.77(d, 1H), 7.71(d, IH), 7.49(d, IH), 7.32(t, 1H), 7.25(s, 1H), 7.19(d, 1H), 6.99(d, iH),

6.96(d, I H), 4.06(s, 211), 3 02-3.74(m, 1211).

Example 54 7-(2-(4-(benzo[bithiophen-4-vl)piperazin-1-yl)ethyl)quinoline-2(1L)-thione The product of Example 9 (200mg, 0.51mmol) was suspended in toluene (20ml), Lawesson's reagent (416mg, 1.02mmol) was added and the mixture was stirred at 80 'C for 14 hours. The reaction mixture was concentrated, and the residue was purified by column chromatography to obtain a yellow solid (60mg, yield: 28.8%). 'H-NMR(300Hz, DMSO-d6): 6 ppm 13.64(s, 11-1), 7.80(d, 111), 7.72(m, 211), 7.63(d, 1H), 7.51(s, 111), 7.43(d, IH), 7.28(m, 21-1), 7.21(d, 1HI), 6.92(d, 1H4), 3.14(brt, 4H4), 2.64-3.06(m, 8H). ESI-MvIS (i z): 406.2 [M+H].

81 Example 55 2-(2-(4-(beizo[b]thiopien-4-yl)piperazin-1-yl)ethvI)-5,6-diethylpyrimidin-4(3H-l)-one hydrochloride The product of Reference Example 37(270mg, 0.72mmol), the product of Reference Example 1 (314mg, 1.44mmol) were dissolved in acetonitrile (1OmI) under a nitrogen atmosphere and the mixture was stirred at reflux overnight. The reaction mixture was cooled to room temperature, concentrated, subjected to column chromatography to obtain a crude (160mg). The crude was dissolved in methanol (5ml), added with hydrogen chloride-methanol solution (1.0ml), stirred for 3 hours at room temperature, concentrated and the residue was purified by column chromatography to give the target (35mg, yield: 12.2%). 'H-NMR(300Hz,

DMSO-d6 ): 6 ppm 12.23(brs, 1H), 7.69(d, 1H), 7.61(d, 1H), 7.40(d, IH), 7.27(t, IH), 6.89(d, 11-1), 3.05(brt, 41), 2.61-2.86(m, 8H), 2.31-2.57(m, 4H), 1.13(t, 3 1), 0.99(t, 31H). ES1-MS (mnX): 397.2 [M+H]'.

Example 56 2-(2-(4-(benzo[bithiophen-4-yl)piperazin-1-yl)ethyl)pyrimidin-4(3H)-one hydrochloride

By a similar method as in example 55, 2-(2-(4-(benzo[b]thiophen-4-yl )pi perazin- I -yl)ethyl )py rimi din -4(3H[')-one hydrochloride was prepared from Reference Example 38 and Reference Example 1. 'H-NMR(300Hz, DMSO-d 6 ): 6 ppm 9.45(brs, 1H), 7.96(d, 1H), 7.77(d, 1H), 7.70(d, 1H), 7.50(d, 1H), 7.31(t, 1H), 6.96(d, 11H), 6.36(d. Hli), 3.63(t, 21-), 3.17-3.57(m, 10H). ESI-MS (n z): 341.0 [M+H].

The table below shows compounds of Examples 57 to 154, these compounds can be prepared by a similar method as in example 1-55, using the corresponding starting materials and intermediates.

Example No. name H NIR T ESI-MS

57 7-(2-(4-(2-fIuorobenzo[b]thi H NMR (300MHz, DMSO-d 6) 3.12-3.55 (m, ophen-4-yl)piperazin-1-yl)et 6H), 3.66 (d, 2H), 4.94 (br, 4H), 6.47 (d, 1H), hyl)quinolin-2(lH)-one 7.03 (d, 1H), 7 16 (i, 3K), 7.32 (t, 11), 7.61 hydrochloride (d, 1H) 7.65 (d, 1H), 7.89 (d, IH), 11.59 (s 1H), 11.83 (s, 1H). ESI-MS m/z 408.7 [M-H]

58 21((4-(benzo[b]thiophen-4-y H NMR (300Ml~z, DMSO-d6 ) 6 2.73(br, 4-1)

1)piperazin-1-yl)methyl)-1H 3.11(br, 4H1), 3.83(s, 2H), 6.90(d, 1H), 7.14( m benzo[d]imidazole 2H), 7.27(t, 1H), 7.40(d, 1K), 7.45(d, 1H)

82 7.57(d, 1II), 7.61(d, 1K)l 7.68(d, IlK), 12.35(s, 11-1). ESI-M S rn/z 3 49.3 [LM4+Kf. 59q 6 (l_ (4-(benzorb]thiophen-4 R(0M~.D S J 32-3.2HN0 6 3(m,

yl)piperazin- I- '1)ethvl)ben 101), 3.70(d, 2K), 6.98(d, 1II), 7,32(t, III) zo[d]thiazoie 7.50(in, 21-), 7.70(d. 11-1), 7.77(d, 11-), 8 09(rni 21-1), 9.38(s, 11-1), 11.45(s, IF[) ESI-m i'nZ 80.0 [M±H]-.

60 7-(2-(4-(2-tfi orobenzo[b]thi "I N IR (3(X) 1Hz, D) SO-d 6) 6 2.69(rn, 6H-I ephen-4-y'piperazin-1I-vl)et 2.8_5(t 2H), 3.02(br, 4H), 6.89-7.01(m, 3K), hyl)bcnzordlthiazo-2-amine. 7. 1 (mn,2KH) 7.28(t, 1KI), 7.43(s, 2K), 7.54d,

______11-1). ESI-MS rn/z 413.7 [M4 If.

61 '1N-( 7(2-(4-(2/'-fluorobenzorb 'K NMR (300MV1-z, DMSO-d 6) 6 2.20(s, 3K) ]thi ophen-4- ri)pi perazin-I-y 2.72(mn, 6H--), 3.02(in, 6K-), 6.95(d, 1K-), 7.00(d i)etl )benzo[d]thiazoi-2-vi) III), 7,21(d, 114), T.27(t, IF[)781, 11 1acetarnide '.52(d, 1H), 7.60(d, 1K), I12.33(s, I1H). ESJ-1\'S 1nMz 155.0 [M+KF'.

62 ~5(l_(4-(2-tluorobenzr~h 'H NMR (300N'Hz, DMSO-d 6) 6 2.90-3.78(m, ophen -4- '1)piperazin-1I-.yl)et 12HK), 6.94(d, 1K), 7.02(d, IIK), 7.13(s, 1K), hylbenzo[dithiazoV-2-amine 7.30(in. 2K-), 7.48(s, 21-I), 7.60(d, 2K-), 10.70(s, hydrochloride 11-1) 1SI- IS in/z 413,1 [M4 Uf.

63 N-(5-(z (4-(2-fluorobenzo[b '11 NMR (300M1lz, DMSO-d 6) 6 2. 19(s, 31-1), Jtliophen-4-vi)piperazin-1-vy 2,69(mn, 614, 2.91(t, 21]), 3,02(br; 4H), 6.97(m,

l1)ethylhbenzord]thiazol-2-vl) 21-), 7.21(d, 1K), 7.28(t, 1H), 7.52(d, 1KH), 1acetainide 7.63(s, 1Kl), 7.85(d, IIK), 12.30(s, 1K). ESJ-MS

n lV7z 454.9 [M+H]K>. 64 7-( 2(4-(2-fluorobenzo[bjthi 'K NMIR (300-M1-z, DMSO-d,.) d2.43(t, 2K) *ophien 4-yl)piperazin- I-vl)et 2.84(t, 2K-). 2.99-3.53(mn, 10K-), 3.65(d, 2K4). h)3 4-dihydroquinolin-2( 6.75(s, 1K-), 6.8'5(d, 11l), 7.02(d, IHI), 7,15(m, 11KH)-oneh 'drochioride H), 7.32(t, 1K'), 7.61(d, 1H), 10.15(s, 1K) 11.32(s, 1K). ESI-VS in/z 4.10.5 rM+KY-.

65 6 (l_ (4-(2-tluorobenzorb]thi 'H NMR (300MHz, DMSO-d6) 6 2.42(t, 2KH) *ophen-4- '1)piperazin-1I-yl)et 2.55(t, 2K), 2.66(in. 6K), 2.83(t, 2K1), 3.01(br

______yl) 3.4-dihydroquinolin-24 411). 6.76(d, 1K-), 6.99(in. 4ff-U 7.27(t, 1I-I), 83 111)-one, 7.52)(d, III), 9.99(si 111i). ESI-I\S rn/z 410.5

66 16 (I_(4-(benzorb]thiophen-4 11 M 30~.D S.d)~ 2.55 (t, 21 yl)piperazin-i- ')ethvl)-7-f 12.7 0(r, 611), 3.0 8(br. 411), 4.56(s, 211), 6.87(mi 'i uoro-211-benzo[b][i,4]oxaz il311). 727(t, 11-1), 740(d, I1ffi 7.6 1(d, 11I),

in4H-one 69(d, 11) 10.70(s, 11-1). ESI- IS rn/z41.

67 7-(2-(4-(3-methylberizo[b]th Ij N IR (300! 11Hz, D! SO-dc,) ) 2.26-2.60(m, iophen-4-yIhpiperazin- I-vl)e 61-), 2.63-3,00(rm, 1_311), 6.13 (s, I H), 6.790, thyI) 3,4- lihvdroquinolin-2( 111) 7.06(d, 111), 7.11(d, 111), 7.27(m, 211), I11)-or 'I764(d, 111), 10.01i(s, 1i-1). ESI-MS rn/z 406.1

68 '16-(2-(4-(benzorjthiophen-4 11H NMR (300M1-iz. DMS0-d,) 6 260(t, 211).

zord]oxazoI-2(31)-one 11), 7.01(mn, 211), 7.22(s, 111). 7.27(t, 111)i 7.39(d, 111), III(,1), -7.69(d, 111), 11.52(s,' 111). FSJ-MS rn/z 3180.2 LM+H11v. 69 4 (4(benzorb]thiophen-4-v 111 NMIR (300 1Hz, DM50-d6c) 6 2.73(br, 411) 'i )piperazin-i-yi1)rnethi)quini 3.08(br, 411). 3.78(s, 21-1), 6.56(s, 11-1), 6.90(d, Iolin-2(11-b)-one 11-1), 7.15-7.36(mn, 3 ) ) 7,41 (d, IF[), 7.50(t1 III), 7.61(d, 111), 7.70(d, 111), 7.96(d, 111) 11. 7 1(s, I11). E SI- IS rn/z 3 76.2 [M+-IHF

70 3-(4-(4-(benzorb]thiophen-4 '11 NMR (300OMHz, DMSO-d,) (5 1.75(m, 411), 1y)piperazIn-1-y1)buty1)-iH 2.79(t. 211). 3.23(rn, 611), 3.55(t, 411), 6.96(d, indoic. 5-carbonitrile 11-1), 7.3 1(t. 11-1), 7.41(in, J-U., 750(rn, 21-1). 7.70(d, I1-H), 777(d, 11-1), 8.12(s, 11-1), 11 .49(S, 111) 1-SI-MS rn/z 415.3 [M±11FH].

71 117-5(4-(6-fluorobenzo[b]thi 'U- NMR (300M/-lz, LWIiSO-dc,) (5 I33 (in, 21-1), ophen-4-vl)piperazi n-I-yIi)p 1.40 (rn, 2H), 1..2(m, 211H), 2.3 5(t, 211), 2.5 7 (Lr, entyl)quinolIn-2(i11)-one 111), 2.64(t, 211), 3.06(br; 411), 6.4 1i(d, 111), '6.71(d, 11-1), 703(d, 11-1), 7.10(s, 11-1), 7.35(d, 1-1-), 7,49(d, 11-1), -1,55(d, lHO, 7.65(d, 11-I) 7.84(d, 111), 11.65(sI H). ESI-MS rn/z 449.9 ' 84 [Mv+H] .

72 6- 4-(4-(benzo[b]thiophen-4 f-1 NMR (300M/11-z, DN/lSO-d 6) (5 I .8(in, 2-11), 1)lpiperazin- I yl)butyl)-8-f 1.56'm, 1-H, 2.38(t, 2H), 2.52(t, 2H-), 2.58(br, luoro-2H-.benzo[b][I,4]oxaz 4H), 3.0C(br, 4H-), 4.61(s, 2H), 6.55(s, iH),

in-3(411)-one 6.75(d, 11-1), 6.89(d, 1141), 7.27(t. i111-.T 19(d, 11-1), 7.61(d, ,7 69(d, 11-1), 10.83(s, 1IH). lzSI MS rn/z 440.2 [M±H]-.

73 1 -(benzo[b]thiophen-4-v1)-4 Ij N IR (300! 1z, 1)! SO-16) 2.63-2.3(m, -((2,3 -dihydrob enzo [b 1l,4 61-1), 308(b-t, 4H-), 4.00(dd, I1-H), 4.3 3(dd, I1H), dioxin-2-yl)methvl)piperazi 4.410(mn, 1H1), 6.78-6.93(m., 5H), 7.27(t, i1H) fe40(d, 11-1), 7.61(d. 11-1), 76(,11-1). ESI-NIS rnZz 66.7 [M-1-1-1]+,

74 6-(4-(4 (2.-fluor-obenizo[b]tii ~11 NM/R (300M1-iz, DMSO-d 6) 6 1.47(mn, 2N-1), ophien-4-yl)piperazin-1-yl)b I.56(mn, 21-1), 2,39(mn, 41), 2.54(mn, 61-1), 2,83(t, ut i') '14-dihydroquinolin-2!( 12H), 2.99(Lr. 4H-), 6.7 5(d, IH), 6.96(mn, 4H', IH)-one 7.27(t, 1H), 7.51I(d, 1H), 9.97(s, iH). ESI-ms In/z 438.6 M411i 75 /'-(2-(4-(benzo[blthiophen-4 'H NMIR (300 1Hz, DMS0- 16) 6 2.72(br, 4H),

benzold]irnidazoie 121-1), 7,26(t, 1141), 7.4 1l(d, 11-1), 7.48(in,21I 7.61(d, 1H), 7.69(d, iH), 12.20(s, 1H). ESI-MS rn/z 362.9 [M+H]Y.

76 IN-(6 (2-(4-(2-fluorobenzo[b 1H NMR (300M-Hz, DMSO-d 6) 2i2.20(s, 3H), ]thiophen-4-y1)piperazin-i-v. 3.14-3.75(rn, 12H), 7.04(d, 1H), 7.17(d, 1H),

acetarnide hydrochloride 1-1), ii .03(s, 11-1), 12.36(s, 11-1). ESI- IS n/Z 1 45-55 [M+H]-.

771 S-(2-(4-(2'-fluorobenzo[b]thi 'U N IR (300OMI-z, DM SO-d 6) ~ . t, 21-1),

oph en- 4-vl)pip erazi n- I-y I)et 266(bi,zI 4H), 2.74(t, 2H), 3.0 I(br, 4H), 6.81I(m, hv1) iH-benzo[d]irnidazol-2 3H), 6.96(mn, 2H), 727(t, 1H), 1.2dH), (31-1) one 10.46(s. 11-1), 10.50(s, 11-1). ESI-MS rn/z 3197.1 [MI +1

78 6-(' (4-(6-fluorobenzo[b]thi 1-1 NM/R (300M-lz, DN4SO-d 6) 6 2.57(t, 21-1), 85 iophen-4.-y)piperazin- I-yl)et 2.69(mn, 611), 3.i1(br, 411), 4.53(s, 211), h '1) 211-benzo[jb][i,4]oxazi 6.72 6.89(m, 41-1), 7 37(d, 114), 7 50(dd, 111). n-3(4fH[-one 7.66(d, 11-1), 10,65(s, IF). ESI-N/1S rn/z 412.1 [M±H]+.

79 ~ 5-(' (4-(2-fluorobenzo[b]thi 11 M 30~z NS- 6 2. _55(,2 ophen-4-yl)piperazin-1-ylhet 2,68(mn, 6fH[), 3.01(br; 4H), 3,43(s, 21-1), 6.72d, 'hvl)indlin-2-one 111), 6.96(mn, 2H1), 7.0_3(d, Ill), 7.09(s, 111) 7.271(t, 11), 7.52(d, 11i), 10.28(s, 111). ESI- IS

rn'i,396.0 [M±11]v. s0 6-( 2(4-(benzorb]thiophen-4 '11 NMR (3001V1Iz, DMSO-d 6) 652.33(s, 311) yl)piperazini-yI)etliyl)-2- 2. 5(mn, 61-1), 2.95(t, 211). 3.08(br, 4141), 6.90(d rnethy iqujinazolini-4(311)-onie I I-I) 7.27(t.H, 7.3 9(m, 2H), 7.47(s, 111),

______11-1). ESI- IS rn/z 405.1 [M+11f.

81 17 (l_ (4-(benzorb]thiophen-4 111 NMR (300MHz. DMSO-d 6) 6 2.(, 21) yl)piperazin- I- '1)ethyl)- :)14-349(mn, 811), 3.57(m, 411), 3.69(d, 211), '11 dioxide-3,4-dihydro-2- 6.98(d, 11-1), 733(rn, 21-1), 748(rn, 31-1), 770(rni benzole][l,2]ti jazine 1211), 1.77(d, 11-), 11 .26(s, if-). ESI-i iS m/'Z

lihdrochloride 142 8. 0 [M-+HF

82 5-(2-(4-(benzolb]thiophen-4 'Hj N IR (300M1Hz, I) iSO-d6) 6~ 1.83(mi, 4H1 yl)piperidin-l-vl)eth '1)indo 2. 31(m, 111), 2.69(mn, 411), 3.1 4(br, 4H), 3 .44(s, Iln-2-one 211), 6.73(d, 111), 7.04(d, 111), 7.10(s, 111) "25(d, 114), 7.32(t. 11-1). 7.62(d, 11-I), 7.76(d. 11-1 7,84(d, 1,]) 10.3 1(s, 11-), ES1-MS rn/z 377.0 [M±11Y.

8 3 (2-(4-(benzo[b]thiophen-4 FlI NMR (300MO/11-z, DN/1SO-d 6) (5 1 .79(in, 5-11), 1)'piperi dinl-I - ')ethvl)-3,4 2214rn 2H), 2.40(t 211). 2.53(mn, 211), 2.69(Lr -dihydroquinolin-2(111)-one 211), 2.80(t, 211), 3.09(br, 211), 6.70(s, 111), 6.7 8(d, 11-1), 7.05(d, III), 7.23(d, 11-1), 7.31(t, 11-1), 7,60(d, 11-1), 7,75(d.H, 7.82(d, I F) 11 00(s, 111). ESI-MS m/z 391.1 [M±11y. 84 5-(2-(4-(6-tit oroberizo[b]thi '--I NMR (300! 11Hz, DMS(I)-dr-) 6~ 2,56(1,21)

86 hyl)indoliin-2-one K1/-)l 7.03(d, lET), 7.09(s, 1K), 7.37(d, 1K), 49(d, Ifi-.7(, 11-), 10.27(s. Iffi. ESJ-MS

85 7-(2-(1 (6-fluorob enzo[b]thi 'K NMR (300M'--./Hz, DMS O-d 6) (5 2.42(t, 2K), 1ophen-4-yl)piperaziti- I-yl)et 2.571(t. 2H1), 2 68(rn, 61-4), 2.82(t, 2K-), 3 10(bt, hy1) 3,4-di hydroquinolin-2(4 ' 41-1), 6.76(t, 31-1), 7,06(d, 1[11), 7.')7,(d, Hi] 11-one 7.49(d, 1H), 7.66(d, 11-), 10.0 1(s, 1H). ESI-MS Mn/z 4 10. 5 [M+K]v'.

86 6-(2-(4-(benzo[b]thiophen-4 HK NMR (300OMHz, DNISO-d 6 ') (5 2.62(t, 2H),

inothyli 14-betizo[d]itiiiazo 31-1), 6,89(mn, 3K-), 6.99(s, 11K), 7.27(t, 11K) 1-2(31-1) one 7.40(d, 1i-), 7,61(d, Ilfl). 7,69(d, 11-1), 10.70(s, 11-). ESI-MS rn/z 393.5 [M--KL]-.

871 5,-(2-(4-(benzo[b]thiophen-4 'U- NMRIt (300OMf z, [)MSo-d 6-) 6 3,13-3,47(Mn yl'piperazin-1-yl)ethyI)-I,3 14K), 3.56(d, 2K), 3.68(d, 2H), 6.90't,2K -dimcthyi-1KH-benzo[d]irnid 7.12(mn, 2K), 7.32(t, 1K), 7.49(d, 1K), 7.70(dl azol-243K-)-otie 11-1). 777(d, 1K-), 11 .44(s, 1K-). ESJ-MS rniz hy drochloride 407.0 [NM +H]7

88 5-(2-(4-(benzo[b]thiophen-4 -KNMIR (300MNf-z, DMSO-d 6) 6 2.59(t, 21-1), yhpiperazin-1-yl)ethyl)-i- I2,69(br, 41-1), 2. 78 (t 21-1), 3.07(br, 411), 3.25(s, methyl 1H-benzo[d]imidazo KH), 6.89(m,. 3 H), 6.98(d, 1H), 7.27(t, 1K) I 2( K?)-one 7.410(d, 1K), 7.6 1(d, 1K), 7.69(d, 1K), 10.741(S

______1__-i1). ESI-M S rni/z 3 93.5 [M4+K].

89 6-( 2(4-(2-rnethoxybenzo[b] HK NMTR (300M-{-lz, DMSO-d.6 ) d 2.42(t, 2K) thlophen-4-yl)piperazini-]-yl 2.53-2.93(rn, 10H-), 3.05(br, 41-1), 6.43(s. 11K). *)ethyl) 3,4-dihydroquinoli- 6.78(d, 11-1), 6.89(d, H1i), 7.03(m,. 211), 7.13(t, -.0 K)-one 1K) 7.40(d, 1K), 10.01(s, 1K). ESI-N4S m/,z 422. 0 [M±K]'-.

90 33-(/l(4-(6-fluorobenzo[b]thi 'K NMR '300M~z, DMSO-d 6 ') 6 i.76(m, 2K) *ophen-4-yl)piperazin-1I-yl)et 1.85(mn, 2K), 2.22(s, 3K), 2.4.3(t, 2KH)

byl) 2 rnethvi-6,7,8,9-tetrah z.5 1282(in, 81-1). 3.i0(br. 4H-). 3.78(t, 21-1), 1ydi-o-4-11-pvrido[1, .2-a]pyrirni' 6,75(d, 11), 7,37(d, 111), 7.49(d, 1-1), 7.65(d, idin-4-one I1K). LSJ-MS rn/'Z 427.5 [M'HKF. 87 91 17-(- (4-(2-oxo-.2-,3-dihy7drob '1H NMTR (300-{z, DMSO-d,) d 2.42(t, 211) enho[b]thiophen-4-vi)pipera 'I2.84(t, 211). 2.98-3.45(m, 121-1), 3.59(d, 211). izn-l vi)ethy1)-3,4-dihiydroq 4.15(s, 214, 6.74(s, 11-1), 6.83(d, 114). 6.99(d, iuinolin-2(111)-one 11-), 7.14(d, 1H-), 7.26(d, 1H), 7.35(t, 111)

408A1 [M±11-ly.

92 6-(2-(4-(2-.fluorobenzorb]thi 'H1 NMR (300OMHz, DNISO-d 6 ') (5I2.55(t, 211), ophen4z1vl)piperazin- I y1)et 2. 64m, 611), 3.02(br, 411), /1.52(s, 211), 6.82(m, hiyl) 21-benzo[b][i,4]oxazi 31-1), C 97(rn, 21-1), 7.28(t, 11l). 1.52(d, 114). n-3(4H-[-one 10,66(s, 11-1), ESI--MS rn/Z 412.2 [N/1+14]l

93 5-(2-(4-(2 -fluor-obenizo[blthi 'H1 NMNR (300MI-z. DMSO-d 6) (5 3.03-3.55(m. ophen-4-yl)piperazin- I-yI)et 1611), 3.62(d, 21-1), 7.00(mn, 2H), 7. 11 (m, 31-1),

hyl)- 1,-dirnethyl-1H-benzo ' T,0(t, 1H), 7.59(d, I H'), 8.59(br, 2-H). 11. 53(s, [d]irnidazoi-2(311)-one 111). ESI- IS rn/z 425.1 [M-1 H]'. hy drochloride

94 6-fluoro-542.44-(2-fluorobe iH NMR (300MN11z, DM5 O-d6) (5 2.54(t, 211),

1nzo[b]thiophen-4-yI)piperaz z.66(br, 4H1), 273(t, 21-), 3.01(br, 41-1), 3.42(s, in-1 yl)ethyl)indolin-2-one 21-1), 6,58(d, 11-1), 6,95(d. , 6.98'(d, I1I) 7.16(d, I1H), 7.2'7(t, 111), 7.52(d, 111). 10.40(s,

______111). ESI-VS m/z 4.14.1 [M'H].

95 '15-(2-(4-(benzorb]thiophen-4 'H NMR (300OMHz, DMSO-d6 ') (5 2.5 5(t, 211),

I uoroindoiin-2-one 11-1), 6.89(d. 11-1), 7 16(d, 111), 7.2-1(t, 11-1). 7.40(d, lH), 7,61(d, I1I). -1,68(d, 11-1), 10.41(S, 111) 1-SI-MS rn/z 396.0 [M-11]-.

96 -(2-(4-(benzo[b]thiophen-4 'H NMR.t (300Mf-z, [)MSO-d6 ) 6 3..i-3,46(rni 1)'piperazin-I-yl)ethyI)-1-b 1111), 3.53(d, 2H), 3.62(d, 211), 5.40(s, 21)j

Ienzyl3i methyiquinazoline- 6.97(d, 111), 7.21i-7.39(m, 811), 7.48(d, 111), 2,4(]H131-1)-dione 7.70(d, 11-1), 777(d, 11-1), 8.07(d. 11-1), 11.18(s,

______111 1SI- IS rn/z 511,7 [M-+H]-.

97 6-(2-(4-(benzo[b]thiophen-4 '14 NM/R (300MHz, DMSO-d 6) 6 1.54(in, 11-1), yhpiperidin-1-yl)ethvi)-2[11 1,84( r, 41-1, 2,72( r, 414), 3,14( rt, 4141 -benzo[b][l,4]oxazin-3(41) 14.51(s, 211), 6.8 1(m, 311), 7.2_3(d, 111), 7.32(t 88 -one 111) 7.61i(d, 111), 7.75(d, 111), 7.83(d, 111) 10.66(s, 11-1). ESI-MS rn/Z 393 0 [M-1-1F.

98 6 (l_ (4-(benzorb]thiophen4 11H NMR (300MHz, DMSO-d 6') 6 i.54(m, I1-M yl)piperidin-i-y1)ethyi)-3,4 1.79(mn, 411), 2.15(bi;21,24(,21,26( -ditdroquinioin- (11)-onie 41-1). 2.81(t, 211), 3.34(br, 21-1), 6 75(d, 11-1), 6,99(d, 1141), 7,02(s, Hi, 7,23(d, 1H,7.31 (t I1H), 7.59(d, I1-1, 7.74(d, 11-), 7.82(d, 11-), 9.97'(s, 111). ESJ-MS rn/z 391.0 [M+11'-. 99 3-(2-(4-(benzorb]thiophen-4 N R(0M ,D1LS.d)I .3(m,3H 4H-),

1l)piperidin- I-y)ethy}2- /2.05(mn, 4H-), 2.29(s, 311), 2.84(mn, 411) rncthil6,7!,8,9-tetrahy7dro-4 13.07-3.55(mn, 51-4), 3.79(m. 41-1), 7.24(d, 114) H-pyrido~l,2-a]pyrirnidin-4 17.38(t, 1141), 7.70(d, 11-1), 7.85(d. 1, 7.9,2(d, one hydrochloride 11-), 9.28(s, 11H). ESPM S rn/z 408.2 [M _1H] 100 6-(2-(4-(2-fluorobenzo[b]thi 'U- NMRl (30M , DMOd)-1.5t,61 ophen-4-vl)piperazin-1.-yl)et 2.82(t, 211), 3.01(br, 411). 6.47(d, IH), 6.95(d, hvl)quinolin-2(iH)-one 111) 6.98(d, 111), 7.23(d, 111), 7.24(t, 111) 7.40(d, 11-1), 7im.21-1). 7.84(d, I H), 11.66(S,

______1) 151- IS rn/z 408.3 [M±1-1f.

101 5-(4-(4-(2-fluorobenzo[b]thi 1 1 NIR. (300Mliz, DMSO-d 6) 6 1.52 in, 41-1), ophen-4-yl)piperazin-lI-yI)b 2,36(t, 21-4), 2.54(mn, 61-1), 2.99(br, 4H-), 3 31(s, utv1)indolin-.2-one ')) 6.71(d, 1H), 6.06(m, 311), 7.04(s, 1I) 17.271(t, 111), 7.51(d, 111), 10.25(s, 111). ESI- IS

rn/i 424. 5 LM+1f]v-.

102 7-( 2(4-(6-fluorobenzo[bjthi '11 NMR (300MHz, DMSO-d 6) 6 2.66(mn, 611), opheti 4-yl)piperazin- I-vI)et 12.85(t, 21-1), 3.i0(br, 41-1), 6.42(d, lfi, 6.75(d, hly)quinoiin-2(1H)-one IF1I), 7.09(d, 11-1), 7.1 8(s, 1141), 7.37(d, 1-1-1), 749(d IH,7.7d IH), 7.66(d, 1H), 7.85(d,

111) 11.68(s, 111). ESI-VS m/'z 408.7 rM4-.

103 3-(4-(1 (benzo[bjthiophen-4 'H NMIR (300 111z. D ISO-d 6) (5 i.53(m, 411),

diniethoxv-4H-chrornen-4- 31-1), 3.90(s, 3-11), 6.89(d, 1141) 7,17(s, 11-1) one 7.27(t, 111). 7.38(s, 111), 7.39(d, I1H), 7.61 (d, 89 1K)l 7.69(d, 1K), 8.19(s, 1K). ESI-MS mnZ

1479.0 [M+K] V.

104 6-(4-(4-(benzorb]thiophen-4 'H NMR (300MHz, DMSO-d 6') 6 1.46(m, 211) yl)piperi din- I-YI)butyl)-3,4 1.5I(m, 2K), 1. 76(mn, 4K), 2.07(t, 2H), 2.33(t -ditdroquinioiin-2 (iK-)-oie 21-), 2-41 (t, 2H1), 2. 5 1l(d, A2l)f, 2.83(t, 2K-), 2,96(d, 2[11), 3.05(m, 11-1), 6.75(d, 114), 6.95(d, I1K), 6.99(s, I1K), 7.24(d, I1K), 7.31 (t, IK), 7.59(d, 1K), 7.74(d, 1K), 7.82(d, 1K), 9.96(s,

______i1).1_ ESI-M S rn/z 419.5 [M4 If.

105 1')(-. (4-(benzorb]thiophen-4 'K NMR (300MHz, DMSO-d 6) 6 2.72(mn, 6H), yl)piperazini-yl)eth '1)-S.- 2.87(t, Al). 3.11 (bi-, 411), 3.77(s, 3K-), 6.7 1(dd. nethoxy.-IK--indole IFI), 6.91(d, 114), 7.0l(d, 1Kf), 7,14(d, 1[-1),

1K), 7.69(d, 1K), 10. 61 (s, 1KH). ESI-MS rn/z 392A1 [M±11-Iy.

106 3-(3-(1 (benzo[bjthiophen-4 'K NMIR (300 IIz. D ISO-d 6) (5 1.84(m, 2KH), yl)ptpprazin-l-v1)proy1-5 2. 4 5 211) 2.62(br, 414) 2.69(t, 21-1,3 08( mehx -1idl 41-1), 3.76(s, 314I), 6.70(dd, 11-1), 6.90(d, IFlI)

6. 8(d, 1K), 7.08(d, I1K), 7.2 1(d, I1K), '7.27@ 1K)l 7.39(d, 1K), 7.61(d, 1K), 7.68(d, 1K) 10.57(s, 1K4). ESI-MS rn/Z 4068 [M-1-1-1

107 f?(4(LIen- 4(benzorb]thipe- 'K NMR (300M~z, DMSO-d 6) 6 i. 5 5(m, 2K), vl~herazn-i-1)buyl)-- 1.68(mn, 21-i), 2.41(t. 211), 2.59(br, 41-1), 2.68(t nethoxy.-IK--indole H), 3.05(br; 41-1), 1.7(s, 3H1), 6.70(dd, 11-1), 6.88(d, 1H), 6.98(d, 1H), 7.06(d, 11H), 7.2 1(d, 1K), 7.27(t, 1K), 7.3 8(d, I1K), 7.60(d, 1K)l 7. 8 (d, 11-1), 1i0.56(s. li). ESJ-MS rniz 420. 1 [MI 11]

108 3-(3 (4-(benzo[b]thiophen-4 '11 NM/R. (300M~lz, DMSO-d 6) 6 I .85(in, 2K-), ylhpiperazin-.1-yl)propyhl 12,41(t, 21-1), 2.61(br, 411), 2,76(t, 2J-14), 3.09(b, KIHindol e-5.",-cart)oni tril e 14K), 6.90(d, 11-). 7.27(t, 1H), 7.38(m, 3K), 7.419(d, 1K), 7.61(d, 1K), 7.9d,1), 8.11i(s,

______11-1), 11 .38(s. 111). ESI-MS m/z 401.0 [M+I-1f.

90 109 ( (4-(benzorb]thiophen-4 '1H NMR (300MHz, DMSO-d 6) d 2.72(m, 611), yl)piperazin-i-y1)ethy1>-1-f1 2.94(t, 21-1), 3.i0(br, 411), 6.91i(d. 11-1) 7.2'8(t. I dole 5-carbonitri le 1 II) 7.41(mn, 31-1), 7.50(d, IFl), 7,622(d, 11-1), .70'd, 111). 8.13(s, I111), 111.41(s, 1H). ESI MS ! rn z -387.6 [M+H]'.

110 1 -acetNxl-3-(4-(4-(benzo[b]th !1 1 N IR (300M 1z, D) S0-d 6 ) 6~ 1.58(m, H,) iophen-4-yIhpiperazin- I-l)b 1.72(m, 211), 2.44(t, 2H), 2.60(bi; 411), 2.6(s, Utyi) IH-indole-5-carbonitni 311), .74(t, 211), 3.06(br, 411), 6.89(d, 11) I e 7.6(t, 11-I), 7.3 9(d, 11-1). 7.60(d, 11-I), 7.6 8(d. HI), 7,-2(dd, 11-1), 7.8'4(s, 1141), 8.222( 11), 8.4 5'd, I H). E S -M S m/z 457. 6 [M -1H]

III 6- 4-(4-(benzo[b]thiophen-4 f-1 NMR (300M/11-z, DN/1SO-d 6) (5 I .52(mn, 4-11), yl'piperazin- I-yl)butyl)-3,4 /2.41(t, 411), 2.57(m,. 6 H), 2.8 3(t, 211), 3.05(br -dihydroquinolin-2(111)-one 111), 6.76(d, 111), 6.89(d, 1H1), 6.96(d, 111), 7.00(s, ifi. 7.27(t. 1141), 739(d, 114), 76 1(d, 1-1-), 7,69(d, 11-1), 9,97(s, 114). [iSII-MS mn/Z

112 5-(4-(4-(benzolb]thiophen-4 11jN IR (300M 1z, D) S0-d 6 ) 6~ 1.52(mn, 4f1I)

olin-2-one 1/2H), 6.71(d, 1H1), 6.88(d, 111), 6.98 (d, I11) 04(s, 11-1), 7.26(t, 111), 7.38(d, 11-1), 7.60(d. I f-1 7,68(d, 14) 10,25(s, 11-1), [ISl-MS rn/z 1 405.8 [M±H]Y. 2 113) 6-chlilo-5-( -(4-(2-fluorobe -1IN IR (300M]-z, DM SO-d 6) .5t 11

nzorb]thiophen-4-yl)piperaz /68(bi,z1 411), 2.84(t, 211), 3.02(br, 4H), 3.46(s, in I xl)ethy1)indolin-2-one 211), 6.8 1(s. 1IM) 6.97(m, 211), 7.23(s, 111), 7.28(t. 1141), 7 52(d, 111). i0.40(s. 1141). ESI-MS ' Miz 430.1 IIM-1$.1

114 6-('2 (4-(benzo[b]thiophen-4 !'1-1 NMIR (300M~f-z, DN4SO-d 6) 6 2.62(t, 21-1), yhpiperazin-1-yl)ethyl)-4- 12,7 1( r, 41-1), 2.7W(t 2141), 3 .08(br, 4H-), 3.28(s. Imethy1-2H-benzo[b][l,4]ox 11), 4.60(s, 211), 6.91(m, 21), 7.08(s, 111), azin-3411)-one ' 21(t, 111), -7.40(d, 111), 7.61(d, 111), -7.69(d,

______11-1). ESI-MS mn/z 408.2 [M-+H14. 91 115 17-(.2(4-(benzorb]thiophen-4 '1H NMTR (300-{z, DMSO-d,) d 2.51(t, 211)

yl~ipeazi-i-l~eh 1-I 12.63(t, 211), 2.74~ ,.41-1), 280(rn, 41-1), 3.08(br

rnethyl-3,44dhydroquiioiin- 4H), 3.26(s, 31-1), 6.90(tn, 2),7.00(s, 1ll), -(011)-one 17.11 I(d, IH), .7(,1H1), 7.40(d, 111), 7.61(d,

116 5-(2-(4-(benzolb]thiophen-4 'Hj N IR (300M 1z, D) SO-d 6 ) 6~ 2.66(mn, 6H-I yl)piperazin-1- i'ethvl)ben 2.79(t 2H1-), 3.08(br, 4H), 6.90(m, 21-), 7.26(rn zord]thiazoi-2-amine 11H)7.41(m, 311), 7.53(d, 111), 7.61(d, 111)

______.69(d, 111). ESI-MS m/z 395.0 [M-14f

1171 7-(2 (4-(benzorb]thiophen-4 '1H NMR (300MHz, DMSO-d 6) d 2.70(mn, 611),

yl)piperazini-yl)eth '1)ben 2.86(t, 2141), 3.09(b , 411), 6.91 (t, 2141), 7. 17(r zo[d]thiazol-2-arnine 2H), 7,27(t, 11-1), 7.41(d, 11-1), 7.44(s, 211), 6 1'd, 111). 7.60'd, 111'. ESI-MS m'/z 395.0

118 N-(5-(2-(4-(benzo[btio e 111 NMR (300MHz, DMSO-d 6) 62.19(s, 31)

ii 4 -~piperazin-1-y1)cth '1) 'I2.70(m, 6H), 2.91(t, 211), 3.08(br, 411), 6.90(d, benzo[d]thiazoi -2-yi)acetam 11-1). 7.21(d1, 1li), 7 27(t, 111), 7.40(d. 11-1), ide 61(d, I H) 7.63(d, 11H), 7.69(d, I f-), 7.8 5(d,

119 N-(7-(2-(4-( enzo[b]thiophe HINMR (300Mf-z, DMSO-d 6) 6 2.20(s, 3-1~ n-4 yi)piperazin- I -l)ethy1) 2.74(m, 611), 3.03(t, 211), 3.09(br, 4H), 6.90(d, bcnzord]thiazoi-2-v1)acetam 111), 2d 111), 7.27(t, 111), '7.3 8(t, I11) Iid. 'I742(d, 11-1), 7.60(t, -1i) 7.69(d, 11-1), 12.33(s. I H). E11-S m/Z 43)7.1 [--I

120 4-(2-(4 (benzo~b~thiophen-4 1-1 NM/R (300MI-z, DMSO-d 6) 6 2.69(m, 611).

zord]thiazol-2'-amine 111), 7.28(t, 111), 7.41(d, 111), 7.49(m, 311)

17.61(d, 111), 7.69(d, 111). ESI-MS rn/z 395.0

121 IN-(/I ( ,,(4-(benzorb]thiophe 'H N R(300Mvffz, DMSO-d 6) ci 2.20(s, 311), 1n-4-y1)piperazin-i-vi)ethy1) 2.72(n, 611), 3.09(br, 411), 3 19(t, 211), 6.90(d, benzold]thiazoi-2-yl)acetain 11-1), T26(tn, 311) 7,40(d, 1[11), 7.61l(d, H1i) ide 7.69(d, 111), 7.79(d, 111), 12.3 8(s, 111). ESI-MS 92 Mn/z 43-7.1 [M+KY-'

122 (2-(4-(2-rnethylbenzo[b]th 'II N R(0M(,5 IS- 6 2.42(t, 21)

iophen-4-yl)piperazin-.i-yI'e 12.56(mn, -5H), 2.68(m, 6H), 2.82(t, 2H-), 3.04(br, thvl1)-3,i-dihydroquioin-2( IK4), 6.73(s, 1K), 6.80(d, IK), 6.85(d, 1K), 11-1) one 7.06(d, 11-I), 7.10(s, 11K), TIM8(, 114), 7.47(d,

______11-1), 10,02(s, I H). ESh-MS m/Z 406. 1 [m -- 1][

123 3-((4-(benizo[b]thiiophien-4-y . 11 NM/R. (300MHz, DMSO-d 6) 6 3. 16(in, 2K-), 1)piperazmn-i -vi)rethy[)-I- I3,37(mn 4, 3,52(br, 41-1), 3.85(s, 3f--[, 4.57(s, meth 1 1H-indole ')) 6.94(d, 1H), 7.137.34(m, 3H), 7.47(d, hydrochloride 1K), 7.5 1(d, I1K), 7.68(m, 2H), 7.74(d, 1K) 91(d, 111), 10.67(s, 1K-). ESI-MS rn/z 362.1

124 1 (3-(2 (4-(benizo[b]thiophe 'H1 NMIR (300MI-z, DMSO-d 6) 6 2.03(mn, 11K) in-4 y1)piperazin-i-vi)ethy1)i 2. 19(s, 314I), 2,28(mn, ifl) 3,24(mn, 21-), 154(d, Indolin- LyI)ethanone 3K), 3.64(d, 2K), 3.86(rm, 5H), 4.26(t, I1K) hx drochioride 6.97(d, 1KM 7.05(t 1K), 7.20(t, 1KM 7.32(rn 214). 7.48(d, 1K-), 7.70(d, 1K-), T77(d, 1K-), 8,06(d, 1, 11,06(s, 11-1. ESI-MS rn/z 406,5

125 -(2-(4-(benzolb]thiophen-4 I11 NMR (300Mf-z, DMSO-d 6) 6 2.29(s, 31-1

osyl iK-indole-5-carbonitri1 1K), .2( 1), 7.39(m, 3K), 7.62(d, 1K) e 'I7.7~0(d, lHi), 7.731(dd, 1K-), 7.88(m, 3K-), 8.08(d 11-1 8.26(d, 11-]). ES1-MS rn/z 541 1 [M-1-K]7l+

126 3-(3-(4 (benzo~b~thiophen-4 '11 NMIR (300MI-z, DMSO-d 6) 6 i.84(mi, 21-1),

-1pieazin--1po1)1 - ( 3) 2.35(t, 2H), 256(br; 4K1-), 2,72(t, tosw1 1K-indole---carbonitr 1 K-), 3.03(br, 4K), 6.87(d, 1K1), 7.28(t, 1H-) 1l 7.39(mn, 3K), 7.61(d, 1K), 7.69(d, 1K), 7.73(dd, 111). 7.81(s, 111), 79(,2K-), 8.08(d, 1K-),

8,"-5(d, 11-) ESI-MS tr/z 555.7'M±Y

127 13-(4-(4-(benzo[b]thiophen-4 -11NM/R. (300MHz, DMSO-d 6) 6 1.47(in, 2K-), yl)piperazin-I-yl)butyl)-5- 1,65(m 2I, 2.28(s, 31-I), 2.38(t, 21-1), 2.55(br I methoxy-l-tosyl-1-indole 414), 2.64(t, 2H), 3.03(br, 414). 3.76(s, 3K), 93 6.88(d, 11), 6.93(dd, 111), 7.05(d, 111)

'22-7.42(rn, 4H1), 74(,11-1), 7.6 1(d, 11-1). 7.69(d, 11-1), 7,77(mn, 31-1). ESf-MS rn/z 573.9 [M±1H]+.

P8 3-(3 (4-(benzo[b]thiophen-4 '14 NM/R (300MHz, DMSO-d 6) dI I .. in, 21-1), yhpiperazin-1--yl)propyl)-5 2,2_9(s, 31-1), 2,35(t, 2-1-1), 2.57(br, 4H1), 2.65(t rnethoxy-1-tosy{-iH4-indole 214), 3.06(br, 41-), 3.77(s, 3H), 6.8 8(d, I11), 16.93(dd, 11-), 7.04(d, 111), 7.27(t, 111), 7.34(d, 21-1), 7.39(d, il--b. 7.50(s, 11-I), 7.61 (d. 111). 7.69(d, 11-1), 7,79(mn, 31-1). FSf-MS rn/z 560.7 [M±1-1+.

129 3-(2-(4-(benzo[b]thiophen-4 'FI NMR (300MIz, [)MSO--d 6 ) ) 2.27(s, 3-1-), 1)'piperazin-l-yl)ethyl)-5- 771 'n, 6H-), 2.83(t, 2H), -3.07(br, 4H), 3.77(s rncthoxy-1-tosyi-iH-indole 3H), 6.92(m, 2H1), 7.10(d, 1K), 7.3 1im, 3H-), 7. 41(d, 11-1), 7 5 8 (s. 11-1), 7.62(d, 11-1), T.70(d,

______11-1), 7,78(mn, 31-1). ES 1-MS in/z 545,9 [M 1

130 6-(2-(4-(2/-oxo-2 ,3-dihvdr-ob '14 NMIR (300M~fz, DN4SO-d 6) 6 2.4 1(t, 21-1), enzo~b~thiophen-4-:vi)pipera 2,52-2,73(rn, 8-1-1), 2,83(t, 211,2.95(br, 41-4 * nl I l)eth ')-3-,4-dih 'droq 14.09(s, 2H-), 6.76(d, Il-H), 6.93 (d, 1H', 7.00(d, Uinohin-2(111)-one 11), 7.03(s, 111), 7. 17(d, 111), 7.29(t, 11), 9.98(s, 11-1). ESI-MS rn/z 408.1 [IM-1-11]

131 '?(. (4-(2-fluorobenzo[blth' 1H NTINIR (300MHz, DMSO-d 6) 6 1.78-2.11(m, *ophen -4-yl)piperazin- I-vI)et 41-1), 2.50(s. 31-1), 3. 04(rn, 21-i), 3 .15 -3 .430(n, hvl ) 9-hydroxy-2-rnethyl-6, 6H), 3.49(d, 21-1), 3,68(d, 21-1), 3.77(m, 11-1),'

7,8,9-tetrahydro-4H-pyrido[ 3.9 4(mn, 11-), 4.75(t 1H'), 7.02(d, 111), 7.17(d, 1,2-a]pyrimidin-4 -one I H), 7.3 2(t, 111), 7.1(, 1), 11.52(s, 11). hydrochloride ESI MS rn/Z 443.0O [M-1-1.

132 * -(2-(4-(benzo[bjthiophen-4 'H NMIR (3f00MHz, DMSO-d.6 ) 6 3.16-3.71(m! y )ppazin l-I)ty)2-1 1014), 3. 84(m, 21-1), 4. 78(m, 11-1), 6. 97(rn. 51-1),

benzob][1,4]oxazin-3 (4141 731(t, 11-1), 7.49(d, 1141), 770(d, 11-1), 7.76(d, one h4drochloride III), 10.84(s, III), 11.06(s, 111). ES1-MS rn/z 394.0[ M1±H .

94 133 7-(.2(4-(benzorb]thiophen-4 '1 NMIR (300MHz, D ISO-d 6) 6 2.43 (t, 2H-) yl)piperazini-yl)eth 1>)3,4 2.84 (t, 214_), 3.06 (in, 21-1,3034 n,61 -dihydroquinoline-2(l f-[-thi 3.56(d, 21-1), 3.67 (d, 21-1), 6.76 (s, I l) 6.86(d, one hydrochloride I1H), 6. 98 (d, IH), 7. 15 (d, I1H), 7.3 2 (t, Il-H) 7.49 (d, 111), 7.0(d, 111), 7.77 (d, 1H), 10.13 (s, 111). 11].3 0 (s, Ilib. ESI-MS m/,,z 408.0 [M 11J]

134 '1(3aR,4R,6aS)-4I-(5-(4-(benz 'I1H NNMIR (300MHz, CDCI,) d1.44 (in, 411) 0[bjthiophien-4-yi)piper-azin-' 1.68 (mn, 41-1), 2,60 (in, 211), 2.74 (d, 114).

I -v )pentvi)tetrahydro- IH1-t 2. 8 8(m, 51-1), 3..16 (1,lH,328 (bi-, 41-1), hieno['",4.-d]irnidazol-2-(311') 4_.1(d d, 1H', 4.50 (dd. 1H', 6.91 'd, 111). 7.27

one (t, 11H), 7.39 (MI, 211H), 7.56 (d, 111). ESI-VS in/z 431 .6 [M1If

135 .pentyl '1H NMR (3f00MN/Hz, DM5 O-d6) (5 0.88(t, 311), (6 (Q (4-(benzo[b]thiophen- 1.32(in, 4141), i.64(m, 2H), 2.68(in, 61-1), 2.87(t, 4 yl)piperaziri-1-vI)ethvl)be 121-1), 3,08(br, 41-1), 4.18(1, 21-IH 6.89(d, ILL) nzo[d]thiazol-2-yl)carbaiat 7.27(m, 211), 7.40(d, 111), 7.60(in, 2H), 7.68(d, 111H) 7.81(s, 111), 1i.94(s, 111). ESI-I\S mn/z 5 09.1 [M'+14]'

136 113 -(/l (4-(benzo[b]thiophen-4 11H NMR (300MHz. DMSO-d 6) ci1.97.-2.28(m, yl)piperazii - 1)ethvl)-2- 711), 2.47(t, 211), 2.68(mn, 611), 3.08(br, 411), rnuhyi1-4-oxo-6,7,8,9-tetr-ah 3.76(in, 111), 4.O2(in, 111), 5.96(t, 111), 6.89(d 1ydi-o-4-11-pvrido[1, .2-a]pyrirni' 11-1), 1.27(t, 1141), 7,40(d, 11-1), 7.53( , 21-I) idin - -.l benzoate I7.61(d, 11), 7.67(mn, 2H), 8.00(d, 211H). ESI-MS

137 '16-(4-(4-(benzo[b]thiophen-4 111 NMR (300OMHz, DMvSO.-d 6) 6I 1.5 1(mn, 411),

i benzolb][1,4]oxazin-3(411) 41-1), 4.5 1l(s, 21-1), 6.74(rn, 21-1). 6.87(m, 21-1). -one 7.27(t, 1141), !39(d, 11-1), 7.61(d, IH}4) 7 68(d, 111) 10.62(s, I1H'). ESI-MS mn/ 422.0 [M±11]'.

138 '11(bcnzo[bjthiophen-4-vl)-4 '11 NM_.IR (300T 11Hz, DMSO-d 6) 6 1.16-2204 (in

-______(4-(l-clihexv- I H-tetraz 1411), 2.98 (t, 211), 3 25 (i, 61-1). 3 5 6 (t, 41-1).

95 ol-5-yl)butyl)piperazine 4.43 (m, 1H), 6.96 (d, 1H), 7.32 (t, 1H), 7.49 hydrochloride (d, H), 7.7 (d, lHi), 7.77 (d, 1H), 10.82 (s, fH). ESI-MS m/z 425.3 [M+H]

139 6-(2-(4-(benzo[b]thiophen-4 'H NMR (300MHz, DMSO-d6 ) o 3.07 (t, 2H), 1yl)piperazin-1-yl)ethyl)-8-f 3.33 (m, 61H), 356 (d, 2K), 3.66 (d, 2K), 4.65

luoro-21--benzo[b][1,4]oxaz (s, 21), 6.65 (s, 1H), 6.88 (d, 11), 6.98 (d, I H),

in-3(4H)-one 7.32 (t, 1H), 7.48 (d, 1H), 7.70 (d, 1H), 7.76 (d, 1H), 11.00 (s, 1H), 11.26 (br, 1H). ESI-MS m/z 411.6 (M+HKY.

140 7-(2-(4-(benzo[b]thiophen-4 H NMR (300N1Hz, DMSO-d6 ) o 2.54 (d, 1H) -yl)piperazin-1-yl)-i-hydrox 2.60 (dd, IH)i, 2.75 (brt, 4H), 3.07 (brt, 4K),

yethyl)quinolin-2(1-1)-one 4.83(m, 1H), 5.29 (d, 1H), 6.44 (d, 11), 6.89(d, 1H), 7.18 (d, 1H), 7.27 (t, 1H), 7.37 (s, 1H) 7.39 (d, 1H), 7.60 (t, 2H), 7.69 (d, 1H), 7.87 (d, 1H), 11.75 (s, III). ESI-MS m/z 406.1 [M+KH]

141 6-(2-( 4(benzo[b]thiophen-4 HKNM (300MHz, DMSO-d6 ) 6 2.39-2.61 (m,

-yl)piperazin-1-yl)-I-hydrox 2H), .73 (brt, 41-1), 3.07 (brt, 4H), 4 54 (s, 2H), yethyl)-2H-benzo[b][1,4]ox 4.68(m, 1H), 5.04 (d, IH), 6.90 (m, 31)

* azin-3(4H)-one 6.96(s, 1H), 7.27 (t, 1K), 7.39 (d, 1H), 7.61 (d, 1H), 7.68 (d, 1H), 10.68 (s, 1K). ESI-MS m/z 410.1 [M+H]*.

142 6-(2-(4-(benzo[b]thiophen-4 H NMR (300MiHz, DMSO-d 6) o 2.41-2.63 (m, -yl)piperazin-1-yl)-i-hydrox 2H), 2.74 (brt, 4H), 3.07 (brt, 41H), 3.43 (s, 2H),

yethyl)-2H-benzo[b][1,4]thi 4.70(m, lH), 5.14 (d, 11H), 6.89 (d, 11), azin-3(4H)-one 6.97(dd, 1H), 7.04 (s, 1H), 7.27 (m, 2H), 7.30

(d, 1K), 7.60 (d, 1H), 7.68 (d, 1H), 10.54 (s, 11). ESI-MS rn/z 426.0 [M+K]

143 5-(2-(4-(benzo[b]thiophen-4 H NMR (300MHz, DMSO-d6 ) o 3.30 (t, 2H), yl)pipeazin-l-yl)acetyl)ind 3.40-3.75 (ml, 8K), 5.16 (s, 2K), 7.01 (t, 2K) olin-2-one hydrochloride 7.33(t, lH), 7.50 (d, 1H), 7.72 (d, 1I), 7.78(d,

1H), 7.88 (s, 1H), 7.93 (d, 1H), 10.49 (s, 1H), 11.05 (s, 1H). ESI-MS m/z 392.2 [M+ H].

144 8-(2-(4-(benzo[b]thiophen-4 H NMR (300M1z, DMSO-d6 ) a 2.55 (d, 1H), 96 yl)piperazin- I-yl)-I -metho 2.71 (m, 5H), 3.06 (brt, 4-H), 3.18 (s, 3H), xyethyl)-2H-benzo[b][1,4]o 4.60(s, 2H), 4.77 (dd. 111), 6.79-7.02 (i, 411)

xazin-3(41)-one 7.27(t, 1-1), 7.40 (d, 1-1), 7.60 (d, 11), 7.68 (d, 1H), 10.72 (s, 1H). ESI-MS m/z 424.1 [M+H] .

145 5-(2-(4-(benzo[b]thiophen-4 Hj-NMR (300MHz, DMSO-d 6) 6 2.45 (dd, ypiperazin-1-y)-1-hydrox 11), 257 (dd, 111), 2.73 (bi, 411), 3.06 (br, 411)

yethyl)indolin-2-one 3.46(s, 2H), 4.70 (m, 1H), 4.95 (d, 1H), 6.75(d, 1H), 6.89 (d, 1H), 7.15 (d, 1H), 7.22 (s, 1H), 27 (t, 111), 7.39 (d, 111). 7.61 (d, 11H). 7.68 (d, H ), 10.33 (s, 11H). ESI-MS m/z 394.5 M+H)

146 6-(2-(4-(benzo[b]thiophen-4 11 NMR (300MHz, DMSO-d6 ) 5 2.77 (bit, yl)piperazin-1-yl)acetyl)be 4H), 3.08 (brt, 4H), 3.90 (s, 21H), 6.90 (d, 1H), nzo[d]thiazol-2(3H)-one 71(d 1H), 7.27 (t, 1H), 7.40 (dd, 1H), 7.61(d,

1H), 7.69 (d, 1H), 7.98 (dd, 11H), 8.31 (d, 1H), 12 28 (s, 11). ESI-MS in/z 410.2 [M-H] .

147 5-(2-(4-(benzo[b]thiophen-4 H NMR (300MHz, DMSO-d6 ) 6 2.76 (brt, -yl)piperazin-1-yl)acetyl)-1 411) 3 .08 (brt, 41H), 3.89 (s. 211), 6.90 (d, 111), H -benzo[djimidazol-2(3H)- 7.02(d, I H), 7.27 (t, 1H), 7.40 (d, 1H), 7.57 (d,

one 1H), 7.61 (d, 1H), 7.69 (d, 1H), 7.75 (dd, 1H), 10.90 (s, 1H), 11.07 (s, 1H). ESI-MS m/z 393.2 [M+ H]*.

153 1N-(6-(2-(4-(benzo[b]thiophe 'H NMR (300MHz, DMSO-d 6) o 2.19 (s, 31H) n-4-yl)piperazin-i-yi)ethyl) 2.69 (m, 61-1), 2.90 (t, 211), 3.08 (br, 4H), 6.90

benzo[d]thiazol-2-yl)acetam (d, 111), 7.27 (t, H, 7.32 (d, 1 H), 7.41 (d, 11), ide .63 (t, 2H), 7.70 (d, 1H), 7.84 (s, 1H), 12.29 (s, 1H). ESI-MS m/z 437.0 [M+H]*.

154 6-(2-(4-(benzo[b]thiophen-4 'H NMR (300MHz, DMSO-d 6) 6 2.61 (t, 2H) yl)piperazin-1-yl)ethyl)ben 2.69 (br, 4H), 2.79 (t, 2H), 3.08 (br, 4H), 6.90 zo[d]thiazol-2-amine (d, 111), 7.09 (dd, 111), 7.26 (m. 211), 735 (s 211), 740 (d, 11-), 7.53 (d, lH), 7.61 (d, 11-1) 7.69 (d, 1H). ESI-MS m/z 396.2 [M+-1H].

Pharmacological test

97 1) 5--H IA receptor agonism activity test The 5-HTiA receptor agonism activity test (The agonism activity of test compounds on 5-HTIA receptor expressing human recombinant 5-HTiA receptor in HEK293 cells) was performed using LANCE TM cAMP 384 Kit (Product of USA PerkinElmer Inc.). The 5-HTiA receptor agonism activity of test compounds was evaluated through their inhibition on cAMP production in HEK293 cells. cAMP concentration test was performed according to the method documented in the kit instructions. The concentration of the test compounds was

0. InM-IOOnM, 8-O1-DPAT was used as a positive control, EC50 value was calculated by the Excelfit software and the results are shown in Table 1.

2) D2 receptor antagonism activity test

The D2 receptor antagonism activity test (The antagonism activity of test cmpounds on D receptor expressing human recombinant D2 receptor in HEK293 cells) was performed using

LANCE TA cAMP 384 Kit (Product of USA PerkinElmer Inc.). The D2 antagonism activity of test compounds was evaluated through their inhibition on dopamine-induced decrease of cAMP production in HEK293 cells. cAN'P concentration test was performed according to the method documented in the kit instructions. The concentration of the test compounds was 0.InM-10000nM, risperidone was used as a positive control, IC50 value was calculated by the Excelfit software and the results are shown in Table 1.

3) 5-HT 2A receptor antagonism activity test The 5-HT2 receptor antagonism activity test (The antagonism activity of test compounds on

5-HT2A receptor expressing human recombinant 5-HT2A receptor in CHO-KI cells) was performed using FLIPR@ Calcium 5 Assay Kit (Product of Molecular Devices USA Inc.) according to the method documented in the kit instructions. The concentration of the test compounds was 0.inM-10000nM and risperidone was used as a positive control. Test method is as follows: On the first day the seed cells are placed in T-175 flask containing 25ml growth medium (F-12 nutrient mixture + 10% FBS + 1% penicillin / streptomycin + 1.2% 50mg / ml

Geneticin) at a density of 14 million per bottle, cells were cultured under 37 'C/5%

CO2/humidified conditions for 24 hours; On the next day the seed cells were inoculated to the 384-well cell culture plate (each well containing 20,000 cells), the growth medium was replaced by 50 gL detecting medium (F-12 nutrient mixture + 1.5% activated carbon-treated

FBS), the cells were cultured under 37 'C/5% CO 2/humidified conditions for 16 hours; On the third day the medium was removed, each well of the cells plates were added with 24pL freshly

98 prepared loading dye solution (formulated according to the instructions), the plates were placed

0 in an incubator and incubated under 37 C/5% C0 2 /humidified conditions for 120 minutes, transfer 6[iL test compound solution to the assay plate and gently shaking for one minute, incubated under 37 'C/5% CO2/humidified conditions for 30 minutes; each well of the assay plate was added with 10pL freshly prepared a-methyl-5-hydroxytryptamine solution (1.2VM, the final concentration of ca-methy l-5-hydroxytryptamine is 300nM), data were detected and analyzed by FLIPR (Product of US Molecular Devices Corporation). Inhibition rate of the compounds at different concentrations was calculated, IC5 0 value was calculated by the Excelfit software and the results are shown in Table L

Table 1:

Test compound 5 -HTi receptor D 2 receptor 5-HT2A receptor agonism antagonism antagonism

(ECo mnoi/L) (IC50 , mol/L) (IC50 , mol/L) Compound of example 1 3.3 1E-09 5.69E-08 2.27E-07

Compound of example 2.86E-08 1.18E-08 2.64E-08

Compound of example 3 4.57E-09 2.61 E-09 1.51E-08

Compound of example 4 9.75E-09 543E-09 29E-09

Compound of example 4la 3.83E-08 6.89E-09 1.72E-09

Compound of example 4b 6.03E-08 2.IE-08 3.46E-09

Compound of example 5 3.29E-08 5.7E-08 4.4E-08

Compound of example 7 7.2E-09 3 .32E-09 1.02E-08

Compound of example 8 1.67E-09 8.83E-09 6.36E-09

Compound of example 9 9.72E-10 7.06E-09 9.56E-08

Compound of example 11 1.95E-09 1.02E-08 2.09E-07

Compound of example 15 1.05E-09 I.29E-08 7.46E-08

Compound of example 16 1 .2E-08 1.67E-08 7.72E-08

Compound of example 17 6.94E-09 2.07E-08 3.5- 07

Compound of example 18 1.07E-08 2.67E-08 7.13E-08

Compound of example 19 9.26E-10 8.62E-09 1.69E-07

Compound of example 23 4.63E-07 8.12E-08 9.76E-08

Compound of example 24 2.59E-08 5.07E-08 7.81E-07

Compound of example 25 8.24E-10 8.5 1E-08 7.79E-08

99 Compound of example 26 9.98E-09 4.82E-07 4.95E-08

Compound of example 27 1.91E-08 1.95E-08 4.91E-09

Compound of example 28 1.72E-08 351E-09 254E-08

Compound of example 29 2.13E-09 4.88E-08 7.64E-09

Compound of example 30 6.26E-10 3.42E-08 4.21E-08

Compound of example 31 6.8-10 9 27E-08 5 22E-08

Compound of example 33 2.24E-09 3.56E-08 2.44E-07

Compound of example 34 5.4E-08 3.24E-07 2.01E-07

Compound of example 35 4.19E-08 2.16E-07 2.15E-08

Compound of example 36 3.41E-08 7.54E-08 7.66E-09

Compound of example 37 3.1IE-09 5 19E-08 281E-08

Compound of example 38 1.OIE-09 6.98E-08 8.46E-09

Compound of example 41 8.99E-07 9.6E-07 6.54E-08

Compound of example 42 1E-07 27E-07 I1 5E-07

Compound of example 43 1.23E-09 2.4 1E-07 2.86E-07

Compound of example 52 9.69E-09 5.49E-09 1.22E-08

Compound of example 57 4.5 1E-09 8 4E-09 3 68E-07

Compound of example 58 4.55E-09 1.01E-07 2..17E-06

Compound of example 59 9.33E-09 2.67E-08 1.02E-08

Compound of example 64 3.16E-08 2.94E-09 2.57E-07 Compound of example 65 1 .25E-09 7.76E-09 4.03E-08

Compound of example 66 1.29E-09 6 17E-08 8 15E-08

Compound of example 68 1.55E-08 5.46E-09 4.82E-09

Compound of example 70 9.7E-09 7.97E-08 3.32E-07

Compound of example 72 2.53E-09 1 32E-08 9 51E-07

Compound of example 74 2.08E-08 1.06E-09 8.74E-07

Compound of example 77 4.80E-09 6.91E-09 1.57E-07

(ompound of example 78 5.99E-10 4 56E-08 3 28E-07

Compound of example 79 7.7E-10 3.87E-09 1.68E-08

Compound of example 80 1.74E-09 2.51E-08 1.19E-08

Compound of example 81 1.05E-09 1.43E-08 1.67E-09

Compound of example 82 2.8E-09 1.09E-08 1.15E-08

100 Compound of example 83 4.91E-09 1.04E-08 2.5E-08

Compound of example 84 2.35E-10 1.09E-08 1.75E-08

Compound of example 85 1.3,8E-09 5 32E-09 7 75E-08

Compound of example 86 2.16E-08 2.3 5E-08 9.33E-08

Compound of example 87 4.5E-09 9.24E-09 8.8E-08

Compound of example 88 6.3 1E-09 2 15E-07 3.56E-07

Compound of example 89 1I.29E-09 8.06E-09 1.05E-06

Compound of example 90 2.77E-08 1.04E-08 1.36E-08

Compound of example 97 2.23E-10 6.81E-09 1.73E07

Compound of example 98 2.9E-09 1.24E-08 1.85E-07

Compound of example 99 7.62E-08 104E-08 5 12E-09

Compound of example 101 1.68E-08 1.84E-09 7.59E-07

Compound of example 102 3.29E-09 1.06E-07 1.90E-06

Compound of example 104 1.23E-08 9 88E-08 106E-07

Compound of example 105 5.64E-09 4.4 1E-07 2.55E-08

Compound of example 106 1.04E-08 5.43E-07 6.62E-07

Compound of example 107 7.95E-09 8 43E-09 3.93E-07

Compound of example 108 4.49E-08 2.17E-08 8.19E-07

Compound of example 109 9.99E-08 2.43E-07 2E-07

Compound of example 110 8.4E-08 5.76E-08 1.76E-06 Compound of example 111 2.95E-08 2.39E-08 4E-07

Compound of example 112 3.46E-08 281E-08 2 57E-07

Compound of example 113 9.09E-09 6.iE-08 7.16E-07

Compound of example 114 8.08E-09 2.69E-08 4.61E-07

Compound of example 115 8.52E-09 2.931-08 5 37E-08

Compound of example 116 3.79E-10 5.97E-09 9.03E-09

Compound of example 117 3.97E-10 6.02E-09 1.59E-08

(ompound of example 118 6.02E- 10 1 19E-07 7.5-08

Compound of example 119 7.87E-10 4.69E-09 3.43E-08

Compound of example 120 7.61E-10 2.29E-07 7.33E-09

Compound of example 121 3.2E-08 2.16E-07 4.1E-08

Compound of example 124 1.42E-08 1.21-07 5.36E-07

101 Compound of example 131 2.60E-08 1.91E-07 5.13E-08

Compound of example 132 11 8E-08 1.14E-07 9.92E-07

Compound of example 133 1.02E-09 109E-08 5.54E-08

Compound of example 134 7.5E-10 3.79E-08 1.67E-08

Compound of example 137 1.81E-09 3.02E-08 7.11E-07

Compound of example 138 1 .02E-09 9.4E-09 4.18E-08

Compound of example 139 7.66E-10 7.96E-08 1.04E-07

Compound of example 144 8.93E-09 6.58E-08 1.7E-08

Compound of example 145 6.3E-09 1.92E-07 1.47E-08

Compound of example 150 1.57E-08 4.54E-09 1.08E-07

Compound of example 153 2.35E-09 38E-09 189E-08

Compound of example 154 1.32E-09 2.0 IE-09 1.61E-09

risperidone >1 .OE-04 1.33E-08 4.67E-09 aripiprazole 1.88E-06 279E-06

4) D2 receptor agonism activity test

The D2 receptor agonism activity test (The agonism activity of test impounds on D2 receptor expressing human recombinant D2 receptor in HEK293 cells) was performed using

LANCE TM cAMP 384 Kit (Product of USA PerkinElmer Inc.). The D2 agonism of test compounds was evaluated through their inhibition on cAMP production in REK293 cells. cAMP concentration test was performed according to the method documented in the kit instructions. The concentration of the test compound is 0.InN'-10000nM, dopamine was used as a positive control, EC50 value was calculated by the Excelfit software and the results are shown in Table 2 Table 2:

Test compound D2 receptor agonisn

. .(IComol/L) Compound of example 9 3.39E-09

Compound of example 11 2.06E-09

Compound of example 19 223E-09

Compound of example '22 2.16E-09

Compound of example 27 3.84E-10

102 Compound of example 57 4.8E-10

Compound of example 64 2.42E-10

Compound of example 65 9.2 1E- I1

Compound of example 72 6.72E-10

Compound of example 74 3.20E-10

Compound of example 77 2.19E-1 0

Compound of example 79 1.2E-09

Compound of example 83 7.4E-09

Compound of example 101 1.30E-09

Compound of example 131 I.53E-09

risperidone >1E-4

aripiprazole I.01E-08

5) in vivo efficacy test (PCP-induced high locomotor activity in mice)

PCP solution was prepared in a suitable concentration for 7mg/kg dosage with saline. Solutions of aripiprazole and all the test compounds in a suitable concentration were prepared with 0.5%

CMC-Na solution respectively. Male ICR mice (I 8-22g) were used as test animals. All the test mice were randomly divided into vehicle control group, model control group, positive control group, and treatment group(8 mice per group). Mice of each group were orally administered test compounds or vehicle. After 45 minutes PCP solution was administered (7mg/kg) through intraperitoneal injection. The mice track after drug or saline administration was recorded and analyzed by the spontaneous, open-field video analysis system. Then the mice track in 75 min after PCP administration was recorded. The mice track was recorded and analyzed by the spontaneous, open-field video analysis system. The total distance in each group was calculate and expressed as mean + SD and statistical evaluation was performed by one way ANOVA.

After PCP was administered, a significant increase in locomotor activity was observed compared with the saline group. The test compound can significantly reduce PCP-induced hyperactivity in mice at following doses (Table 3), and showed statistical significances compared with the model group.

Table 3:

Test ompound Effective dose (mg/kg)

103 Compound of example 3 0.03-0.1

Compound of example 4 0 1-3

Compound of example 5 0.1-0.3

Compound of example 7 0.1-0.3

Compound of example 8 0.1-0.3 Compound of example 15 0.1-1

Compound of example 19 0 1

Compound of example 27 0.3

Compound of example 29 0.3

Compound of example 30 0.3

Compound of example 31 1

Compound of example 33 1

Compound of example 46 1

Compound of example 47 0.3

Compound of example 49 1

Compound of example 50 1

Compound of example 51 0

Compound of example 57 1

Compound of example 59 0.3

Compound of example 64 1

Compound of example 65 3

Compound of example 8 0.3

Compound of example 71 3

Compound of example 72 3

Compound of example 74 3 Compound of example 77 3

Compound of example 78 3 Compound of example 79 3 Compound of example 80 1

Compound of example 81 1

Compound of example 82 1

Compound of example 83 1

104 Compound of example 85 1

Compound of example 87 1

Compound of example 88 1

Compound of example 89 1

Compound of example 102 3 Compound of example 112 1 Compound of example 124 3

Compound of example 131 3

Compound of example 133 1

Compound of example 137 3

Compound of example 4a 0.03

Compound of example 4b 0.03 aripiprazole 3

105 THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A heterocyclic compound represented by formula (I), a stereoisomer or a pharmaceutically acceptable salt thereof:

L®

N

-R 3

E R2 R1

B D S

5 wherein, A is C, and B and D are each independently C or N; = represents a single or double bond; E is CH, N or C; when E is CH or N, the bond connected to E represents a single

10 bond; and when E is C, the bond - - connected to E represents a double bond;

R1 is hydrogen or 1 to 4 substituents each independently selected from the group consisting of halogen, hydroxy, mercapto, oxo(=0), thioxo(=S), CI-C6 alkoxy, halogenated CI-C6 alkoxy, C1~C6 alkylthio, C1~C6 alkyl, halogenated C1~C6 alkyl, nitro, amino, C1-C6 alkyl-substituted amino, cyano, carboxyl, aldehyde group, amino CI-C6 alkyl, 15 hydroxyl C1~C6 alkyl, cyano C1-C6 alkyl, CI-C6 alkanoyl, halogenated C1~C6 alkanoyl,

sulfonic group (-SO 2OH), aminosulfonyl (-SO 2 NH 2 ), carbamoyl (-CONH 2), C1-C6 alkyl substituted carbamoyl, carboxyl C1-C6 alkyl, C1-C6 alkylsulfonyl, halogenated C1~C6 alkylsulfonyl, C1-C6 alkyl-substituted amino C1-C6 alkyl, carbamoyl C1~C6 alkyl and C1-C6 alkyl-substituted carbamoyl C1-C6 alkyl;

20 R2 does not exist, or is 1 to 3 substituents each independently selected from the group consisting of halogen, hydroxy, mercapto, C1-C6 alkoxy, halogenated C1-C6 alkoxy, C1~C6 alkylthio, C1-C6 alkyl, halogenated C1-C6 alkyl, nitro, amino, C1-C6 alkyl-substituted amino, cyano, carboxyl, aldehyde group, amino C1~C6 alkyl, hydroxyl C1-C6 alkyl, cyano

C1-C6 alkyl, C1-C6 alkanoyl, halogenated C1-C6 alkanoyl, sulfonic group (-SO 2OH),

25 aminosulfonyl (-SO 2NH), carbamoyl (-CONH 2 ), Cl-C6 alkyl-substituted carbamoyl, carboxy C1-C6 alkyl, C1-C6 alkylsulfonyl, halogenated C1~C6 alkylsulfonyl, C1-C6 alkyl substituted amino C1-C6 alkyl, carbamoyl C1-C6 alkyl and C1-C6 alkyl-substituted

106 carbamoyl C1~C6 alkyl;

R3 is hydrogen or 1 to 4 substituents each independently selected from the group consisting of hydroxyl and C1~C6 alkyl; L does not exist or is Cl~C5 alkylene, and when L is C1~C5 alkylene, the alkylene is 5 optionally substituted with one or more substituents selected from the group consisting of hydroxy, C1~C6 alkoxy and oxo (=0); ring G is a heteromonocyclic or heterobicyclic group, wherein said heterobicyclic group is a phenyl-fused heteromonocyclic group, a cyclohydrocarbyl-fused heteromonocyclic group or a heteromonocycle-fused heteromonocyclic group, wherein said heteromonocyclic group 10 contains at least one heteroatom selected from the group consisting of N, S and 0; ring G is connected to L through a carbon atom on ring G; and ring G is optionally substituted with one or more substituents which are identical or different; the substituent on the ring G is selected from the group consisting of halogen, C1~C6 15 alkyl, halogenated C1-C6 alkyl, C1~C6 alkoxy, halogenated C1-C6 alkoxy, nitro, cyano, hydroxy, mercapto, amino, Cl~C6 alkyl-substituted amino, azido, Cl~C6 alkanoyl, halogenated C1-C6 alkanoyl, C2~C6 alkenyl, C2~C6 alkynyl, carboxy C1~C6 alkyl, cyano

C1-C6 alkyl, C2~C6 alkenyloxy, C2~C6 alkynyloxy, carbamoyl (-CONH2), Cl~C6 alkyl substituted carbamoyl, carboxyl, hydroxyl C1-C6 alkyl, oxo (=0), thioxo (=S),

20 aminosulfonyl (-SO 2NH 2), C1-C6 alkylthio, Cl~C6 alkylsulfonyl, halogenated C1~C6

alkylsulfonyl, sulfonic group (-SO 2OH), aldehyde group, amino C1~C6 alkyl, C1-C6 alkyl substituted amino Cl~C6 alkyl, carbamoyl C1-C6 alkyl, C1-C6 alkyl-substituted carbamoyl C1~C6 alkyl, C3-C10 cyclohydrocarbyl, C3~C10 cyclohydrocarbyl C1-C6 alkyl, C3-C10 cyclohydrocarbylformamido, furyl, thienyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, 25 triazolyl, triazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, pyranyl, pyrazinyl, piperazinyl, pyridazinyl, pyridyl, piperidinyl, pyrimidinyl, imidazolyl, C3C1O cyclohydrocarbyl C1~C6 alkoxy, furyl Cl-C6 alkyl, furanyl Cl~C6 alkoxy, thienyl C1-C6 alkyl, thienyl C1~C6 alkoxy, pyrrolyl C1~C6 alkyl, pyrrolyl C1~C6 alkoxy, pyrrolidinyl C1-C6 alkyl, pyrrolidinyl C1~C6 alkoxy, pyrazolyl 30 C1~C6 alkyl, pyrazolyl C1~C6 alkoxy, triazolyl C1~C6 alkyl, triazolyl C1~C6 alkoxy, thiazolyl C1~C6 alkyl, thiazolyl C1-C6 alkoxy, isothiazolyl C1~C6 alkyl, isothiazolyl Cl~C6 alkoxy, oxazolyl C1~C6 alkyl, oxazolyl C1~C6 alkoxy, isoxazolyl C1~C6 alkyl, isoxazolyl C1~C6 alkoxy, pyrazinyl CI-C6 alkyl, pyrazinyl C1~C6 alkoxy, pyridazinyl C1~C6 alkyl, pyridazinyl C1~C6 alkoxy, pyridyl C1~C6 alkyl, pyridyl C1-C6 alkoxy, pyrimidinyl C1-C6 35 alkyl, pyrimidinyl C1-C6 alkoxy, phenyl, phenoxy, phenylsulfonyl, phenyl C1~ C6 alkyl,

107 phenyl C1~C6 alkoxy, phenyl C1~C6 alkanoyl, and phenyl C1-C6 alkanoyloxy; said C3~C10 cyclohydrocarbyl, C3-C1O cyclohydrocarbyl C1~C6 alkyl, furyl, thienyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, triazolyl, triazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, pyranyl, 5 pyrazinyl, piperazinyl, pyridazinyl, pyridyl, piperidinyl, pyrimidinyl, imidazolyl, C3~C10 cyclohydrocarbyl C1-C6 alkoxy, furyl C1-C6 alkyl, furanyl C1~C6 alkoxy, thienyl C1-C6 alkyl, thienyl C1~C6 alkoxy, pyrrolyl C1~C6 alkyl, pyrrolyl C1~C6 alkoxy, pyrrolidinyl CI-C6 alkyl, pyrrolidinyl C1-C6 alkoxy, pyrazolyl C1-C6 alkyl, pyrazolyl C1~C6 alkoxy, triazolyl C1~C6 alkyl, triazolyl C1-C6 alkoxy, thiazolyl Cl~C6 alkyl, thiazolyl C1~C6 10 alkoxy, isothiazolyl C1-C6 alkyl, isothiazolyl C1-C6 alkoxy, oxazolyl Cl-C6 alkyl, oxazolyl C1~C6 alkoxy, isoxazolyl C1~C6 alkyl, isoxazolyl C1~C6 alkoxy, pyrazinyl C1~C6 alkyl, pyrazinyl C1~C6 alkoxy, pyridazinyl C1~C6 alkyl, pyridazinyl C1-C6 alkoxy, pyridyl C1~C6 alkyl, pyridyl C1~C6 alkoxy, pyrimidinyl C1~C6 alkyl, pyrimidinyl C1~C6 alkoxy, phenyl, phenoxy, phenylsulfonyl, phenyl C1~C6 alkyl, phenyl C1~C6 alkoxy, phenyl C1~C6 alkanoyl 15 and phenyl C1~C6 alkanoyloxy are optionally substituted with one or more substituents selected from the group consisting of halogen, C1~C6 alkyl, halogenated C1~C6 alkyl, C1~C6 alkoxy, C1-C6 alkoxycarbonyl, halogenated C1--C6 alkoxy, nitro, cyano, hydroxy, amino, C1-C6 alkanoyl, halogenated C1-C6 alkanoyl, carbamoyl, and carboxyl; provided that the following compounds are excluded: 20 1) 1-(2-(4-(2-cyano-7-fluorobenzo[b]thiophen-4-yl)-2-methylpiperazin-1-yl)ethyl)iso chroman-6-carboxamide; and 2) 1-(2-(4-(7-fluorobenzo[b]thiophen-4-yl)-2-methylpiperazin-1-yl)ethyl)isochroman-6 carboxamide.

25 2. The heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof according to claim 1, wherein, ring G is a 3 to 10-membered heteromonocyclic group, a phenyl-fused 3 to 10-membered heteromonocyclic group, a C3C 10 cyclohydrocarbyl-fused 3 to 10-membered heteromonocyclic group or 3 to 10-membered heteromonocycle-fused 3 to 10-membered heteromonocyclic group. 30 3. The heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof according to claim 2, wherein ring G is a 5 to 7-membered heteromonocyclic group, a phenyl fused 5 to 7-membered heteromonocyclic group, a C5-C7 cyclohydrocarbyl-fused 5 to 7 membered heteromonocyclic group or a 5 to 7-membered heteromonocycle-fused 5 to 7 35 membered heteromonocyclic group.

108 4. The heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof according to claim 3, wherein, ring G is a heterocyclic group selected from the group consisting of furyl, dihydrofuranyl, tetrahydrofuranyl, thienyl, dihydrothienyl, 5 tetrahydrothienyl, pyrrolyl, dihydro-pyrrolyl, pyrrolidinyl, pyrazolyl, dihydro-pyrazolyl, pyrazolyl, pyrazolidinyl, triazolyl, dihydrotriazole, triazolidinyl, thiazolyl, dihydro-thiazolyl, thiazolidinyl, isothiazolyl, dihydro-isothiazolyl, isothiazolidinyl, oxazolyl, dihydro-oxazolyl, oxazolidinyl, isoxazolyl, dihydro-isoxazolyl, isoxazolidinyl, pyranyl, dihydro-pyranyl, tetrahydropyranyl, pyrazinyl, dihydro-pyrazinyl, tetrahydro-pyrazinyl, piperazinyl,

10 pyridazinyl, dihydro-pyridazinyl, tetrahydro-pyridazinyl, N H H N H

N N HN H N N N H N N H N N H H

H HN:* K0 KS, rCN N N C N HN N HN HN HN HN

H H H H

N- _0 HN-0 0 N-0 0 H H H HNOHHNo HN ONN> K-NKHN- , > KN > II - N:N N (\ ) (~ (NN

H HO N N 0 O NH O N 0zN O N O N O"' NH N HNH)( N H H N N K H H

O NH HN HN N N 15 H H H H H H H

N NNN

N N(NN N )nNNH N' H H H N H H ( N H

,N ['N,- NH - NH r- -N N/

O -N> N NH H NC Nn 0:0 COO

109 H " ' ' N " ' ' N N ~ N j -,N \> > N crH H N H

N "' NH ri N H N N NHN N NH H C S IS S ~s H H N N N N N N N N r NH S >\N " NH

HH N

NN NN

NH _N N 5 H N

N[::C [[)N N N 0 / 0

N N--N) N

H H NNH H

H H N N

NH ~ N--N I N N N) N)N- N N H H H NH H H N N NH H N NH N NNN Nk. N N-j-KII~~~ H NNH00 H H N> N N NNN

0 0 SSS H H

H N~ r" NH NN

N NN 0)N~ N N/0 NO> -N' '-S) H N0N _N H H

N NN jN N ~ N N

Nl: N NNNH Z NH -N , NH

110 N HNN N N NH

I NHN

H H N

N N N N H H N H

N :H HN O H N HNO N '

H H .S ( \NC--\ NN (::N N~ KN

5 1 N N N s s s sss, N N /> N / / ::/ / :IN N NN, HH H

NN N- ' N

N- NH s N s NS HH H H N N

SN N N N N N 10 N NHK HN N -N N

N N r NHN-D N NN -N \ N\ S N N N N( NH NH N N N H ' -N'

N N \N N - N H H

NJ1 [-Ns

N - N ~ N N' N< N N~

NH5rN N H

H N N N/ N n , N N NH NH N NH NH NH NH

N N N N N N N N N N N 'HN N .M H H H'NHH H H H N' , N N N ',, N -j NH N NJI HN N H N N N N N N N N H H H H H H

H NH / H N]N N HNN!N N N N H

S H H S N N HNO - HN /Q N})HN§ D NH HN/ C N 5 S SN H S SN

H H

HN )H CN N 0 and N

5. The heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof according to any one of claims 1 to 4, wherein,

10 R1 is hydrogen or 1 to 4 substituents each independently selected from the group consisting of halogen, hydroxy, mercapto, oxo (=0), thioxo (=S), CI~C4 alkoxy, halogenated C1-C4 alkoxy, C1~C4 alkylthio, C1~C4 alkyl, halogenated Cl~C4 alkyl, nitro, amino, C1-C4 alkyl-substituted amino, cyano, carboxyl, aldehyde group, amino C1-C4 alkyl, hydroxyl C1-C4 alkyl, cyano C1-C4 alkyl, C1~C4 alkanoyl, halogenated C1-C4 alkanoyl,

15 sulfonic group (-SO 2OH), aminosulfonyl (-SO 2NH2 ), carbamoyl (-CONH2), C1-C4 alkyl substituted carbamoyl, carboxyl C1-C4 alkyl, C1-C4 alkylsulfonyl, halogenated C1-C4 alkylsulfonyl, C1-C4 alkyl-substituted amino C1~C4 alkyl, carbamoyl C1~C4 alkyl, and C-C4 alkyl-substituted carbamoyl C1-C4 alkyl;

R2 does not exist, or is I to 3 substituents each independently selected from the group 20 consisting of halogen, hydroxy, mercapto, C1~C4 alkoxy, halogenated C1~C4 alkoxy, C1-C4 alkylthio, C1~C4 alkyl, halogenated Cl~C4 alkyl, nitro, amino, C1~C4 alkyl-substituted amino, cyano, carboxyl, aldehyde group, hydroxyl C1-C4 alkyl, cyano C1-C4 alkyl, C1~C4

alkanoyl, halogenated C1~C4 alkanoyl, sulfonic group (-SO 2OH), aminosulfonyl (-S02NH2),

carbamoyl (-CONH 2), C1-C4 alkyl-substituted carbamoyl, carboxy C--C4 alkyl, C1~C4

112 alkylsulfonyl, halogenated C1-C4 alkylsulfonyl, amino C1~C4 alkyl, Cl-C4 alkyl-substituted amino C1-C4 alkyl, carbamoyl C1-C4 alkyl, and C1~C4 alkyl-substituted carbamoyl C1~C4 alkyl;

R3 is hydrogen or I to 4 substituents each independently selected from the group 5 consisting of hydroxyl and C1-C4 alkyl; L does not exist or is C1~C4 alkylene, and when L is C1-C4 alkylene, the alkylene is optionally substituted with one or more substituents selected from the group consisting of hydroxy, Cl-C6 alkoxy and oxo (=0); ring G is connected to L through a carbon atom on ring G; and ring G is optionally 10 substituted with one or more substituents which are identical or different; the substituent on the ring G is selected from the group consisting of halogen, C1-C4 alkyl, halogenated C1~C4 alkyl, C1-C4 alkoxy, halogenated CI-C4 alkoxy, nitro, cyano, hydroxy, mercapto, amino, C1-C4 alkyl-substituted amino, azido, C1~C4 alkanoyl, halogenated C1~C4 alkanoyl, C2~C4 alkenyl, C2~C4 alkynyl, carboxyl C1~C4 alkyl, cyano

15 C1~C4 alkyl, C2~C4 alkenyloxy, C2-C4 alkynyloxy, carbamoyl (-CONH 2), C1~C4 alkyl substituted carbamoyl, carboxyl, hydroxyl C1~C4 alkyl, oxo (=0), thioxo (=S),

aminosulfonyl (-SO2 NH 2), C1~C4 alkylthio, C1-C4 alkylsulfonyl, halogenated CI~C4

alkylsulfonyl, sulfonic group (-SO 2 OH), aldehyde group, amino Cl~C4 alkyl, Cl~C4 alkyl substituted amino C1-C4 alkyl, carbamoyl C1-C4 alkyl, C1-C4 alkyl-substituted carbamoyl 20 C1~C4 alkyl, C3~C7 cyclohydrocarbyl, C3-C7 cyclohydrocarbyl Cl~C4 alkyl, C3-C7 cyclohydrocarbyl formamido, furyl, thienyl, pyrrolyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl, triazolyl, triazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl, isothiazolidinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, pyranyl, pyrazinyl, piperazinyl, pyridazinyl, pyridyl, piperidinyl, pyrimidinyl, imidazolyl, C3-C7 cyclohydrocarbyl C1-C4 alkoxy, furyl C1~C4 25 alkyl, furanyl C1~C4 alkoxy, thienyl C1~C4 alkyl, thienyl C1-C4 alkoxy, pyrrolyl CIC4 alkyl, pyrrolyl C1~C4 alkoxy, pyrrolidinyl C1~C4 alkyl, pyrrolidinyl C1-C4 alkoxy, pyrazolyl C1~C4 alkyl, pyrazolyl C1~C4 alkoxy, triazolyl C1~C4 alkyl, triazolyl C1-C4 alkoxy, thiazolyl C1-C4 alkyl, thiazolyl C1-C4 alkoxy, isothiazolyl C1-C4 alkyl, isothiazolyl C1~C4 alkoxy, oxazolyl CI-C4 alkyl, oxazolyl C1~C4 alkoxy, isoxazolyl C1-C4 alkyl, isoxazolyl 30 C1~C4 alkoxy, pyrazinyl Cl~C4 alkyl, pyrazinyl C1~C4 alkoxy, pyridazinyl Cl~C4 alkyl, pyridazinyl C1~C4 alkoxy, pyridyl C1~C4 alkyl, pyridyl Cl~C4 alkoxy, pyrimidinyl ClC4 alkyl, pyrimidinyl C1~C4 alkoxy, phenyl, phenoxy, phenylsulfonyl, phenyl C1~C4 alkyl, phenyl C1-C4 alkoxy, phenyl C1-C4 alkanoyl, and phenyl C1-C4 alkanoyloxy; said C3-C7 cyclohydrocarbyl, C3-C7 cyclohydrocarbyl C1~C4 alkyl, furyl, thienyl, pyrrolyl, pyrrolidinyl, 35 pyrazolyl, pyrazolidinyl, triazolyl, triazolidinyl, thiazolyl, thiazolidinyl, isothiazolyl,

113 isothiazolidinyl, oxazolyl, oxazolidinyl, isoxazolyl, isoxazolidinyl, pyranyl, pyrazinyl, piperazinyl, pyridazinyl, pyridyl, piperidinyl, pyrimidinyl, imidazolyl, C3-C7 cyclohydrocarbyl C1-C4 alkoxy, furyl C1~C4 alkyl, furanyl C1-C4 alkoxy, thienyl C1~C4 alkyl, thienyl C1-C4 alkoxy, pyrrolyl Cl~C4 alkyl, pyrrolyl Cl~C4 alkoxy, pyrrolidinyl 5 CI~C4 alkyl, pyrrolidinyl C1~C4 alkoxy, pyrazolyl C1-C4 alkyl, pyrazolyl C1~C4 alkoxy, triazolyl C1-C4 alkyl, triazolyl C1-C4 alkoxy, thiazolyl Cl~C4 alkyl, thiazolyl C1-C4 alkoxy, isothiazolyl C1-C4 alkyl, isothiazolyl C1-C4 alkoxy, oxazolyl CI~C4 alkyl, oxazolyl C1IC4 alkoxy, isoxazolyl C1~C4 alkyl, isoxazolyl C1-C4 alkoxy, pyrazinyl C1~C4 alkyl, pyrazinyl C 1-C4 alkoxy, pyridazinyl C1 ~C4 alkyl, pyridazinyl C1 ~C4 alkoxy, pyridyl Cl ~C4 10 alkyl, pyridyl C1~C4 alkoxy, pyrimidinyl C1-C4 alkyl, pyrimidinyl C1~C4 alkoxy, phenyl, phenoxy, phenylsulfonyl, phenyl C1 ~C4 alkyl, phenyl C 1 -C4 alkoxy, phenyl C1 ~C4 alkanoyl and phenyl C1~C4 alkanoyloxy are optionally substituted with one or more substituents selected from the group consisting of halogen, C1~C4 alkyl, halogenated C1~C4 alkyl, C1-C4 alkoxy, C1~C4 alkoxycarbonyl, halogenated C1-C4 alkoxy, nitro, cyano, hydroxy, 15 amino, C1~-C4 alkanoyl, halogenated C1-C4 alkanoyl, carbamoyl, and carboxyl.

6. The heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof

according to claim 5, wherein, R1 is hydrogen or 1 to 4 substituents each independently selected from the group consisting of fluorine, chlorine, bromine, hydroxy, mercapto, oxo

20 (=0), thioxo (=S), methoxy, ethoxy, trifluoromethoxy, -SCH 3, -SCH 2CH 3, methyl, ethyl, propyl, isopropyl, t-butyl, trifluoromethyl, bromomethyl, chloromethyl, nitro, amino, N methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino, cyano, carboxyl,

aldehyde group, -CH 2 NH2 , -CH 2 CH2 NH 2, -CH2OH, -CH 2CH2OH, -CH 2 CN, -CH 2CH 2CN,

formyl, acetyl, propionyl, trifluoroacetyl, sulfonic group (-SO 2OH), aminosulfonyl (

25 SO2NH 2 ), carbamoyl, N-methylcarbamoyl, N,N-dimethylcarbamoyl, N-ethylcarbamoyl, N,N

diethylcarbamovl, -CH2C0 2H, -CH 2CH2CO2H, -SO 2 CH 3, -SO2 CF 3 , -CH 2NHMe, -CH 2NMe2,

CH 2CONH2, -CH 2 CONHMe and -CH 2CONMe 2;

R2 does not exist, or is I to 3 substituents each independently selected from the group consisting of fluorine, chlorine, bromine, hydroxy, mercapto, methoxy, ethoxy,

30 trifluoromethoxy, -SCH 3, -SCH 2CH 3, methyl, ethyl, propyl, isopropyl, t-butyl, trifluoromethyl, bromomethyl, chloromethyl, nitro, amino, N-methylamino, N-ethylamino, N,N

dimethylamino, N,N-diethylamino, cyano, carboxyl, aldehyde group, -CH 2 OH, -CH 2 CH2 OH,

CH 2CN, -CH 2 CH 2CN, formyl, acetyl, propionyl, trifluoroacetyl, sulfonic group (-SO 2 OH),

aminosulfonyl (-S O2NH2), carbamoyl, N-methylcarbamoyl, NN-dimethylcarbamoyl, N

35 ethylcarbamoyl, N,N-diethylcarbamoyl, -CH 2CO 2H, -CH 2CH 2CO2 H, -SO 2 CH3, -SO 2 CF3,

114 CH 2NH2 , -CH 2 CH2 NH 2, -CH 2NHMe, -CH2NMe2 , -CH 2 CONH2, -CH 2CONHMe and

CH 2 CONMe2 ;

R3 is hydrogen or 1-4 substituents each independently selected from the group consisting of hydroxy, methyl and ethyl; 5 the substituent on the ring G is selected from the group consisting of fluorine, chlorine, bromine, methyl, ethyl, propyl, isopropyl, t-butyl, trifluoromethyl, methoxy, ethoxy, trifluoromethoxy, nitro, cyano, hydroxy, mercapto, amino, N-methylamino, N-ethylamino, N,N-dimethylamino, N,N-diethylamino, azido, formyl, acetyl, propionyl, trifluoroacetyl,

CH 2 CO2H, -CH 2CH 2 CO2 H, -CH 2 CN, -CH2CH2CN, carbamoyl, N-methylcarbamoyl, N,N 10 dimethylcarbamoyl, N-ethylcarbamoyl, N,N-diethylcarbamoyl, carboxyl, -CH-OH,

CH 2 CH20H, oxo (=0), thio (=S), aminosulfonyl (-SO 2 NH 2), -SCH3, -SCH 2 CH 3, -SO 2CH3,

SO 2 CF 3, sulfonic group(-SO 2OH), aldehyde group, -CH 2NH 2, -CH 2CH2NH2, -CH2NHMe,

CH 2NMe, -CH 2NHEt, -CH 2NEtz, -CH 2 CH2)NHMe, -CH 2CH 2NHEt, -CH2CH 2NMe 2,

CH 2 CH 2 NEt 2 , -CH 2 CONH 2 , -CH 2 CONHMe, -CH 2 CONMe 2, -CH 2CONHEt, -CH 2 CONEt2,

15 CH 2CH2CONH2, -CH 2CH 2CONHMe, -CH 2CH 2 CONMe 2, -CH2CH 2CONHEt,

CH 2CH 2 CONEt2, phenyl, phenoxy, phenylsulfonyl, -CHPh, -CH 2CH 2Ph, -OCH 2 Ph,

OCH 2CH 2Ph, -COPh, -COCH2Ph and -CH 2 Ph(OMe) 2.

7. The heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof 20 according to any one of claims I to 6, wherein,

A

D S is:

S S , N S N S N S ,or N5 / S

8. The heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof

A

25 according to claim 7, wherein D S is6 ) .

9. The heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof according to any one of claims I to 6, wherein the compound of the formula (1) is selected

115 from the group consisting of:

N R3N NR3 R3 N N

R-R2- R2 R2

(1-a) (1-b) (1-c) (1-d)

L-- L L L

(N -3N -3N -3N-R

N N

- R N R2 2S-1R 2N R2

( I-e )(If(Ig) (1-h ) N N N N

N -R R3 -R3 N N>

I I R2 - R2- R2 NR2 N S N S N S N S N S

( i) (I-j) (1-k)

116 KL-(® KL O KL-® L N N N N

-R 3 -R 3 -R 3 R3

R1 R1 R1 R1

R2 R2 R2- R2 s S NS NS (1-n) (1-0) (1-p) (1-q) NN N

R3 R3

R1 R1

R2 R2 N S N S (1-r) and (I-s)

wherein, R1, R2, R3, L and ring G are defined the same as those in the corresponding claim. 5 10. The heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof according to claim 9, wherein the compound of general formula (1) is selected from:

-R3 Ci-R3 N N

S S F (1-t ) and (1-u)

wherein, RI, R2 , R3, L and ring G are defined the same as those in the corresponding 10 claim.

117 11. The heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof according to any one of claims I to 10 selected from the group consisting of: (1) 6-chloro-5-(2-(4-(2,3-dihydrobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)indolin-2-one; (2) 3-(2-(4-(2,3-dihydrobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-9-hydroxy-2-methyl 5 6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one; (3) 3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-2-methyl-6,7,8,9 tetrahydropyrido[1,2-a]pyrimidin-4-one; (4) 3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9 tetrahydropyrido[1,2-a]pyrimidin-4-one; 10 (4a)(+)-3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9 tetrahydropyrido[1,2-a]pyrimidin-4-one; (4b)(-)-3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9 tetrahydropyrido[1,2-a]pyrimidin-4-one; (5) 3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-2-methyl-7,8-dihydro-6H 15 pyrido [1,2-a]pyrimidine-4,9-dione; (6) 3 -(2-(4-(benzo [b]thiophen-4-yl)piperazin- 1-yl)ethyl)-9-hydroxy-2,9-dimethyl-6,7,8,9 tetrahydropyrido [1,2-a]pyrimidin-4-one; (7) 3 -(2-(4-(benzo [b]thiophen-4-yl)piperazin- 1-yl)ethyl)-9-fluoro-2-methyl-6,7,8,9 tetrahydropyrido [ 1,2-a]pyrimidin-4-one; 20 (8) 5 -(2-(4-(benzo [b]thiophen-4-yl)piperazin- 1-yl)ethyl)indolin-2-one; (9) 7-(2-(4-(benzo [b]thiophen-4-yl)piperazin- 1-yl)ethyl)quinolin-2(1 H)-one; (10) 7-(5 -(4-(benzo [b]thiophen-4-yl)piperazin- I -yl)pentyl)-3,4-dihydroquinolin-2(1 H)-one; (11) 7-(5-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)pentyl)quinolin-2(1 H)-one; (12) 7-(5-(4-(2-chlorobenzo[b]thiophen-4-yl)piperazin- 1-yl)pentyl)quinolin-2(1 H)-one; 25 (13) 7-(5 -(4-(2-fluorobenzo [b]thiophen-4-yl)piperazin- I -yl)pentyl)quinolin-2(1 H)-one; (14) 7-(5 -(4-(benzo [b]thiophen-4-yl)-5,6-dihydropyridin- 1(2H)-yl)pentyl)quinolin-2(1 H) one; (15) 5-(2-(4-(benzo [b]thiophen-4-yl)piperazin- 1-yl)ethyl)-6-chloroindolin-2-one; (16) 3 -(2-(4-(benzo [b]thiophen-4-yl)piperazin- I -yl)ethyl)-2-methyl-6,7-dihydropyrido [1,2 30 a]pyrimidin-4-one; (17) 3 -(2-(4-(benzo [b]thiophen-4-yl)piperazin- 1-yl)ethyl)-9-(benzyloxy)-2-methyl-4H pyrido[1,2-a]pyrimidin-4-one; (18) 3 -(2-(4-(benzo [b]thiophen-4-yl)piperazin- I -yl)ethyl)-9-hydroxy-2-methyl-4H pyrido[1,2-a]pyrimidin-4-one; 35 (19) 7-(2-(4-(benzo [b]thiophen-4-yl)piperazin- 1-yl)ethyl)-3,4-dihydroquinolin-2(1 H)-one;

118 (22) 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)butyl)-3,4-dihydroquinolin-2(1H)-one; (23) 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)-6-chloro-3,4-dihydroquinolin 2(1H)-one; (24) 6-(5-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)pentyl)-2-methylquinazolin-4(3 H)-one; 5 (25) 7-(2-(4-(2,3-dihydrobenzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)quinolin-2(1 H)-one; (26) 5-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)-4-methylthiazole; (27) 5-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-1H-benzo[d]imidazol-2(3H)-one; (28) 3-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-9,9-difluoro-2-methyl-6,7,8,9 tetrahydropyrido[ 1,2-a]pyrimidin-4-one; 10 (29) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)benzo[d]thiazol-2(3H)-one; (30) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)-2H-benzo[b] [1,4]oxazin-3(4H) one; (31) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-2H-benzo[b] [1,4]thiazin-3(4H) one; 15 (33) 7-(4-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)butyl)quinolin-2(1H)-one; (34) 6-(5-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)pentyl)quinazolin-4(3H)-one; (35) 2-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)quinazolin-4(3H)-one; (36) 3-(2-(4-(benzo[b]thiophen-4-yl)piperidin- 1-yl)ethyl)-9-hydroxy-2-methyl-6,7,8,9 tetrahydropyrido[1,2-a]pyrimidin-4-one; 20 (37) 5-(2-(4-(benzo[b]thiophen-4-yl)piperidin- 1-yl)ethyl)-6-chloroindolin-2-one; (38) 4-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)indolin-2-one; (39) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)indolin-2-one; (40) 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)-6-chloroquinolin-2(IH)-one; (41) 9-hydroxy-2-methyl-3-(2-(4-(thieno[2,3 -c]pyrid-4-yl)piperazin- -yl)ethyl)-6,7,8,9 25 tetrahydropyrido[1,2-a]pyrimidin-4-one; (42) 6-chloro-5-(2-(4-(thieno[2,3-c]pyridin-4-yl)piperazin- 1-yl)ethyl)indolin-2-one; (43) 7-(2-(4-(thieno[2,3-c]pyrid-4-yl)piperazin- 1-yl)ethyl)quinolin-2(1 H)-one; (44) 7-(3-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)propyl)quinolin-2(1H)-one; (45) 7-(3-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)propyl)-3,4-dihydroquinolin-2(1)-one; 30 (46) 3-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-1H-indole; (47) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-3,4-dihydroquinolin-2(1H)-one; (48) 5-(3-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)propyl)indolin-2-one; (49) 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)-4,5-dihydro- 1H-benzo[b]azepin 2(3H)-one; 35 (50) 3 -(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-2-methyl-4H-pyrido[1,2

119 a]pyrimidin-4-one; (51) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)-3-methyl-3,4-dihydroquinazolin 2(1H)-one; (52) 3 -(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-9-chloro-2-methyl-6,7,8,9 5 tetrahydropyrido[ 1,2-a]pyrimidin-4-one; (53) 5-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)indoline-2-thione; (54) 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)quinoline-2(1 H)-thione; (55) 2-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-5,6-diethylpyrimidin-4(3H)-one; (56) 2-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)pyrimidin-4(3H)-one; 10 (57) 7-(2-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)quinolin-2(1 H)-one; (58) 2-((4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)methyl)- 1H-benzo[d]imidazole; (59) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)benzo[d]thiazole; (60) 7-(2-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)benzo[d]thiazol-2-amine; (61) N-(7-(2-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)benzo[d]thiazol-2 15 yl)acetamide; (62) 5-(2-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)benzo[d]thiazol-2-amine; (63) N-(5-(2-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)benzo[d]thiazol-2 yl)acetanide; (64) 7-(2-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)-3,4-dihydroquinolin 20 2(1H)-one; (65) 6-(2-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-3,4-dihydroquinolin 2(IH)-one; (66) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)-7-fluoro-2H benzo[b] [1,4] oxazin-3 (4H)-one; 25 (67) 7-(2-(4-(3 -methylbenzo [b]thiophen-4-yl)piperazin- 1-yl)ethyl)-3,4-dihydroquinolin 2(IH)-one; (68) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)benzo[d] oxazol-2(3H)-one; (69) 4-((4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)methyl)quinolin-2(1 H)-one; (70) 3 -(4-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)butyl)- 1H-indole-5-carbonitrile; 30 (71) 7-(5-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin- I -yl)pentyl)quinolin-2(1 H)-one; (72) 6-(4-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)butyl)-8-fluoro-2H benzo[b] [1,4] oxazin-3 (4H)-one; (73) 1-(benzo[b]thiophen-4-yl)-4-((2,3 -dihydrobenzo[b] [1,4]dioxin-2-yl)methyl)piperazine; (74) 6-(4-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin- I -yl)butyl)-3,4-dihydroquinolin 35 2(IH)-one;

120 (75) 2-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)- I H-benzo[d] imidazole; (76) N-(6-(2-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)benzo[d]thiazol-2 yl)acetamide; (77) 5-(2-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)- 1H-benzo[d] imidazol 5 2(3H)-one; (78) 6-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-2H-benzo[b] [1,4]oxazin 3(4H)-one; (79) 5-(2-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)indolin-2-one; (80) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)-2-methylquinazolin-4(3H)-one; 10 (81) 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)- 1,1 -dioxo-3,4-dihydro-2H benzo[e] [1,2]thiazine; (82) 5-(2-(4-(benzo[b]thiophen-4-yl)piperidin- 1-yl)ethyl)indolin-2-one; (83) 7-(2-(4-(benzo[b]thiophen-4-yl)piperidin- I -yl)ethyl)-3,4-dihydroquinolin-2(1H)-one; (84) 5-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)indolin-2-one; 15 (85) 7-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-3,4-dihydroquinolin 2(1H)-one; (86) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)- 1-methyl-i H-benzo[d]imidazol 2(3H)-one; (87) 5-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-1,3-dimethyl- 1H 20 benzo[d]imidazol-2(3H)-one; (88) 5-(2-(4-(benzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-1-methyl-I H-benzo[d]imidazol 2(3H)-one; (89) 6-(2-(4-(2-methoxybenzo[b]thiophen-4-yl)piperazin- 1-yl)ethyl)-3,4-dihydroquinolin 2(1H)-one; 25 (90) 3-(2-(4-(6-fluorobenzo[b]thiophen-4-yl)piperazin- I -yl)ethyl)-2-methyl-6,7,8,9 tetrahydro-4H-pyrido [1,2-a]pyrimidin-4-one; (91) 7-(2-(4-(2-oxo-2,3 -dihydrobenzo [b]thiophen-4-yl)piperazin- 1-yl )ethyl)-3,4 dihydroquinolin-2(1 H)-one; (92) 6-(2-(4-(2-fluorobenzo [b]thiophen-4-yl)piperazin- I -yl)ethyl)-2H-benzo [b] [1,4] oxazin 30 3(4H)-one; (93) 5 -(2-(4-(2-fluorobenzo [b]thiophen-4-yl)piperazin- 1-yl)ethyl)- 1,3 -dimethyl- 1H benzo[d]imidazol-2(3H)-one; (94) 6-fluoro-5-(2-(4-(2-fluorobenzo [b]thiophen-4-yl)piperazin- 1-yl)ethyl)indolin-2-one; (95) 5 -(2-(4-(benzo [b]thiophen-4-yl)piperazin- 1-yl)ethyl)-6-fluoroindolin-2-one; 35 (96) 7-(2-(4-(benzo [b]thiophen-4-yl)piperazin- 1-yl)ethyl)- 1-benzyl-3 -methylquinazoline

121 2,4(1H,3H)-dione; (97) 6-(2-(4-(benzo[b]thiophen-4-yl)piperidin- 1-yl)ethyl)-2H-benzo[b] [1,4]oxazin-3(4H) one; (98) 6-(2-(4-(benzo[b]thiophen-4-yl)piperidin- 1-yl)ethyl)-3,4-dihydroquinolin-2(1 H)-one; 5 (99) 3 -(2-(4-(benzo[b]thiophen-4-yl)piperidin- 1-yl)ethyl)-2-methyl-6,7,8,9-tetrahydro-4H pyrido[1,2-a]pyrimidin-4-one; (100) 6-(2-(4-(2-fluorobenzo [b]thiophen-4-yl)piperazin- I -yl)ethyl)quinolin-2(1 H)-one; (101) 5-(4-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)butyl)indolin-2-one; (102) 7-(2-(4-(6-fluorobenzo [b]thiophen-4-yl)piperazin- I -yl)ethyl)quinolin-2(1 H)-one; 10 (103) 3-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-6,7-dimethoxy-4H-chromen-4 one; (104) 6-(4-(4-(benzo[b]thiophen-4-yl)piperidin-1-yl)butyl)-3,4-dihydroquinolin-2(1H)-one; (105) 3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-5-methoxy-1H-indole; (106) 3-(3-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)propyl)-5-methoxy-1H-indole; 15 (107) 3-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-5-methoxy-IH-indole; (108) 3-(3-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)propyl)-1H-indole-5-carbonitrile; (109) 3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-1H-indole-5-carbonitrile; (110) 1-acetyl-3-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-1H-indole-5 carbonitrile; 20 (111) 6-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-3,4-dihydroquinolin-2(1H)-one; (112) 5-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)indolin-2-one; (113) 6-chloro-5-(2-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)indolin-2-one; (114) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-4-methyl-2H benzo[b][1,4]oxazin-3(4H)-one; 25 (115) 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-1-methyl-3,4-dihydroquinolin 2(IH)-one; (116) 5-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)benzo[d]thiazol-2-ainine; (117) 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)benzo[d]thiazol-2-amine; (118) N-(5-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)benzo[d]thiazol-2 30 yl)acetainide; (119) N-(7-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)benzo[d]thiazol-2 yl)acetamide; (120) 4-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)benzo[d]thiazol-2-amine; (121) N-(4-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)benzo[d]thiazol-2 35 yl)acetamide;

122 (122) 7-(2-(4-(2-methylbenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinolin 2(1H)-one; (123) 3-((4-(benzo[b]thiophen-4-yl)piperazin-1-yl)methyl)-1-methyl-I1H-indole; (124) 1-(3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)indolin-1-yl)ethanone; 5 (125) 3 -(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-1-tosyl-IH-indole-5-carbonitrile; (126) 3-(3-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)propyl)-1-tosyl-IH-indole-5 carbonitrile; (127) 3-(4-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)butyl)-5-methoxy-1-tosyl-1H-indole; (128) 3-(3-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)propyl)-5-methoxy-1-tosyl-IH-indole; 10 (129) 3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-5-methoxy-1-tosyl-1H-indole; (130) 6-(2-(4-(2-oxo-2,3-dihydrobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-3,4 dihydroquinolin-2(1H)-one; (131) 3-(2-(4-(2-fluorobenzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-9-hydroxy-2-methyl 6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one; 15 (132) 2-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-2H-benzo[b][1,4]oxazin-3 (4H) one; (133) 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-3,4-dihydroquinoline-2(1H) thione; (134) (3aR,4R,6aS)-4-(5-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)pentyl)tetrahydro-1H 20 thieno[3,4-d]imidazol-2(3H)-one; (135) pentyl (6-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)benzo[d]thiazol-2 yl)carbamate; (136) 3-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-2-methyl-4-oxo-6,7,8,9 tetrahydro-4H-pyrido[1,2-a]pyrimidin-9-yI benzoate; 25 (138) 1-(benzo[b]thiophen-4-yl)-4-(4-(I-cyclohexyl-IH-tetrazol-5-yl)butyl)piperazine; (139) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)-8-fluoro-2H benzo[b][1,4]oxazin-3(4H)-one; (140) 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)-1-hydroxyethyl)quinolin-2(1H)-one; (141) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)-l-hydroxyethyl)-2H 30 benzo[b][1,4]oxazin-3(4H)-one; (142) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)-1-hydroxyethyl)-2H benzo[b][1,4]thiazin-3(4H)-one; (143) 5-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)acetyl)indolin-2-one; (144) 8-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)-1-methoxyethyl)-2H 35 benzo[b][1,4]oxazin-3(4H)-one;

123 (145) 5-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)-l-hydroxyethyl)indolin-2-one; (146) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)acetyl)benzo[d]thiazol-2(3H)-one; (147) 5-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)acetyl)-1H-benzo[d]imidazol-2(3H) one; 5 (148) 7-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)acetyl)-3,4-dihydroquinolin-2(1H)-one; (149) 7-(5 -(4-(benzo [b]thiophen-4-yl)piperazin- 1-yl)valeryl)quinolin-2(1 H)-one; (152) N-(6-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)benzo[d]thiazol-2-yl) cyclopentylformamide; (153) N-(6-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)benzo[d]thiazol-2 10 yl)acetamide; and (154) 6-(2-(4-(benzo[b]thiophen-4-yl)piperazin-1-yl)ethyl)benzo[d]thiazol-2-amine.

12. A pharmaceutical composition comprising a therapeutically effective amount of the heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof according to 15 any one of claims 1 to 11, and one or more pharmaceutically acceptable carriers.

13. A method of preparing a pharmaceutical composition comprising mixing the heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof according to any one of claims 1 to 11 with one or more pharmaceutically acceptable carriers. 20 14. A use of the heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof according to any one of claims 1 to 11 in preparing a medicament for the prevention and/or treatment of central nervous system disease associated with 5-HTIA and/or 5-HT2A and/or D2 receptors. 25 15. The use according to claim 14, wherein said central nervous system disease

associated with 5-HTIA and/or 5-HT 2A and/or D2 receptors is selected from the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar I type disorder; bipolar II type 30 disorder; depression; endogenous depression; major depression; refractory depression; dysthymic disorder; cyclothymic disorder; panic attack; panic disorder; social phobia; obsessive-compulsive disorder; impulse disorder; post-traumatic stress disorder; anxiety disorder; acute stress disorder; hysteria; anorexia nervosa; sleep disorder; adjustment disorder; cognitive disorder; autism; neuropathic headache; mania; Parkinson's disease; Huntington's 35 disease; Alzheimer's disease; dementia; memory disorder; hyperkinetic syndrome; attention

124 deficit/hyperactivity disorders, and tic disorder.

16. A method of preparing the heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof according to any one of claims 1 to 11, which is one of the following 5 5 methods: Method 1: the compound of formula (II) or a salt thereof reacts with the compound of formula (III) or a salt thereof as shown in Reaction Formula 1:

H N N

R3-R

X + R2 R1 R2 R A ------ReactionFormula1

D S D S (111) (I)

wherein, ring G, L, A, B, D, E, R1, R2 and R3 are defined the same as those in the 10 corresponding claim; X represents a leaving group; Method 2: the compound of formula (IV) or a salt thereof reacts with the compound of formula (V) or a salt thereof as shown in Reaction Formula 2:

LO

LN

R3 + R2 R1 ~~~~~~~ Reaction Formula 2 D S H (V) B (IV) D S (Ia)

15 wherein, ring G, L, A, B, D, R1, R2 and R3 are defined the same as those in the corresponding claim, Ei represents a nitrogen atom; and

X1 represents halogen or trifluoromethylsulfonyloxy; Method 3: the compound of formula (VI) or a salt thereof reacts with the compound of formula (III) or a salt thereof through amidation to obtain the compound of formula (VII) or a

125 salt thereof, and the compound of formula (VII) or a salt thereof is treated with a reducing agent to give a compound of formula (I), as shown in Reaction Formula 3:

5

H 0O L--LG N N R3R N R 3 C N "- R 3 EE R2 ---- R1 ------Reaction R2 R1Formula 3 (VI) B D S B B D S D S (|||) (VIlI) (Il)

10 wherein, ring G, L, A, B, D, E, R1, R2 and R3 are defined the same as those in the corresponding claim; Method 4: the compound of Formula (VIII) or a salt thereof reacts with the compound of formula (III) or a salt thereof through a reductive amination to obtain the compound of Formula (I), as shown in Reaction Formula 4:

H L N N

-Ra -R 3

E +- OHC-L G ,b R2 R1+------R2 R1 ------Reaction Formula 4 (Vill) I B B~ D S D S 15 (111) (I)

wherein, ring G, L, A, B, D, E, R1, R2 and R3 are defined the same as those in the corresponding claim; Method 5: the target compound is obtained through a functional group conversion from the compound of formula (1) obtained by any one of the Methods I to 4. 20 17. The method according to claim 16, wherein in Method 1, the leaving group is 126 halogen, C1~C6 alkylsulfonyloxy, phenylsulfonyloxy, or naphthylsulfonyloxy, said C1~C6 alkylsulfonyloxy, phenylsulfonyloxy and naphthylsulfonyloxy are optionally substituted with one or more substituents selected from the group consisting of halogen, C1~C6 alkyl, C1~C6 alkoxy, nitro, hydroxy, amino, and C1~C6 alkanoyl group. 5 18. A method for preventing and/or treating a central nervous system disease associated

with 5-HTA and/or 5-HT 2A and/or D2 receptors in a subject in need thereof, comprising administering a therapeutically effective amount of a heterocyclic compound, stereoisomer or pharmaceutically acceptable salt thereof according to any one of claims 1 to 11. 10 19. The method according to claim 18, wherein said central nervous system disease associated with 5-HTA and/or 5 -HIT2A and/or D2 receptors is selected from the group consisting of schizophrenia; refractory, intractable or chronic schizophrenia; emotional disturbance; psychotic disorder; mood disorder; bipolar I type disorder; bipolar 11 type 15 disorder; depression; endogenous depression; major depression; refractory depression; dysthymic disorder; cyclothymic disorder; panic attack; panic disorder; social phobia; obsessive-compulsive disorder; impulse disorder; post-traumatic stress disorder; anxiety disorder; acute stress disorder; hysteria; anorexia nervosa; sleep disorder; adjustment disorder; cognitive disorder; autism; neuropathic headache; mania; Parkinson's disease; Huntington's 20 disease; Alzheimer's disease; dementia; memory disorder; hyperkinetic syndrome; attention deficit/hyperactivity disorders, and tic disorder.

127